Could your patients with cardiomyopathy or heart failure symptoms have transthyretin amyloidosis (ATTR)?
Recognizing clinical red flags early can support earlier diagnosis. Learn
more: www.attr-amyloidosis.com/red-flag-symptoms
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. More on Wikipedia
-
Alnylam Pharmaceuticals
@Alnylam
-
Alnylam Pharmaceuticals
@Alnylam
Rock, paper, scissors is a game of chance but recurring kidney stones shouldn’t be.
Across Alnylam, we’re marking #hyperoxaluriaawarenessweek by shining a light on Primary Hyperoxaluria Type 1 (PH1).
💡 Kidney stones in kids or recurring in adults? Ask your healthcare team about PH1.
#ph1 #hyperoxaluria -
Alnylam Pharmaceuticals
@Alnylam
This #veteransday, we honor all those who have served, including the veterans within our Alnylam community. We’re grateful for your service, dedication and the contributions you continue to make each day. Thank you for all that you do.
#alnylamproud -
Alnylam Pharmaceuticals
@Alnylam
Alnylam collaborator Regeneron presented promising first-in-human results for an investigational RNAi therapeutic (also known as an siRNA therapeutic) in patients with metabolic dysfunction-associated steatotic liver disease (#masld) during an oral session at #aasld2026 that were also published by NEJM. go-alnylam.com/4zbGHHE
#sirna #rnai #rnaitherapeutics -
Alnylam Pharmaceuticals
@Alnylam
Early recognition of transthyretin #amyloidosis with cardiomyopathy (#attr-CM) impacts lives, yet it remains underdiagnosed.
We’re proud to support @American_Heart’s IMPACT ATTR initiative to help clinicians diagnose earlier and improve the quality and consistency of care. -
Alnylam Pharmaceuticals
@Alnylam
Every patient story matters.
At @American_Heart (AHA) in Chicago, visit Alnylam booth 2818 to watch former professional football player Pete’s journey with transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and why greater disease awareness matters. -
Alnylam Pharmaceuticals
@Alnylam
Discover the new transthyretin #amyloidosis with cardiomyopathy (#attr-CM) data we’ll be presenting at upcoming congresses.
📍 First stop is the @American_Heart (AHA) #scientificsessions26
📍 Then we’ll be heading to the @ISA_Amyloidosis Symposium #isa2026 -
Alnylam Pharmaceuticals
@Alnylam
This #hyperoxaluriaawarenessweek, we’re helping raise awareness for Primary Hyperoxaluria Type 1 (PH1).
One kidney stone might seem like chance, but recurring stones in adults, or any stones in children, may point to symptoms that shouldn't be ignored. ohf.org
#ph1 #hyperoxaluria -
Alnylam Pharmaceuticals
@Alnylam
As Health Literacy Month comes to a close, we’re breaking down the basics of clinical trials: what they are, why they matter and the important role they play in advancing new medicines.
At Alnylam, helping people understand clinical research is one way we can better connect our science with the people we hope to serve. Watch the video to learn more.
Read more about our trials: go-alnylam.com/4sGrTzeThis media couldn't be displayed. See it on the original post. -
Alnylam Pharmaceuticals
@Alnylam
We've reported Q3 2026 financial results and highlights of recent period activity. Join us LIVE TODAY at 8:30 AM ET to hear from our leadership or access the replay later today at: go-alnylam.com/4BDX1n8
Read the Q3 2026 financial results press release: go-alnylam.com/4yJSgFF -
Alnylam Pharmaceuticals
@Alnylam
Last week employees at Alnylam showed up in a big way to support the communities where we live and work. Just how big was our annual Community Service Week this year?
🌍 13 Countries
🏢 30+ Organizations supported
💪 750+ Volunteers
⏰ 2,000+ Volunteer hours
At Alnylam, making a positive impact goes beyond the innovative medicines we develop. It’s also about fostering a culture of service and giving back, driven by a shared passion for making a difference. -
Alnylam Pharmaceuticals
@Alnylam
Join us for a live webcast this Thursday, October 29th at 8:30 AM ET when we'll share Third Quarter 2026 financial results.
Register, and access the replay later that day: investors.alnylam.com/events
#rnai #rnaitherapeutics #sirna -
Alnylam Pharmaceuticals
@Alnylam
What if you don’t know the question to ask?
Ozzie & Mike took different paths to an ATTR cardiac amyloidosis diagnosis. Now, they’re sharing the key things they’ve learned and the questions they wish they had known to ask sooner. -
Alnylam Pharmaceuticals
@Alnylam
There remains an urgent need for scientific progress in #huntingtonsdisease (HD).
Hear from Toby Ferguson, our Head of Neuroscience, about our commitment to advancing research for people living with HD, and you can watch the replay of our latest #rnai Roundtable here: -
Alnylam Pharmaceuticals
@Alnylam
This @AmyloidosisDay, we’re proud to support #bethelink, shining a light on caregivers’ vital role.
Art’s wife, Liz encourages him to share what he’s really experiencing with his physician, being the “voice” that helps him advocate for himself. -
Alnylam Pharmaceuticals
@Alnylam
For Investors and Media
Join us today at 10:00 AM ET for the 10th #rnai Roundtable webinar featuring a discussion of the latest data from our investigational program in #huntingtonsdisease (HD).
Click the link to join the live webinar or access the replay approximately three hours after the event: events.q4inc.com/attendee/519469432 -
Alnylam Pharmaceuticals
@Alnylam
For #worldamyloidosisday, we’re honoring caregivers.
Caregiving needs can evolve daily and span years, so it’s essential for caregivers to look after their own well-being.
Hear Ester’s' perspective as a former carer & current ATTR amyloidosis patient: news.alnylam.com/patient-focus/articles/celebrating-careg… -
Alnylam Pharmaceuticals
@Alnylam
For the eighth year in a row, Alnylam has been recognized as a Science Top Employer!
It's a reflection of our incredible people, our culture and our commitment to bold science. As we continue to expand the possibilities of RNAi, one thing is clear: we're just getting started.
go-alnylam.com/4eJcHva
#challengeaccepted -
Alnylam Pharmaceuticals
@Alnylam
We’re presenting new data on our investigational #rnai therapeutic in #huntingtonsdisease (HD) at the European Huntington’s Disease Network (EHDN) Clinical Research Congress. #ehdn2026
Read the full press release: go-alnylam.com/4eNHffj -
Alnylam Pharmaceuticals
@Alnylam
For Investors and Media
Join us on 10/26 at 10:00 AM ET for the 10th #rnai Roundtable focused on our latest advances in #huntingtonsdisease (HD).
Hear from the Alnylam team and scientific experts as they discuss our Phase 1b data in HD.
Register here:go-alnylam.com/4z08RpP -
Alnylam Pharmaceuticals
@Alnylam
We’ll be at the European Huntington’s Disease Network (EHDN) Clinical Research Congress presenting new data on our investigational #rnai therapeutic in development for #huntingtonsdisease (HD).
We look forward to connecting with the community and discussing the latest scientific advances in HD. -
Alnylam Pharmaceuticals
@Alnylam
When it comes to ATTR-CM, it’s important to catch the signs early. 🚨
Former pro football player Pete Shaw, his wife Kari, and cardiologist Dr. Rajeev Mohan are teaming up to spotlight this heart condition. Watch below to stay ahead of the game.
Learn more about Pete’s experience living with ATTR-CM: news.alnylam.com/patient-focus/articles/signs-were-there-… -
Alnylam Pharmaceuticals
@Alnylam
Meaningful clinical research is built alongside the communities it aims to serve.
See how community insights guided key aspects of our global TRITON-CM trial in #attr-CM, from expanding opportunities for women to making research more representative of real-world populations. -
Alnylam Pharmaceuticals
@Alnylam
Explore the latest clinical data in transthyretin #amyloidosis with cardiomyopathy (#attr-CM) presented at #hfsa2026.
Learn more: go-alnylam.com/4yblxZP -
Alnylam Pharmaceuticals
@Alnylam
Think of your body as an orchestra. DNA or genes are the sheet music and proteins are the musicians. When the instructions contain errors, disease can occur. #rnainterference (#rnai) helps regulate gene activity, treating disease.
Sponsored content w/ Vox www.vox.com/ad/459936/the-genetic-technology-that-could-s… -
Alnylam Pharmaceuticals
@Alnylam
We're proud to welcome Sandy Waite as our Chief Communications Officer and a member of our Executive Leadership Team. Sandy brings more than 25 years of experience leading communications and public affairs across the biopharmaceutical, healthcare and financial services industries. Prior to joining Alnylam, she held senior leadership roles at Johnson & Johnson Innovative Medicine, CVS Health and Aetna. Learn more about Sandy: go-alnylam.com/4hfGQnL
-
Alnylam Pharmaceuticals
@Alnylam
We're heading to the 58th European Society for Paediatric Nephrology Annual Meeting!
Learn more about this conference at: go-alnylam.com/4hVNKP6
#espn2026 #nephrology -
Alnylam Pharmaceuticals
@Alnylam
This #worldheartday, former pro athlete Pete Shaw, opens up about his toughest opponent, ATTR cardiac amyloidosis.
He’s sharing his journey to help others spot the signs of this under recognized condition.
Read more: investors.alnylam.com/press-releases 🏈 -
Alnylam Pharmaceuticals
@Alnylam
Work continues on the $250M expansion of our Norton, Massachusetts #biomanufacturing facility. To mark our exciting progress, Alnylam employees and representatives of our construction and engineering partners Commodore Builders and CRB recently signed their names to a structural beam that was lifted into position.
Our Norton facility is at the center of Alnylam's global RNAi therapeutics manufacturing operations. It's also where we're continuing to innovate in the manufacturing of #rnai therapeutics by building out new capacity and siRNA enzymatic ligation capabilities. Learn more about what's going on in Norton and how we make our medicines: go-alnylam.com/4AimAcD -
Alnylam Pharmaceuticals
@Alnylam
Bob’s experience living with uncontrolled #hypertension and elevated cardiovascular risk reinforces the "why" behind Alnylam’s work and our commitment to advancing innovation for the people like Bob who are living with unmet need.
Hear Bob share his story in his own words. 👇 -
Alnylam Pharmaceuticals
@Alnylam
⚽ Football and healthcare share something powerful: the ability to bring people together, inspire strength, and support communities. 💛🖤
In Germany, we are partnering with football club Borussia Dortmund (@BVB) women's team to raise awareness about acute hepatic porphyria (AHP).
This exciting collaboration is an example of how Alnylam is building alliances and leveraging community connections to support disease awareness and education in the countries we serve.
#borussiadortmund #womensfootball
#acutehepaticporphyria #porphyria #raredisease -
Alnylam Pharmaceuticals
@Alnylam
Zilebesiran Program Lead, Simon Fox, shares his top 3 takeaways from our recent #rnai Roundtable. Zilebesiran is an investigational RNAi therapeutic being evaluated in patients with high cardiovascular risk and uncontrolled #hypertension.
Find out more here:This media couldn't be displayed. See it on the original post. -
Alnylam Pharmaceuticals
@Alnylam
On World Alzheimer’s Day, we’re sharing this year’s message: The Earlier You Know, The More You Can Do. This message is important because early recognition is a significant step towards accessing information, support and care. At Alnylam, we stand with the dementia community in advocating for greater awareness, understanding and informed conversations.
#dementiadiagnosismatters, #alzheimerdiagnosismatters, #earlydiagnosismatters -
Alnylam Pharmaceuticals
@Alnylam
Join us this morning for our 2nd RNAi Roundtable on our investigational #rnai therapeutic zilebesiran. Learn about the challenges in hypertension management and the impact of prolonged uncontrolled blood pressure on cardiovascular risk.
Join live or catch the replay later. -
Alnylam Pharmaceuticals
@Alnylam
Join us on Thursday for the second installment of our #rnai Roundtable.
Alnylam researchers and experts will discuss the significant unmet need in #hypertension, importance of blood pressure control, and ongoing research aimed at advancing cardiovascular care. -
Alnylam Pharmaceuticals
@Alnylam
Managing a #raredisease like primary #hyperoxaluria type 1 (PH1) can be difficult, so it’s helpful to work with patient advocacy groups to answer questions and get more information. Hear from Kim Hollander of @OHFTweet in an episode of Medical Stories. www.youtube.com/watch?v=kWTU1CPv7d8
-
Alnylam Pharmaceuticals
@Alnylam
Alnylam's strategic collaboration with Inceptive is combining RNAi expertise and advanced AI models to accelerate the design of next-generation RNAi therapeutics. Our CEO Dr. Yvonne Greenstreet and Inceptive CEO and Co-founder Jakob Uszkoreit recently sat down to discuss why the two companies came together and what we hope the collaboration will yield.
➡️ Read more and watch the full interview: go-alnylam.com/45XcobF -
Alnylam Pharmaceuticals
@Alnylam
HCPs: Diagnosing patients earlier matters in transthyretin #amyloidosis with cardiomyopathy (ATTR-CM) and Alnylam aims to change the course. @BrettSperryMD discusses more in @HCPLiveNews: www.hcplive.com/view/treating-attr-cm-with-urgency-how-st…
#cardiology #clinicalinsights -
Alnylam Pharmaceuticals
@Alnylam
Reflecting on an inspiring #esccongress in Munich!
Beyond the energy on the floor, we were thrilled to present new clinical data on our RNAi-powered innovations, advancements in earlier diagnosis, and coordinated care in ATTR-CM.
Press play to watch our key takeaways from the congress 👇This media couldn't be displayed. See it on the original post. -
Alnylam Pharmaceuticals
@Alnylam
Calling all researchers working on RNA-based therapeutics! 🧬 Submit an abstract to the upcoming event "RNA at the Bench and Bedside V" through Oct 1, 2026 for a chance to present your work to leaders, experts and peers in the nucleic acid medicines field. We're proud to be co-organizing this conference with Nature Portfolio, Nature Biotechnology, Ionis Pharmaceuticals, Inc., and UC San Diego Center for RNA Technologies and Therapeutics!
go-alnylam.com/4grxSlE
#rnabench2bedside #rna #rnai #rnainterference #rnaitherapeutics #sirna -
Alnylam Pharmaceuticals
@Alnylam
HCPs: Transthyretin #amyloidosis with cardiomyopathy (ATTR-CM) can progress before it’s diagnosed, making earlier recognition especially important. Read more from @BrettSperryMD on why this matters.
#cardiology #clinicalinsights -
Alnylam Pharmaceuticals
@Alnylam
Learn more about our latest evidence in transthyretin #amyloidosis with cardiomyopathy (ATTR-CM) and #hypertension from the recent #esccongress. capella.alnylam.com/2026/08/30/esc-2026
-
Alnylam Pharmaceuticals
@Alnylam
We’re pleased to share the ESC Heart Failure Guidelines announced today at #esccongress.
-
Alnylam Pharmaceuticals
@Alnylam
Despite growing awareness of ATTR-CM, many patients still face missed signals, delayed referrals and fragmented care pathways.
Through collaborations across the healthcare ecosystem, Alnylam is supporting solutions designed to help advance patient care.
Learn more: -
Alnylam Pharmaceuticals
@Alnylam
For HCPs: Professor Marianna Fontana shares why the myth that transthyretin amyloid with cardiomyopathy (ATTR-CM) only affects men is causing significant underdiagnosis in women.
👇 Watch her insights here. -
Alnylam Pharmaceuticals
@Alnylam
We’re presenting new data at the #esccongress, highlighting our progress in amyloidosis and uncontrolled hypertension.
Read the full press release: investors.alnylam.com/press-releases -
Alnylam Pharmaceuticals
@Alnylam
HCPs: Do you have a patient presenting with severe, diffuse abdominal pain and seemingly unrelated symptoms? It could be acute hepatic #porphyria (AHP). Random (spot) urine tests are the primary method to help diagnose AHP and a genetic test can determine the type.
-
Alnylam Pharmaceuticals
@Alnylam
Curiosity fuels innovation. Our Chief R&D Officer, Pushkal Garg, shares why seeking different perspectives, asking questions, and embracing what we don't yet know are essential to discovering new possibilities for patients.
Read more: news.alnylam.com/perspectives/articles/five-keys-scaling-… -
Alnylam Pharmaceuticals
@Alnylam
We're honored AMVUTTRA (vutrisiran) has been nominated for the 2026 #prixgalien USA Award for Best Biotechnology Product. Thank you to the patients, families, researchers, investigators & employees whose dedication helps advance the possibilities of #rnai therapeutics. @GalienFdn
-
Alnylam Pharmaceuticals
@Alnylam
RNAi therapeutics target disease at its roots rather than just treating symptoms. Based on Nobel Prize-winning science, these genetic medicines silence disease-causing genes before unwanted proteins are made.
5 key facts: news.alnylam.com/rnai/articles/rnai-therapeutics-5-things…
#rnai #geneticmedicine -
Alnylam Pharmaceuticals
@Alnylam
As we celebrate #rnaday, expand your #rna knowledge by learning about #rnaitherapeutics. Alnylam pioneered this class of #genesilencing medicines and 8 years ago this month, the world’s 1st approved #rnai therapeutic (& our 1st commercial medicine) was approved by the FDA.
-
Alnylam Pharmaceuticals
@Alnylam
We are proud to support the DETECT-ATTR study, evaluating Invision Precision Cardiac Amyloid – an AI-enabled, echocardiography-based screening approach designed to identify cardiac #amyloidosis, including #attr-CM, within a large health care system in CA serving 4.5M+ members.
-
Alnylam Pharmaceuticals
@Alnylam
We’ve reported Q2 2026 financial results and highlights of recent period activity. Join us LIVE TODAY at 8:30 AM ET to hear from our leadership or access the replay later today at: go-alnylam.com/3RFyVWE
Read the Q2 2026 financial results press release: go-alnylam.com/4pMkLjb -
Alnylam Pharmaceuticals
@Alnylam
It's her big game. You want to be there AND be fully present. Living with disease makes that difficult. Over time, the sounds of disease - doctor visits, tests, managing medication - mute the joy of life. But what happens when you #silencedisease?
#amplifylife #rnaitherapeutics -
Alnylam Pharmaceuticals
@Alnylam
What does it take to sustain innovation as an organization grows? Pushkal Garg says it starts by keeping patients at the center of every decision. Read why patient focus is foundational to a lasting culture of innovation: news.alnylam.com/perspectives/articles/five-keys-scaling-…
-
Alnylam Pharmaceuticals
@Alnylam
Primary #hyperoxaluria type 1 (PH1) is an inherited disease and can affect family members differently. For one family with three children with PH1, each has had a different experience. Hear from Aubrey, diagnosed with PH1, in an episode of Medical Stories. www.youtube.com/watch?v=kWTU1CPv7d8
-
Alnylam Pharmaceuticals
@Alnylam
How do we advance RNAi therapeutics from discovery to patients with industry-leading speed and success rates? Using precise chemistry, innovative delivery methods, advanced analytics, and cutting-edge manufacturing, we’re bringing new treatments to more patients, sooner.
-
Alnylam Pharmaceuticals
@Alnylam
HCPs: Characterized by severe, diffuse abdominal pain and a range of other seemingly unrelated symptoms, acute hepatic #porphyria (AHP) can be misleading and is often misdiagnosed.
Learn when to suspect AHP: www.porphyria.com/hcp/signs-and-symptoms -
Alnylam Pharmaceuticals
@Alnylam
As Alnylam grows, so does our responsibility to reduce our environmental impact. Learn how we're integrating sustainability across our operations, from renewable energy to manufacturing innovations like siRELIS™. news.alnylam.com/responsibility/articles/scaling-responsi…
#sustainability #rnai -
Alnylam Pharmaceuticals
@Alnylam
Think of your body as an orchestra. DNA or genes are the sheet music and proteins are the musicians. When the instructions contain errors, disease can occur. #rnainterference (#rnai) helps regulate gene activity, treating disease.
Sponsored content w/ Vox www.vox.com/ad/459936/the-genetic-technology-that-could-s… -
Alnylam Pharmaceuticals
@Alnylam
Having a #raredisease like primary #hyperoxaluria type 1 (PH1) requires lifelong monitoring. In an episode of Medical Stories, Dr. John Lieske, nephrologist, discusses the importance of early diagnosis and management in relation to one family’s experience. www.youtube.com/watch?v=kWTU1CPv7d8
-
Alnylam Pharmaceuticals
@Alnylam
Neurological diseases have a devastating impact, and #rnaitherapeutics have the potential to offer a promising approach. At Alnylam, we’re exploring ways to silence brain diseases, such as Alzheimer’s and Huntington’s disease.
Read more: news.alnylam.com/rnai/articles/new-therapeutic-approach-s…
#rnai #neurology -
Alnylam Pharmaceuticals
@Alnylam
RNA interference (RNAi) is a naturally occurring process of gene regulation that is already at work inside your body. RNAi therapeutics utilize this process to silence the genes that cause or contribute to disease. Learn more about RNAi? www.alnylam.com/our-science/the-science-of-rnai
#rnaitherapeutics -
Alnylam Pharmaceuticals
@Alnylam
Team Alnylam showed up for Pride 2026! From Strides for Action at Boston Common to marching in Boston Pride for the People with our SAGA ERN, we celebrated, supported, and stood together. Thank you to everyone who participated and volunteered. 🌈 #pride2026
-
Alnylam Pharmaceuticals
@Alnylam
That’s a wrap on #pns2026! Thank you to the neurology community for a week of meaningful discussion and exchange.
Encouraged by the focus on earlier recognition and intervention in hATTR-PN, and grateful to connect with those working to improve outcomes for patients. -
Alnylam Pharmaceuticals
@Alnylam
There is a tremendous unmet need for patients with bleeding disorders, as most conditions have no approved treatment options. Hear from Alnylam Program Leader John Gansner on how ALN-6400 could potentially change that.
#rnaitherapeutics #bleedingdisorders -
Alnylam Pharmaceuticals
@Alnylam
Today we kick off our 10th series of RNAi Roundtable webinars! Tune in live at 11:00am ET for our webcast on ALN-6400 and bleeding disorders. Join the webinar or catch the replay later: events.q4inc.com/attendee/837019401
-
Alnylam Pharmaceuticals
@Alnylam
Navigating life with a #raredisease, like primary #hyperoxaluria type 1 (PH1), can be filled with uncertainty, but it’s important to advocate for your or your loved one’s health. Hear from Becky, a PH1 caregiver, in an episode of Medical Stories. www.youtube.com/watch?v=kWTU1CPv7d8
-
Alnylam Pharmaceuticals
@Alnylam
We’re kicking off our 10th series of RNAi Roundtable webinars this Thursday, June 25 at 11:00am ET! Join us live for a webcast on ALN-6400 and its potential to address rare bleeding disorders. Register here: events.q4inc.com/attendee/837019401
-
Alnylam Pharmaceuticals
@Alnylam
We’re proud to share that Muthiah (Mano) Manoharan has received the 2026 Khorana Prize from @RoySocChem, recognizing innovation at the interface of chemistry and biology. His pioneering work in nucleic acid chemistry has helped advance RNA-based medicines. Congrats, Mano!
-
Alnylam Pharmaceuticals
@Alnylam
Delayed transthyretin-mediated amyloidosis cardiomyopathy diagnosis can lead to a 17% increase in 30-day readmissions.
Join @BeckersHR & Alnylam for a discussion with @advocatehealth, @UChicagoMed & @StLukesHealth to learn about the benefit of pharmacy-cardiology collaboration. -
Alnylam Pharmaceuticals
@Alnylam
We’re pleased to share a pooled analysis evaluating an investigational RNAi therapeutic when added on to RAAS inhibitors in patients with hypertension, including those with reduced kidney function.
Learn more: capella.alnylam.com/2026/06/11/era-2026 -
Alnylam Pharmaceuticals
@Alnylam
We were proud to be back on the court supporting @SpOlympicsMA and partnering again with Heller’s Angels, our longtime Special Olympics MA teammates. Thanks to everyone who played, donated, and cheered us on! #bioball2026
-
Alnylam Pharmaceuticals
@Alnylam
Join our #pns2026 medical symposium for expert perspectives on multidisciplinary diagnosis, monitoring and care of patients with #attr #amyloidosis with neurologic and cardiac manifestations. pnsociety.com/2026-pns-annual-meeting/sponsored-symposia/
For healthcare professionals and registered congress attendees -
Alnylam Pharmaceuticals
@Alnylam
Living with disease is noisy. The sounds of doctor visits, tests, managing medication, and declining things you want to do can mute the joy of life. But what happens when disease is silenced?
#silencedisease #amplifylife #rnai #rnaitherapeutics -
Alnylam Pharmaceuticals
@Alnylam
Nearly 40 of us walked Castle Island in Boston for the @HDSA #teamhopewalk last weekend, raising awareness for #huntingtonsdisease. Thank you to everyone who joined and donated! Learn more at www.hdsa.org/teamhope
-
Alnylam Pharmaceuticals
@Alnylam
Early diagnosis is critical in managing a #raredisease like primary #hyperoxaluria type 1 (PH1). Left undiagnosed, patients are at increased risk for complications. Learn from Dr. David J. Sas, pediatric nephrologist, in an episode of Medical Stories. www.youtube.com/watch?v=kWTU1CPv7d8
-
Alnylam Pharmaceuticals
@Alnylam
We announced an AI collaboration with Inceptive to accelerate #rnai therapeutic discovery.
By combining our RNAi platform and 20+ years of data with Inceptive’s #ai models, we aim to bring RNAi-based medicines to patients sooner.
A step forward in our Alnylam 2030 strategy. -
Alnylam Pharmaceuticals
@Alnylam
Living an amplified life with disease means your disease doesn’t dominate your day-to-day, allowing you to focus on doing what you love with the people who matter most. Helping people get to that place is why we’ve pioneered #rnaitherapeutics.
#silencedisease #amplifylife -
Alnylam Pharmaceuticals
@Alnylam
This June, we’re proud to stand alongside and celebrate the LGBTQ+ community. Led by SAGA, our LGBTQ+ employee resource network, we’re coming together to reaffirm our commitment to equality, visibility, and belonging for all. Happy Pride!
#pride2026 #pridemonth #lgbtq -
Alnylam Pharmaceuticals
@Alnylam
Applications are open for our US Clinical Fellowship Program for Academic Year 2027-2028.
Eligible ACGME-accredited institutions can apply for funding to advance physician training in the diagnosis, treatment, and research of ATTR.
Application window: June 1 - August 28, 2026 -
Alnylam Pharmaceuticals
@Alnylam
HCPs: The burden of living with acute hepatic #porphyria (AHP) can greatly impact your patients’ quality of life. People living with AHP may have higher risk of long-term complications that have an immense emotional toll including depression and anxiety.
-
Alnylam Pharmaceuticals
@Alnylam
We believe all patients, regardless of their diagnosis, have the potential to benefit from the promise that #rnaitherapeutics hold to #silencedisease and #amplifylife. That’s why we’ve pioneered this innovative approach and are working to bring it to as many patients as possible.
-
Alnylam Pharmaceuticals
@Alnylam
We were proud to host @Amyloidosis_ARC this month, building on momentum from the Alnylam Global Advisory Summit. Together, we worked to define the shared priorities for our collaboration, with a focus on improving care for patients with ATTR-CM.
-
Alnylam Pharmaceuticals
@Alnylam
Looking back on #heartfailure26, conversations highlight scientific progress to address unmet needs in transthyretin #amyloidosis with cardiomyopathy (ATTR-CM). As the leader in #rnai therapeutics, we remain committed to advancing innovation to help improve outcomes for patients.
-
Alnylam Pharmaceuticals
@Alnylam
Managing a #raredisease like primary #hyperoxaluria type 1 (PH1) can be difficult, so it’s helpful to work with patient advocacy groups to answer questions and get more information. Hear from Kim Hollander of @OHFTweet in an episode of Medical Stories. www.youtube.com/watch?v=kWTU1CPv7d8
-
Alnylam Pharmaceuticals
@Alnylam
On #worldclinicaltrialsday, Carol Pitcher-Towner, Head of Development Programmes at Alnylam, asks an important question: “Who is represented in the data?”
In rare diseases, inclusion and trust are critical to research that truly reflects the communities it serves. -
Alnylam Pharmaceuticals
@Alnylam
At Alnylam, responsible business practices are essential to creating lasting impact. Our 2025 Corporate Responsibility Report highlights progress across patients, science, employees, communities, governance, and the environment.
#corporateresponsibility #csr #esg -
Alnylam Pharmaceuticals
@Alnylam
Today, Alnylam colleagues are in #purpleforporphyria! 💜
Solving the puzzle of porphyria is complex, but in collaboration with @GlobalPorphyria for #globalporphyriaday, we’re helping piece it together. 🧩
#standwithglobalporphyria #lightupforporphyria #raredisease -
Alnylam Pharmaceuticals
@Alnylam
HCPs: Every acute hepatic #porphyria (AHP) attack matters. Your patient’s next attack could have life-changing consequences, like irreversible neurologic damage. Learn how timely diagnosis and management can help avoid potentially devastating outcomes.
-
Alnylam Pharmaceuticals
@Alnylam
RNAi therapeutics are a type of medicine, pioneered by Alnylam, that treats disease by targeting and disabling specific mRNA (messenger RNA). #sciencecurious to learn more about the science of #rnai? Watch and learn more: www.alnylam.com/our-science/the-science-of-rnai
#rnaitherapeutics #genesilencing -
Alnylam Pharmaceuticals
@Alnylam
New data analyses at #heartfailure26 further strengthen the evidence base in transthyretin #amyloidosis with cardiomyopathy (ATTR-CM), with consistent clinical outcomes across patients with high disease burden.
-
Alnylam Pharmaceuticals
@Alnylam
As #heartfailure26 begins, we’re asking: what does progress in transthyretin #amyloidosis with cardiomyopathy (ATTR-CM) look like?
Dr. Pablo García-Pavía shares his perspective on what’s next for patients. -
Alnylam Pharmaceuticals
@Alnylam
We’re proud to share that our CEO, Dr. Yvonne Greenstreet, was formally appointed an Officer of the Order of the British Empire (OBE) this week in Windsor, recognizing her contributions to the biotech and life sciences industry.
A well-deserved honor. Congratulations, Yvonne! -
Alnylam Pharmaceuticals
@Alnylam
This month, Alnylam celebrates AANHPI Heritage Month by honoring the contributions of colleagues whose perspectives have helped shape science, medicine, and innovation. At Alnylam, diverse experiences strengthen how we discover, develop, and deliver meaningful impact.
-
Alnylam Pharmaceuticals
@Alnylam
Think of your body as an orchestra. DNA or genes are the sheet music and proteins are the musicians. When the instructions contain errors, disease can occur. #rnainterference (#rnai) helps regulate gene activity, treating disease.
Sponsored content w/ Vox www.vox.com/ad/459936/the-genetic-technology-that-could-s… -
Alnylam Pharmaceuticals
@Alnylam
New data analyses are coming to #heartfailure26, continuing to advance understanding of treatment in transthyretin #amyloidosis with cardiomyopathy (ATTR-CM).
These findings show consistent benefit across patient populations commonly encountered in clinical practice. -
Alnylam Pharmaceuticals
@Alnylam
We’ve reported Q1 2026 financial results and highlights of recent period activity. Join us LIVE TODAY at 8:30 AM ET to hear from our leadership or access the replay later today at: investors.alnylam.com/events
Read the Q1 2026 financial results press release: investors.alnylam.com/press-release?id=f5afb36f-7396-4cca… -
Alnylam Pharmaceuticals
@Alnylam
Congratulations to our CEO, Dr. Yvonne Greenstreet on being named one of the Most Influential Bostonians by @BostonMagazine. Her leadership continues to drive the field of RNAi therapeutics forward and create hope for patients around the world. go-alnylam.com/4mYKAv3
-
Alnylam Pharmaceuticals
@Alnylam
The Alnylam Assist® program offers support services to patients who are prescribed one of our products. Our team of experts are here to help patients access and understand treatment.
-
Alnylam Pharmaceuticals
@Alnylam
Ziggy’s parents knew something wasn’t right. Their persistence helped lead to his diagnosis of primary #hyperoxaluria type 1 (#ph1), a genetic #raredisease. For PH1 information and support, check out @OHFTweet. See how Jackie and Colin advocated for Ziggy: www.livingwithph1.eu/support-and-resources
-
Alnylam Pharmaceuticals
@Alnylam
We will share First Quarter 2026 financial results this Thursday, April 30. Register and join us for the live webcast at 8:30 a.m. ET or catch a replay later that day here: investors.alnylam.com/events.
#rnai #rnaitherapeutics #sirna -
Alnylam Pharmaceuticals
@Alnylam
HCPs: Check out this interactive acute hepatic #porphyria (AHP) case study to review a hypothetical diagnostic journey with AHP — see how your knowledge of this #raredisease compares with other physicians.
-
Alnylam Pharmaceuticals
@Alnylam
How do we advance RNAi therapeutics from discovery to patients with industry-leading speed and success rates? Using precise chemistry, innovative delivery methods, advanced analytics, and cutting-edge manufacturing, we’re bringing new treatments to more patients, sooner.
-
Alnylam Pharmaceuticals
@Alnylam
Alnylam is committed to advancing care in ATTR amyloidosis and expanding options for patients. Learn more about the rationale and design shaping research for patients with hereditary transthyretin-mediated amyloidosis polyneuropathy (hATTR-PN): go-alnylam.com/41I2PLz
-
Alnylam Pharmaceuticals
@Alnylam
We’re sharing final results from the Phase 3 ILLUMINATE-A 60-month study in patients with primary hyperoxaluria type 1 (PH1).
Access the full article and accompanying podcast: journals.lww.com/cjasn/fulltext/2026/03000/final_results_…
#rnai #raredisease #nephrology #ph1 -
Alnylam Pharmaceuticals
@Alnylam
Our team was proud to join the Greater Boston community at the 2026 Boston Heart & Stroke Ball, celebrating the progress and promise of the @American_Heart's mission.
Special recognition to Christine Akinc for leading this year’s Heart of Boston campaign.
#hearthealth -
Alnylam Pharmaceuticals
@Alnylam
Proud to sponsor this year’s Asembia Summit! Join our session on Mon, Apr 27: The Current State of Rare Disease Therapeutics in the Payer Landscape, moderated by Irène Girgis, PharmD.
Key insights: go-alnylam.com/4c9HTl9
#asembiasummit #raredisease #alnylaminsights -
Alnylam Pharmaceuticals
@Alnylam
Big congratulations to our @HBAnet 2026 Rising Stars, Daniela Musumeci and Lauren Alves! Excited to celebrate their achievements alongside this year’s honorees.
#hbaimpact #ascendwithhba #hbarisingstar -
Alnylam Pharmaceuticals
@Alnylam
2025 was transformational for Alnylam, from the launch of AMVUTTRA for ATTR-CM to reaching profitability to announcing our next 5 year plan.
Hear from our CEO, Yvonne Greenstreet, on what this means for patients, our pipeline, and the future of our company.
#rnai #biotech -
Alnylam Pharmaceuticals
@Alnylam
We’re growing our U.S. team! Join us as we build on a category-defining ATTR-CM launch and drive the next phase of TTR growth.
Explore opportunities: go-alnylam.com/4bICLWj
#rnai #biotech #pharma -
Alnylam Pharmaceuticals
@Alnylam
We’re proud to be recognized by @FastCompany as one of the Most Innovative Companies of 2026, ranking #3 in Medicines, Therapeutics & Pharmaceuticals. A reflection of our focus on turning bold science into transformative medicines.
#fcmostinnovative #rnai -
Alnylam Pharmaceuticals
@Alnylam
Missed us at #acc26? Check out the data we presented across our cardiology programs. We are proud of the growing role of #rnai therapeutics and we're committed to carrying this momentum forward, beyond the conference floor.
Learn more: capella.alnylam.com/2026/03/30/acc-2026 -
Alnylam Pharmaceuticals
@Alnylam
This month, we celebrated #iwd2025 and #womenshistorymonth with global events through our ERN iTHRIVE. From a fireside chat with Dr. Sheila Gujrathi to local celebrations worldwide, we’re proud to invest in the women of our community every day.
-
Alnylam Pharmaceuticals
@Alnylam
New data are on the way. We’re excited to join the cardiology community at #acc26 to share our latest data in transthyretin #amyloidosis with cardiomyopathy (ATTR-CM) and #hypertension.
-
Alnylam Pharmaceuticals
@Alnylam
This #amyloidosisawarenessmonth, learn how community insight shaped our global TRITON-CM clinical trial, from eligibility criteria that better represent women, to reducing patient burden and building more inclusive research.
-
Alnylam Pharmaceuticals
@Alnylam
We're honored to receive the Scientific Impact Award from @MassBio, reflecting years of work turning RNAi into real medicines for patients, including two FDA approvals in 2025.
Read the full announcement: news.alnylam.com/leadership/articles/alnylam-awarded-2026… -
Alnylam Pharmaceuticals
@Alnylam
Why are fewer women diagnosed with ATTR-CM? This #womenshistorymonth and #amyloidosisawarenessmonth, we’re working with advocacy partners to advance equity in diagnosis. Learn why raising awareness of ATTR-CM is essential during March and beyond.
-
Alnylam Pharmaceuticals
@Alnylam
We’re taking action to accelerate earlier detection and improve care coordination for patients with ATTR-CM through a collaboration with @Viz_ai and support for the @American_Heart.
Learn more: investors.alnylam.com/press-releases
#attr #amyloidosis -
Alnylam Pharmaceuticals
@Alnylam
At today's TTR webinar, we shared our leadership journey in delivering transformative therapies for ATTR amyloidosis patients. Looking ahead to our next phase of growth: scaling our platform, driving category growth, expanding prescribers & building on strong adherence.
-
Alnylam Pharmaceuticals
@Alnylam
Our TTR Webinar is TODAY at 9:30 AM ET. Hear from our Commercial and Medical leadership on our momentum in delivering for patients with ATTR-CM and how our TTR Franchise is shaping the future of #attr #amyloidosis care. Join us live or catch the replay within 48 hours.
-
Alnylam Pharmaceuticals
@Alnylam
We're headed to New Orleans for #acc26. With data spanning across our cardiology programs, we look forward to sharing updates underscoring the potential of #rnai for patients living with #cardiovascular diseases. See you there!
-
Alnylam Pharmaceuticals
@Alnylam
Women’s pain is often dismissed, delaying diagnosis of serious conditions like Donna’s acute hepatic #porphyria (AHP), which took 10+ years. Recognizing seemingly unrelated symptoms can help AHP patients regain control.
-
Alnylam Pharmaceuticals
@Alnylam
We’re hosting a TTR Webinar on Tuesday, March 24 at 9:30 AM ET. Join our Commercial and Medical leaders as they highlight our leadership journey in delivering innovative #rnaitherapeutics for patients with #attr #amyloidosis.
-
Alnylam Pharmaceuticals
@Alnylam
It's her big game. You want to be there AND be fully present. Living with disease makes that difficult. Over time, the sounds of disease - doctor visits, tests, managing medication - mute the joy of life. But what happens when you #silencedisease?
#amplifylife #rnaitherapeutics -
Alnylam Pharmaceuticals
@Alnylam
Rapid advancement of the field of RNA Interference (#rnai) is changing the way that medicine treats rare and more common diseases. Having pioneered this innovative class of #genesilencing medicines, we are proud to be leading the charge. Sponsored content with
@NaturePortfolio -
Alnylam Pharmaceuticals
@Alnylam
In recognition of #amyloidosisawarenessmonth, we’re joining supporters worldwide to “Light the Night for Amyloidosis.” Led by the @Amyloidosisfdn, this campaign illuminates communities in red to raise awareness of and honor those affected by amyloidosis.
-
Alnylam Pharmaceuticals
@Alnylam
We’ve been named to the @LexisNexis 2026 Innovation Momentum Global Top 100, recognizing companies driving breakthrough science through the strength of their patent portfolios.
Proud of the teams making this possible! www.lexisnexisip.com/most-innovative-companies-2026/ -
Alnylam Pharmaceuticals
@Alnylam
When RNAi therapeutics silence the genes that cause disease, the best parts of life can be amplified. Learn more about this innovative approach to treating disease: www.silencedisease.com;
#silencedisease #rnai #rnaitherapeutics -
Alnylam Pharmaceuticals
@Alnylam
Receiving a diagnosis of acute hepatic #porphyria (#ahp) was a life-altering moment for Hannah, who felt separated by her "future" and "past" selves. But, a diagnosis also allowed her to begin to move forward. Learn more about Hannah’s AHP story expressed through dance.
-
Alnylam Pharmaceuticals
@Alnylam
This #iwd2026, we’re proud to announce our partnership with @WomenAs1. Grateful to work with partners that share a commitment to strengthening representation in cardiology and improving patient care. #womenincardiology
-
Alnylam Pharmaceuticals
@Alnylam
Think of your body as an orchestra. DNA or genes are the sheet music and proteins are the musicians. When the instructions contain errors, disease can occur. #rnainterference (#rnai) helps regulate gene activity, treating disease.
Sponsored content w/ Vox www.vox.com/ad/459936/the-genetic-technology-that-could-s… -
Alnylam Pharmaceuticals
@Alnylam
HCPs: Do you have a patient presenting with severe, diffuse abdominal pain and seemingly unrelated symptoms? It could be acute hepatic #porphyria (AHP). Random (spot) urine tests are the primary method to help diagnose AHP and a genetic test can determine the type.
-
Alnylam Pharmaceuticals
@Alnylam
Doctor visits, tests, pharmacy trips, medication - the sounds of these things make living with disease noisy. But when you #silencedisease, these things become less prevalent and the joy of life can be amplified. We've pioneered #rnai therapeutics to do just that - #amplifylife.
-
Alnylam Pharmaceuticals
@Alnylam
For Ziggy’s parents, Jackie and Colin, navigating his primary #hyperoxaluria type 1 (#ph1) diagnosis has meant learning, advocating and adjusting to the unknown. But along the way, their journey has been defined by unwavering strength, hope and love.
-
Alnylam Pharmaceuticals
@Alnylam
Less than 1% of drug ideas become approved medicines. Human genetic insights can improve those odds. We've recently partnered with Alliance for Genomic Discovery, FinnGen, and PRECISE Singapore to deepen our access to diverse genetic data to fuel drug development.
#rnai -
Alnylam Pharmaceuticals
@Alnylam
The Alnylam Assist® program offers support services to patients who are prescribed one of our products. Our team of experts are here to help patients access and understand treatment.
-
Alnylam Pharmaceuticals
@Alnylam
The Alnylam #bioventurechallenge brings emerging biotech entrepreneurs together to pitch bold ideas, gain feedback from our leaders, and compete for early-stage funding.
Read more about the program, our partnership with Nucleate, and the 2025 competition: news.alnylam.com/leadership/articles/alnylam-bioventure-c… -
Alnylam Pharmaceuticals
@Alnylam
We believe all patients, regardless of their diagnosis, have the potential to benefit from the promise that #rnaitherapeutics hold to #silencedisease and #amplifylife. That’s why we’ve pioneered this innovative approach and are working to bring it to as many patients as possible.
-
Alnylam Pharmaceuticals
@Alnylam
We’ve reported Q4 2025 financial results and highlights of recent period activity. Join us LIVE TODAY at 8:30 AM ET to hear from our leadership or access the replay later today at: investors.alnylam.com/events
Read the Q4 2025 financial results press release: investors.alnylam.com/press-release?id=cda5bd48-ed15-4c48… -
Alnylam Pharmaceuticals
@Alnylam
On this International Day of Women and Girls in Science, we celebrate stories like Benisha Marseille’s. She once wondered why the moon followed her. Through @SCFG, she found the answer. Today she’s studying computer science at @holy_cross. Read more: www.alnylam.com/sites/default/files/pdfs/alnylam-women-an…
-
Alnylam Pharmaceuticals
@Alnylam
We will report fourth quarter and full year 2025 financial results this Thursday, February 12. Register and join us for the live webcast at 8:30 a.m. ET or catch a replay later that day: investors.alnylam.com/events.
#rnai #rnaitherapeutics #sirna -
Alnylam Pharmaceuticals
@Alnylam
Cells use messenger RNA (mRNA) to carry instructions from DNA to make proteins. Sometimes, unwanted proteins cause or contribute to disease. #rnai therapeutics disrupt this process by targeting specific mRNA molecules and preventing the production of disease-associated proteins.
-
Alnylam Pharmaceuticals
@Alnylam
HCPs: Characterized by severe, diffuse abdominal pain and a range of other seemingly unrelated symptoms, acute hepatic #porphyria (AHP) can be misleading and is often misdiagnosed.
-
Alnylam Pharmaceuticals
@Alnylam
RNAi therapeutics target disease at its roots rather than just treating symptoms. Based on Nobel Prize-winning science, these genetic medicines silence disease-causing genes before unwanted proteins are made.
5 key facts: news.alnylam.com/rnai/articles/rnai-therapeutics-5-things…
#rnai #geneticmedicine -
Alnylam Pharmaceuticals
@Alnylam
Ziggy’s journey with primary #hyperoxaluria type 1 (#ph1) brings many challenges. Still, he embraces life with energy, curiosity and joy. His parents want others to know there is hope and support for families affected by this #raredisease. Learn more: www.livingwithph1.eu/support-and-resources
-
Alnylam Pharmaceuticals
@Alnylam
RNA interference (RNAi) is a naturally occurring process of gene regulation that is already at work inside your body. RNAi therapeutics utilize this process to silence the genes that cause or contribute to disease. Learn more about RNAi? www.alnylam.com/our-science/the-science-of-rnai
#rnaitherapeutics -
Alnylam Pharmaceuticals
@Alnylam
How do we advance RNAi therapeutics from discovery to patients with industry-leading speed and success rates? Using precise chemistry, innovative delivery methods, advanced analytics, and cutting-edge manufacturing, we’re bringing new treatments to more patients, sooner.
-
Alnylam Pharmaceuticals
@Alnylam
Living with disease is noisy. The sounds of endless doctor visits, tests, managing medication and having to decline invitations to do things you really want to do...these sounds mute the joy of life. But what happens when disease is silenced?
#silencedisease #amplifylife #rnai -
Alnylam Pharmaceuticals
@Alnylam
HCPs: The burden of living with acute hepatic #porphyria (AHP) can greatly impact your patients’ quality of life. People living with AHP may have higher risk of long-term complications that have an immense emotional toll including depression and anxiety.
-
Alnylam Pharmaceuticals
@Alnylam
For Ziggy’s parents, Jackie and Colin, the Rowan tree they planted represents more than hope — it’s a symbol of Ziggy’s strength and resilience as they help him navigate life with primary #hyperoxaluria type 1 (#ph1).
Watch Ziggy’s PH1 journey: www.livingwithph1.eu/support-and-resources -
Alnylam Pharmaceuticals
@Alnylam
Proud to be named one of America's Most Responsible Companies by Newsweek for the 4th year running! This recognition reflects our commitment to our communities and responsible corporate citizenship.
Learn more: www.alnylam.com/about-alnylam/corporate-responsibility
#csr #esg #sustainability #newsweek -
Alnylam Pharmaceuticals
@Alnylam
Think of your body as an orchestra. DNA or genes are the sheet music and proteins are the musicians. When the instructions contain errors, disease can occur. #rnainterference (#rnai) helps regulate gene activity, treating disease.
Sponsored content w/ Vox www.vox.com/ad/459936/the-genetic-technology-that-could-s… -
Alnylam Pharmaceuticals
@Alnylam
U.S. HCPs: Navigating a #raredisease like PH1 requires a well-coordinated care team. In this article, pediatric nephrologist, Dr. Raymond Quigley, discusses how specialist collaboration can support timely diagnosis and highlights advances in disease management.
-
Alnylam Pharmaceuticals
@Alnylam
Our CEO, Dr. Yvonne Greenstreet, joined @KatieGreifeld on @BloombergTV from #jpmhealthcare this week to discuss the powerful foundation we’ve built at Alnylam and our strategy for driving the next era of growth.
-
Alnylam Pharmaceuticals
@Alnylam
Our CEO, Dr. Yvonne Greenstreet, joined @matthewherper and @statnews at the STAT@JPM event this week, highlighting our phenomenal progress at Alnylam and our ambitious vision for the future.
Watch the fireside chat: www.statnews.com/event/stat-at-jpm-live-event-2026/ -
Alnylam Pharmaceuticals reposted
BiotechTV
@BiotechTV
𝐒𝐅 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐖𝐞𝐞𝐤: @Alnylam CEO Yvonne Greenstreet discusses the launch of Amvuttra in ATTR-CM and the company's new 2030 ambitions. $ALNY
Full video: www.biotechtv.com/post/alnylam-pharmaceuticals-january-13…This media couldn't be displayed. See it on the original post. -
Alnylam Pharmaceuticals
@Alnylam
When RNAi therapeutics silence the genes that cause disease, the everyday joys of life can be amplified. Learn more about this innovative approach to treating disease, pioneered by Alnylam: [www.silencedisease.com
#silencedisease #rnai #rnaitherapeutics -
Alnylam Pharmaceuticals
@Alnylam
Earlier today, our CEO Dr. Yvonne Greenstreet presented at #jpm26, providing updates on our performance, platform, and pipeline.
Missed our presentation? Catch the replay here: investors.alnylam.com/events
#rnai #rnaitherapeutics #sirna #biotech -
Alnylam Pharmaceuticals
@Alnylam
We've unveiled our new five-year strategy and shared preliminary Q4 and FY2025 global net product revenues, 2026 pipeline goals and product sales outlook.
Read the press release: investors.alnylam.com/press-release?id=bed48a74-b01e-454e…
Join our live #jpm26 webcast tomorrow at 9 AM PT: investors.alnylam.com/events -
Alnylam Pharmaceuticals
@Alnylam
HCPs: Every acute hepatic #porphyria (AHP) attack matters. Your patient’s next attack could have life-changing consequences, like irreversible neurologic damage. Learn how timely diagnosis and management can help avoid potentially devastating outcomes.
-
Alnylam Pharmaceuticals
@Alnylam
The Alnylam Assist® program offers support services to patients who are prescribed one of our products. Our team of experts are here to help patients access and understand treatment.
-
Alnylam Pharmaceuticals
@Alnylam
Living with disease is noisy. The sounds of doctor visits, tests, managing medication, and declining things you want to do can mute the joy of life. But what happens when disease is silenced?
#silencedisease #amplifylife #rnai #rnaitherapeutics -
Alnylam Pharmaceuticals
@Alnylam
RNAi therapeutics are a type of medicine, pioneered by Alnylam, that treats disease by targeting and disabling specific mRNA (messenger RNA). #sciencecurious to learn more about the science of #rnai? Watch and learn more: www.alnylam.com/our-science/the-science-of-rnai
#rnaitherapeutics #genesilencing -
Alnylam Pharmaceuticals
@Alnylam
This past year has been truly remarkable as we celebrated important advancements in #rnai science, worked to deliver innovative medicines for patients, and strengthened our award-winning culture. Wishing everyone a joyful new year and best wishes for a fantastic 2026!
-
Alnylam Pharmaceuticals
@Alnylam
Eleven years strong as a Boston Globe #topplacetowork. Exceptional science requires exceptional people, and our team’s “Challenge Accepted!” mindset continues to set us apart as a leader in #rnai therapeutics and a great place to grow. Read more: news.alnylam.com/careers-culture/articles/11-years-11-ins…
-
Alnylam Pharmaceuticals
@Alnylam
Cells use messenger RNA (mRNA) to carry instructions from DNA to make proteins. Sometimes, unwanted proteins cause or contribute to disease. #rnai therapeutics disrupt this process by targeting specific mRNA molecules and preventing the production of disease-associated proteins.
-
Alnylam Pharmaceuticals
@Alnylam
Living with disease is noisy. The sounds of endless doctor visits, tests, managing medication and having to decline invitations to do things you really want to do...these sounds mute the joy of life. But what happens when disease is silenced?
#silencedisease #amplifylife #rnai -
Alnylam Pharmaceuticals
@Alnylam
Last week, we broke ground on a $250M expansion of our Norton, MA (USA) manufacturing facility. This investment reflects our commitment to innovation and the Massachusetts life sciences ecosystem, ensuring #rnai-based medicines are produced here at scale for patients worldwide.
This media couldn't be displayed. See it on the original post. -
Alnylam Pharmaceuticals
@Alnylam
RNA interference (RNAi) is a naturally occurring process of gene regulation that is already at work inside your body. RNAi therapeutics utilize this process to silence the genes that cause or contribute to disease. Learn more about RNAi? www.alnylam.com/our-science/the-science-of-rnai
#rnaitherapeutics -
Alnylam Pharmaceuticals
@Alnylam
We're investing $250M to expand our Norton, MA facility to substantially increase capacity for clinical and commercial drug substance to meet growing worldwide demand for #rnaitherapeutics and support implementation of our siRELIS™ platform.
-
Alnylam Pharmaceuticals
@Alnylam
We’re #alnylamproud to be named a #gptw again in 🇫🇷 France, 🇩🇪 Germany, 🇮🇹 Italy, 🇳🇱 Netherlands, 🇨🇦 Canada, 🇪🇸 Spain, 🇧🇷 Brazil, 🇺🇸 USA - and congratulations to our🇨🇭 Switzerland and 🇬🇧 United Kingdom offices for being certified for eight consecutive years!
-
Alnylam Pharmaceuticals
@Alnylam
Living an amplified life with disease means your disease doesn’t dominate your day-to-day, allowing you to focus on doing what you love with the people who matter most. Helping people get to that place is why we’ve pioneered #rnaitherapeutics.
#silencedisease #amplifylife -
Alnylam Pharmaceuticals
@Alnylam
HCPs: Check out this interactive acute hepatic #porphyria (AHP) case study to review a hypothetical diagnostic journey with AHP — see how your knowledge of this #raredisease compares with other physicians.
-
Alnylam Pharmaceuticals
@Alnylam
Proud to sponsor the 2025 Nature Conferences "Cracking the Code: Nucleic Acid Medicines Coming of Age" with @ionis_pharma and @harvardstemcell. Our SVP Mano Manoharan delivered a keynote on chemistry's role in RNA therapeutics. Thank you for the scientific exchange!
-
Alnylam Pharmaceuticals
@Alnylam
How do we advance RNAi therapeutics from discovery to patients with industry-leading speed and success rates? Using precise chemistry, innovative delivery methods, advanced analytics, and cutting-edge manufacturing, we’re bringing new treatments to more patients, sooner.
-
Alnylam Pharmaceuticals
@Alnylam
Less than 1% of drug ideas become approved medicines. Human genetic insights can improve those odds. We've recently partnered with Alliance for Genomic Discovery, FinnGen, and PRECISE Singapore to deepen our access to diverse genetic data to fuel drug development.
#rnai -
Alnylam Pharmaceuticals
@Alnylam
As one of the top fundraising teams for #bioball, we had the opportunity to hit the court alongside our longtime @SpOlympicsMA partners, Heller’s Angels at TD Garden! Honored to be part of a #biotech community that champions accessibility and inclusion in sports. #specialolympics
-
Alnylam Pharmaceuticals
@Alnylam
Meaningful impact happens when we work together. Through #alnylamchallengers, we’re collaborating with some of Boston’s leading healthcare institutions to empower Care Navigators who connect underserved communities to essential care.
Learn more: news.alnylam.com/responsibility/articles/alnylam-challeng… -
Alnylam Pharmaceuticals
@Alnylam
Eleven years strong as a Boston Globe #topplacetowork. Exceptional science requires exceptional people, and our team’s “Challenge Accepted!” mindset continues to set us apart as a leader in #rnai therapeutics and a great place to grow. Read more: news.alnylam.com/careers-culture/articles/11-years-11-ins…
-
Alnylam Pharmaceuticals
@Alnylam
We've announced Board of Directors changes: The appointment of Stuart Arbuckle, who brings extensive experience at Vertex, Amgen and GSK, and the departures of Mike Bonney and Carolyn Bertozzi. We thank Mike and Carolyn for their leadership and commitment to Alnylam's mission.
-
Alnylam Pharmaceuticals
@Alnylam
Behind each of these logos is a story of change. On this #givingtuesday, discover the organizations we’re honored to parter with year-round, and see how you can make a difference too. #csr
-
Alnylam Pharmaceuticals
@Alnylam
Care Navigators bridge clinical care and lasting well-being for underserved communities. Through our $2M #alnylamchallengers investment, we’re supporting those breaking down barriers to care in Boston.
Learn more: news.alnylam.com/responsibility/articles/alnylam-challeng…
#bostonhealth #corporateresponsibility -
Alnylam Pharmaceuticals
@Alnylam
Congratulations to Sculpta Bio on winning the Alnylam Science and Entrepreneurship Award at our 2025 BioVenture Challenge! This $100k grand prize will help Dr. Neal Amin and the Sculpta Bio team advance their innovative technology. Thank you to all participants and Nucleate!
-
Alnylam Pharmaceuticals
@Alnylam
Alnylam UK were honored to be named Company of the Year at the 2025 PMEA Awards last week. This recognition reflects our commitment to transforming care through innovative approaches that put patients at the center of everything we do. Congrats to our UK and Ireland team. #pmea25
-
Alnylam Pharmaceuticals
@Alnylam
Every day, we work with purpose to bring life-changing therapies to patients. Recently, a TTR patient visited PCI to share his story and inspire our external partners. #patientimpact
-
Alnylam Pharmaceuticals reposted
Nature Conferences
@NatureConf
Reminder that the deadline to register has been extended to November 24!
Join us in Boston with @Alnylam @ionispharma @harvardstemcell @BostonChildrens @NatureBiotech @Nature @NatRevDrugDisc and over 20 global experts. 🧪🧬
Register > go.nature.com/3T44wyv -
Alnylam Pharmaceuticals
@Alnylam
Life expectancy in Boston can vary by 23 years between neighborhoods just miles apart. That’s why we’re investing $2M through #alnylamchallengers to help patients in underserved communities access vital social and medical care.
Learn more: news.alnylam.com/responsibility/articles/alnylam-challeng…
#bostonhealth -
Alnylam Pharmaceuticals
@Alnylam
For HCPs: When it comes to transthyretin amyloidosis with cardiomyopathy (ATTR-CM), progression can be fast and detrimental. If you suspect a patient may have ATTR-CM, a timely diagnosis is essential. Learn how to confirm or rule out ATTR-CM.
-
Alnylam Pharmaceuticals
@Alnylam
This #nationalcaregiversmonth, hear from Marc, who lives with transthyretin #amyloidosis with cardiomyopathy (ATTR-CM), and his wife Ruth, as they share how they work together as a team to face Marc’s condition with resilience and hope.
-
Alnylam Pharmaceuticals
@Alnylam
Congratulations to our CSO Kevin Fitzgerald on being named @PharmaVoice's inaugural Trailblazer! Kevin embodies our "Challenge Accepted" ethos, leading #rnai innovation with vision and commitment to patients. Well deserved!
Read more: www.pharmavoice.com/news/kevin-fitzgerald-alnylam-rna-chi…
#innovation -
Alnylam Pharmaceuticals reposted
MIT Biology
@MITBiology
Alnylam Pharmaceuticals has established a named fund in honor of its co-founder, an MIT Institute Professor and Nobel laureate. The Phil Sharp-Alnylam Fund for Emerging Scientists will support MIT biology graduate students and faculty. @Alnylam
-
Alnylam Pharmaceuticals
@Alnylam
We are excited to partner with FinnGen to unlock genetic insights to accelerate the development of #rnaitherapeutics. This collaboration will help us expand the impact of RNAi therapeutics to treat more diseases. Learn more: www.finngen.fi/en/alnylam-becomes-newest-partner-finngen-…
-
Alnylam Pharmaceuticals
@Alnylam
This #veteransday, we honor the courage and commitment of all who have served, especially the veterans within our Alnylam community. Your service inspires us, and your continued contributions make us #alnylamproud. Thank you.
-
Alnylam Pharmaceuticals
@Alnylam
Doctor visits, tests, pharmacy trips, medication - the sounds of these things make living with disease noisy. But when you #silencedisease, these things become less prevalent and the joy of life can be amplified. We've pioneered #rnai therapeutics to do just that - #amplifylife.
-
Alnylam Pharmaceuticals
@Alnylam
That’s a wrap on #aha25, where we presented our latest research for #rnai therapeutics in transthyretin #amyloidosis with cardiomyopathy (ATTR-CM) and #hypertension. Learn more: capella.alnylam.com/2025/11/08/aha-2025
-
Alnylam Pharmaceuticals
@Alnylam
In transthyretin #amyloidosis with cardiomyopathy (ATTR-CM), damage to the heart can progress over time. At #aha25, we’re highlighting data on #rnai therapeutics and heart function and structure in ATTR-CM. Read our press release: investors.alnylam.com/press-releases
-
Alnylam Pharmaceuticals
@Alnylam
We’re headed to #aha25, where we will be sharing new data from our transthyretin #amyloidosis with cardiomyopathy (ATTR-CM) program. Check out what we have planned.
-
Alnylam Pharmaceuticals
@Alnylam
We were proud to wear blue alongside the @OHFTweet during Hyperoxaluria Awareness Week.
United for #hyperoxaluria, we’re committed to continuing to raise awareness and drive meaningful change for people living with primary hyperoxaluria type 1 (PH1) and their loved ones 💙 -
Alnylam Pharmaceuticals
@Alnylam
The Alnylam Assist® program offers support services to patients who are prescribed one of our products. Our team of experts are here to help patients access and understand treatment.
-
Alnylam Pharmaceuticals
@Alnylam
What is primary #hyperoxaluria type 1 (PH1)? Presenting: PH1, wrapped.
This Hyperoxaluria Awareness Week, turn up the volume on awareness and stream the world’s first album about PH1 on YouTube.
Stream now: www.youtube.com/@TheRecurringStones?cbrd=1&ucbcb=1 -
Alnylam Pharmaceuticals reposted
Nature Conferences
@NatureConf
Hear from previous speakers all you can expect for Cracking the Code 2.
Join us in Boston next month to hear the latest in #nucleicacidmedicines & #clinicalsuccesses. Registration closes this Friday, Nov 7.
🎟️>go.nature.com/3T44wyv
youtu.be/HXyrkKx_YJI -
Alnylam Pharmaceuticals
@Alnylam
Now streaming: The world’s first album about primary #hyperoxaluria type 1 (PH1). United for Hyperoxaluria, we’ve dropped a YouTube playlist featuring a track with @OHFTweet, aiming to turn up awareness of PH1 this Hyperoxaluria Awareness Week. www.youtube.com/@TheRecurringStones?cbrd=1&ucbcb=1
-
Alnylam Pharmaceuticals
@Alnylam
It was inspiring to come together to reflect on the stories that drive our work in ATTR amyloidosis.
Thanks to @AmyloidosisA and the community for reminding us why every voice matters. #worldamyloidosisday -
Alnylam Pharmaceuticals
@Alnylam
We’ve reported Q3 2025 financial results and highlights of recent period activity. Join us LIVE TODAY at 8:30 AM ET to hear from our leadership or access the replay later today at: investors.alnylam.com/events
Read the Q3 2025 financial results press release: investors.alnylam.com/press-releases -
Alnylam Pharmaceuticals
@Alnylam
Women’s pain is often dismissed, delaying diagnosis of serious conditions like Donna’s acute hepatic #porphyria (AHP), which took 10+ years. Recognizing seemingly unrelated symptoms can help AHP patients regain control.
-
Alnylam Pharmaceuticals
@Alnylam
We will share third quarter 2025 financial results this Thursday, October 30. Register and join us for the live webcast at 8:30 a.m. ET or catch a replay later that day here: investors.alnylam.com/events.
#rnai #rnaitherapeutics #sirna -
Alnylam Pharmaceuticals
@Alnylam
On #worldamyloidosisday, we stand with patients, caregivers, clinicians and advocates working to increase awareness and drive action for holistic, person-centered care in ATTR amyloidosis.
Read more about our work to support this effort: news.alnylam.com/patient-focus/articles/looking-beyond-cl… -
Alnylam Pharmaceuticals
@Alnylam
As we approach #worldamyloidosisday, the voices of those living with ATTR amyloidosis and those who care for them remind us that optimal care should reflect individual needs, beyond the clinical symptoms of disease. We’re proud to help raise awareness with the community.
-
Alnylam Pharmaceuticals
@Alnylam
Proud to be named a @ScienceMagazine Top Employer for 2025, marking our 7th consecutive year! Thank you to our incredible team for making Alnylam a place where science and culture come together.
See the full list: www.science.org/content/article/2025-s-top-employers-inno…
#sctopemployers #biotech #pharmacareers -
Alnylam Pharmaceuticals
@Alnylam
It's her big game. You want to be there AND be fully present. Living with disease makes that difficult. Over time, the sounds of disease - doctor visits, tests, managing medication - mute the joy of life. But what happens when you #silencedisease?
#amplifylife #rnaitherapeutics -
Alnylam Pharmaceuticals
@Alnylam
Last week marked the end of Hispanic Heritage Month. Alnylam colleagues celebrated the rich histories, traditions, and contributions of Hispanic and Latinx communities. Through connection and storytelling, we embraced the power of culture and community.
#hispanicheritagemonth -
Alnylam Pharmaceuticals
@Alnylam
This #healthliteracymonth, we’re highlighting how Alnylam is advancing #healthequity through accessible, patient-friendly information.
Read more about our ongoing efforts: news.alnylam.com/patient-focus/articles/alnylams-commitme… -
Alnylam Pharmaceuticals
@Alnylam
Recently, a patient from our TTR community visited Kinovate Life Sciences, our partner in oligonucleotide material supply. Hearing directly from patients brings powerful perspective to our work and reinforces the shared purpose that drives us.
-
Alnylam Pharmaceuticals
@Alnylam
Last weekend, our advocacy team joined the @ABCardio1 to celebrate 50 years of championing health equity. We’re proud to stand alongside ABC in advancing heart health and addressing the unique experiences of different communities in #cardiovascular care. #abc50years
-
Alnylam Pharmaceuticals
@Alnylam
Ziggy’s parents knew something wasn’t right. Their persistence helped lead to his diagnosis of primary #hyperoxaluria type 1 (#ph1), a genetic #raredisease. For PH1 information and support, check out @OHFTweet. See how Jackie and Colin advocated for Ziggy: www.livingwithph1.eu/support-and-resources
-
Alnylam Pharmaceuticals
@Alnylam
We believe all patients, regardless of their diagnosis, have the potential to benefit from the promise that #rnaitherapeutics hold to #silencedisease and #amplifylife. That’s why we’ve pioneered this innovative approach and are working to bring it to as many patients as possible.
-
Alnylam Pharmaceuticals
@Alnylam
HCPs: Do you have a patient presenting with severe, diffuse abdominal pain and seemingly unrelated symptoms? It could be acute hepatic #porphyria (AHP). Random (spot) urine tests are the primary method to help diagnose AHP and a genetic test can determine the type.
-
Alnylam Pharmaceuticals
@Alnylam
What an incredible week! Last week, 1,000+ colleagues across 13 countries volunteered 3,000+ hours supporting 51 charitable organizations during our annual Community Service Week. Thank you to our volunteers and community partners!
#communityservice #csr -
Alnylam Pharmaceuticals
@Alnylam
October is Health Literacy Month. When you’re exploring clinical trials for yourself or a loved one, understanding the information matters. We publish our trial summaries in plain language because everyone deserves access to clear health information.
-
Whittier Street Health Center
@Whittier_Boston
Whittier Street Health Center’s Day of Giving on October 1st was a joyful celebration of community, compassion, and care. We served over 1,500 patients and each received distributed coats, socks, goody bags and health resources.
Post not available here, view on X
Whittier Street Health Center
@Whittier_Boston
On behalf of the patients we serve, we extend a heartfelt thank you to the Alnylam Pharmaceuticals team for their significant contributions during our Day of Giving. our time, talents, and commitment to service is greatly appreciated!
Alnylam Pharmaceuticals
@Alnylam
Thank you for the opportunity to give back alongside your team! We're honored to support the important work you do in our community.
-
Alnylam Pharmaceuticals
@Alnylam
On #manufacturingday, we celebrate our colleagues whose work makes RNAi therapeutics possible. From advancing #sirna manufacturing to managing global supply chains, they’ve helped bring 6 medicines to patients and move dozens more into the clinic.
-
Alnylam Pharmaceuticals
@Alnylam
#rna researchers! Submit your abstract - www.cvent.com/c/abstracts/3a7e09c5-cd05-4307-b56d-79957fd… - by Oct 10 to present at Cracking the Code: Nucleic Acid Medicines Coming of Age, a @Nature conference we’re co-organizing with @ionispharma & @harvardstemcell.
Attend: natureconferences.streamgo.live/cracking-the-code-2/register
#sirna #rnai -
Alnylam Pharmaceuticals
@Alnylam
Didn’t attend #hfsa2025 or want a recap? Discover our latest research and the potential of #rnai therapeutics in #amyloidosis with #cardiomyopathy (ATTR-CM): capella.alnylam.com/2025/09/28/vutri-hfsa-2025
-
Alnylam Pharmaceuticals
@Alnylam
Today we announced that the first patient has been dosed in our Phase 3 Cardiovascular Outcomes Trial evaluating the potential of #rnai in reducing the risk of major adverse #cardiovascular events in patients with uncontrolled #hypertension. Learn more: investors.alnylam.com/press-releases
-
Alnylam Pharmaceuticals
@Alnylam
This week, 1,000 Alnylam colleagues are rallying together for our annual Community Service Week. From Boston to Tokyo and a dozen countries in between, we're supporting 50+ incredible nonprofits working to build stronger, healthier communities worldwide. #communityservice #csr
-
Alnylam Pharmaceuticals
@Alnylam
Last week, we partnered with @alzassociation to #askaboutalzheimer’s and hear moving stories from Dan Hogan and Alnylam’s Cindy Courtney. Their experiences highlighted both the challenges and the resilience behind an Alzheimer’s diagnosis.
-
Alnylam Pharmaceuticals
@Alnylam
At @HFSA we shared new data evaluating the impact of #rnai on gastrointestinal events – a common and challenging manifestation for patients living with #amyloidosis with #cardiomyopathy (ATTR-CM). Read our press release: investors.alnylam.com/press-releases
-
Alnylam Pharmaceuticals
@Alnylam
At #attrcongress, Christine Chiti, Clinical TTR Nurse Specialist previewed a publication exploring gaps in care for people living with #amyloidosis with #cardiomyopathy (ATTR-CM), from mental health to care coordination and beyond.
-
Alnylam Pharmaceuticals
@Alnylam
Proud to be at the #attrcongress. This invaluable forum offers unparalleled engagement with the #attr community. We’re excited to share research on treatment outcomes and physician preferences to deepen understanding and support better care for people with #attr #amyloidosis.
-
Alnylam Pharmaceuticals
@Alnylam
Frances’ story is unique, yet all too common. This World Alzheimer’s Month, we stand with patients and their families to #askaboutalzheimers to raise awareness, whilst working to research the potential of RNAi therapeutics to treat neurological conditions.
-
Alnylam Pharmaceuticals
@Alnylam
Sparking curiosity in #science, one secret message at a time! Our uLearn with Alnylam team had a great day at @cambscifest showing families the chemistry of invisible ink—and watching kids’ faces light up as hidden messages appeared.
#cambridgesciencefestival -
Alnylam Pharmaceuticals
@Alnylam
For the first time ever, Alnylam has been named to Great Places to Work across ALL of Europe! Congratulations to our incredible European colleagues who live our #challengeaccepted mindset every day. This recognition is a testament to the amazing culture you’ve built.
#gptw -
Alnylam Pharmaceuticals
@Alnylam
We're excited to join the Alliance for Genomic Discovery (AGD), strengthening our ability to identify novel therapeutic targets through real-world genomic insights. This diverse dataset will help accelerate #rnaitherapeutics development for patients.
@Illumina -
Alnylam Pharmaceuticals
@Alnylam
Living with disease is noisy. The sounds of endless doctor visits, tests, managing medication and having to decline invitations to do things you really want to do...these sounds mute the joy of life. But what happens when disease is silenced?
#silencedisease #amplifylife #rnai -
Alnylam Pharmaceuticals reposted
Nature Conferences
@NatureConf
Present your research in front of the biggest names in RNA medicine, network and meet new peers. Poster + oral presentation spaces for abstracts still available> go.nature.com/4mhVASr
@Alnylam @ionispharma @harvardstemcell @BostonChildrens @NatureBiotech @Nature @NatRevDrugDisc -
Alnylam Pharmaceuticals
@Alnylam
Happy #hispanicheritagemonth! Sept 15-Oct 15, we celebrate the rich histories, vibrant cultures, and contributions of the Hispanic and Latinx community.
At Alnylam, we're celebrating through internal events that showcase culture, foster connection, and encourage allyship. -
Alnylam Pharmaceuticals
@Alnylam
Excited to welcome Bryan Supran as our new Chief Legal Officer! With 25+ years in pharma legal leadership and a track record advancing science-driven patient initiatives, Bryan will help drive our continued growth as the leader in #rnai therapeutics. Welcome to the team!
-
Alnylam Pharmaceuticals
@Alnylam
Ziggy’s parents knew something wasn’t right. Their persistence helped lead to his diagnosis of primary #hyperoxaluria type 1 (#ph1), a genetic #raredisease. For PH1 information and support, check out @OHFTweet. See how Jackie and Colin advocated for Ziggy: www.livingwithph1.eu/support-and-resources
-
Alnylam Pharmaceuticals
@Alnylam
Alnylam has been named a @FastCompany Best Workplace for Innovators for the fifth year in a row. This honor celebrates cultures that empower employees to innovate at every level.
Read more: news.alnylam.com/careers-culture/articles/five-row-alnyla…
#fastcompany #bestworkplaces #biotech #biopharma -
Alnylam Pharmaceuticals
@Alnylam
HCPs: Characterized by severe, diffuse abdominal pain and a range of other seemingly unrelated symptoms, acute hepatic #porphyria (AHP) can be misleading and is often misdiagnosed.
-
Alnylam Pharmaceuticals
@Alnylam
It’s an honor to be recognized as a Breakthrough Honoree on the @FiercePharma ‘Fierce 50’ list. This acknowledgment underscores the important #rnai research we’re undertaking in #hypertension, one of the leading risk factors for #cvd and death worldwide.
-
Alnylam Pharmaceuticals
@Alnylam
Missed #esccongress or want to revisit the highlights? Discover our latest research updates in #hypertension and ATTR-CM and learn more about the potential for #rnai therapeutics in cardiovascular disease.
Discover the latest data: capella.alnylam.com/2025/08/30/esc-2025 -
Alnylam Pharmaceuticals
@Alnylam
As #esccongress 2025 comes to a close, Tolga Tanguler, our Chief Commercial Officer, shares his top 3 takeaways from the conference. Tune in!
-
Alnylam Pharmaceuticals
@Alnylam
Hear from some of the Alnylam team at the #esccongress in Madrid and how inspired they have been by the patient-centricity of the event and the collaboration to advance care for cardiovascular patients across the world.
-
Alnylam Pharmaceuticals
@Alnylam
Learn more about our new #rnai data in #amyloidosis with #cardiomyopathy (ATTR-CM), presented today at the European Society of Cardiology Congress.
Read our press release: investors.alnylam.com/press-releases
#esccongress -
Alnylam Pharmaceuticals
@Alnylam
Today at the #esccongress 2025 we announced plans to initiate our Phase 3 Cardiovascular Outcomes Trial following Phase 2 results presented highlighting the potential of #rnai in #hypertension, one of the leading risk factors for #cvd and death worldwide. investors.alnylam.com/press-releases
-
Alnylam Pharmaceuticals
@Alnylam
Proud to have Carol Pitcher-Towner represent our team on a gender equity panel at #rise2025 @escardio in Madrid. The conference connects women in cardiology to build skills for career advancement. Carol shared valuable insights with fellow leaders in the field! #esccongress
-
Alnylam Pharmaceuticals
@Alnylam
We’re excited to be at #esccongress to share how we’re harnessing the potential of #rnaitherapeutics in #cardiology. Over the coming days, we’ll present data in ATTR-CM and #hypertension and connect with cardiologists to discuss our research in the cardiovascular space. @escardio
-
Alnylam Pharmaceuticals
@Alnylam
RNAi therapeutics target disease at its roots rather than just treating symptoms. Based on Nobel Prize-winning science, these genetic medicines silence disease-causing genes before unwanted proteins are made.
5 key facts: news.alnylam.com/rnai/articles/rnai-therapeutics-5-things…
#rnai #geneticmedicine -
Alnylam Pharmaceuticals
@Alnylam
HCPs: The burden of living with acute hepatic #porphyria (AHP) can greatly impact your patients’ quality of life. People living with AHP may have higher risk of long-term complications that have an immense emotional toll including depression and anxiety.
-
Alnylam Pharmaceuticals
@Alnylam
Congratulations to our partner @Regeneron on yesterday's positive Phase 3 results for cemdisiran, an investigational #rnai therapeutic in development for generalized myasthenia gravis (gMG). This makes 15 positive Phase 3 trials for Alnylam-discovered #rnaitherapeutics. #sirna
-
Alnylam Pharmaceuticals
@Alnylam
We're honored to be recognized as a #humankind100 company for 2025! This continued recognition reflects our commitment to making a positive impact through our #rnai therapeutics and community engagement.
Learn more about this recognition: rankings.humankind.co/2025/alnylam-pharmaceuticals-inc-2025 -
Alnylam Pharmaceuticals
@Alnylam
We’re taking #rnai on the road to Madrid for @escardio Congress!
Heading to #esccongress? Visit us at Booth E150, Hall 8 to connect with the Alnylam team and explore the potential of RNAi therapeutics in cardiology. -
Alnylam Pharmaceuticals
@Alnylam
#rna researchers! Submit your abstract - www.cvent.com/c/abstracts/3a7e09c5-cd05-4307-b56d-79957fd… - by Oct 10 to present at Cracking the Code: Nucleic Acid Medicines Coming of Age, a @Nature conference we’re co-organizing with @ionispharma & @harvardstemcell.
Attend: natureconferences.streamgo.live/cracking-the-code-2/register
#sirna #rnai -
Alnylam Pharmaceuticals
@Alnylam
Our partnership with Forward·Inc brought together newcomer entrepreneurs creating everything from AI platforms to hot sauce. Congrats to winner Layth Massoud! Learn more about the competition: news.alnylam.com/responsibility/articles/supporting-newco…
-
Alnylam Pharmaceuticals
@Alnylam
HCPs: Every acute hepatic #porphyria (AHP) attack matters. Your patient’s next attack could have life-changing consequences, like irreversible neurologic damage. Learn how timely diagnosis and management can help avoid potentially devastating outcomes.
-
Alnylam Pharmaceuticals
@Alnylam
Investing in the next generation of biotech talent! Our internship, co-op, and fellowship programs offer hands-on experience with RNAi science and real career development opportunities.
Learn more: www.alnylam.com/careers
#internshipprograms #rnai -
Alnylam Pharmaceuticals
@Alnylam
We believe all patients, regardless of their diagnosis, have the potential to benefit from the promise that #rnaitherapeutics hold to #silencedisease and #amplifylife. That’s why we’ve pioneered this innovative approach and are working to bring it to as many patients as possible.
-
Alnylam Pharmaceuticals
@Alnylam
Earlier this year, our own Samip Dhakal took on the #everest Base Camp trek with the Timmerman Traverse, helping raise over $800k for #cancer research. Read his story of challenge, connection and purpose. news.alnylam.com/responsibility/articles/everest-and-ever…
-
Alnylam Pharmaceuticals
@Alnylam
HCPs: Check out this interactive acute hepatic #porphyria (AHP) case study to review a hypothetical diagnostic journey with AHP — see how your knowledge of this #raredisease compares with other physicians.
-
Alnylam Pharmaceuticals
@Alnylam
Join us at the ESC 2025 Congress in Madrid as we unveil new data on the power of #rnai in #cardiology and its potential to transform the treatment of CVD – @escardio Congress, 29 Aug – 1 Sept 2025.
#esccongress -
Alnylam Pharmaceuticals
@Alnylam
Thrilled to celebrate our CEO Yvone Greenstreet’s inclusion on @Forbes 50 over 50 for 2025! The list honors trailblazers driving innovation & impact. Her decades in biopharma have helped deliver life-changing medicines globally. Congrats also to Amy Schulman! #forbes50over50
-
Alnylam Pharmaceuticals
@Alnylam
The Alnylam Assist® program offers support services to patients who are prescribed one of our products. Our team of experts are here to help patients access and understand treatment.
-
Alnylam Pharmaceuticals
@Alnylam
Living with disease is noisy. The sounds of doctor visits, tests, managing medication, and declining things you want to do can mute the joy of life. But what happens when disease is silenced?
#silencedisease #amplifylife #rnai #rnaitherapeutics -
Alnylam Pharmaceuticals
@Alnylam
For Ziggy’s parents, Jackie and Colin, navigating his primary #hyperoxaluria type 1 (#ph1) diagnosis has meant learning, advocating and adjusting to the unknown. But along the way, their journey has been defined by unwavering strength, hope and love.
-
Alnylam Pharmaceuticals
@Alnylam
HCPs: Do you have a patient presenting with severe, diffuse abdominal pain and seemingly unrelated symptoms? It could be acute hepatic #porphyria (AHP). Random (spot) urine tests are the primary method to help diagnose AHP and a genetic test can determine the type.
-
Alnylam Pharmaceuticals
@Alnylam
In Q2, we achieved 64 percent growth in net product revenues, led by the strong U.S. launch of Amvuttra. With approximately 1,400 patients already on treatment, it’s clear we’re meeting a real and urgent need.
-
Alnylam Pharmaceuticals
@Alnylam
This morning, we reported Q2 2025 financial results and key updates. Join our LIVE webcast TODAY at 8:30 am ET or catch the replay later: investors.alnylam.com/events
Read the full press release: investors.alnylam.com/press-releases
#rnai #rnaitherapeutics #sirna -
Alnylam Pharmaceuticals
@Alnylam
A technical oversight in the Inflation Reduction Act misclassifies certain RNA and DNA-based medicines as small molecule drugs. The bipartisan MINI Act would fix this.
Read more in this STAT op-ed by our CEO, Dr. Yvonne Greenstreet: www.statnews.com/2025/07/24/mini-act-inflation-reduction-… -
Alnylam Pharmaceuticals
@Alnylam
We’re proud to celebrate Mano Manoharan’s induction into the 2025 MEDI Hall of Fame! This honor reflects his groundbreaking work in oligonucleotide therapeutics and lasting impact on medicinal chemistry.
#medicinalchemistry #acs #medihalloffame #scientificexcellence -
Alnylam Pharmaceuticals
@Alnylam
We'll be sharing 2nd Quarter 2025 financial results this Thursday, 7/31 at 8:30 AM ET, during a LIVE webcast. Register here: investors.alnylam.com/events and access the replay at the same link later in the day.
#rnai #rnaitherapeutics #sirna -
Alnylam Pharmaceuticals
@Alnylam
Ziggy’s journey with primary #hyperoxaluria type 1 (#ph1) brings many challenges. Still, he embraces life with energy, curiosity and joy. His parents want others to know there is hope and support for families affected by this #raredisease. Learn more: www.livingwithph1.eu/support-and-resources
-
Alnylam Pharmaceuticals
@Alnylam
Our CFO, Jeff Poulton, officially received his 2025 CFO of the Year award from the Boston Business Journal this week. Congratulations again Jeff!
#bbjcfo #cfooftheyear -
Alnylam Pharmaceuticals
@Alnylam
#rna researchers! Submit your abstract - www.cvent.com/c/abstracts/3a7e09c5-cd05-4307-b56d-79957fd… - by Oct 10 to present at Cracking the Code: Nucleic Acid Medicines Coming of Age, a @Nature conference we’re co-organizing with @ionispharma & @harvardstemcell.
Attend: natureconferences.streamgo.live/cracking-the-code-2/register
#sirna #rnai -
Alnylam Pharmaceuticals
@Alnylam
Doctor visits, tests, pharmacy trips, medication - the sounds of these things make living with disease noisy. But when you #silencedisease, these things become less prevalent and the joy of life can be amplified. We've pioneered #rnai therapeutics to do just that - #amplifylife.
-
Alnylam Pharmaceuticals
@Alnylam
HCPs: Characterized by severe, diffuse abdominal pain and a range of other seemingly unrelated symptoms, acute hepatic #porphyria (AHP) can be misleading and is often misdiagnosed.
-
Alnylam Pharmaceuticals
@Alnylam
Rapid advancement of the field of RNA Interference (#rnai) is changing the way that medicine treats rare and more common diseases. Having pioneered this innovative class of #genesilencing medicines, we are proud to be leading the charge. Sponsored content with
@NaturePortfolio -
Alnylam Pharmaceuticals
@Alnylam
For Ziggy’s parents, Jackie and Colin, the Rowan tree they planted represents more than hope — it’s a symbol of Ziggy’s strength and resilience as they help him navigate life with primary #hyperoxaluria type 1 (#ph1).
Watch Ziggy’s PH1 journey: www.livingwithph1.eu/support-and-resources -
Alnylam Pharmaceuticals
@Alnylam
Women’s pain is often dismissed, delaying diagnosis of serious conditions like Donna’s acute hepatic #porphyria (AHP), which took 10+ years. Recognizing seemingly unrelated symptoms can help AHP patients regain control.
-
Alnylam Pharmaceuticals
@Alnylam
Living with disease is noisy. The sounds of endless doctor visits, tests, managing medication and having to decline invitations to do things you really want to do...these sounds mute the joy of life. But what happens when disease is silenced?
#silencedisease #amplifylife #rnai -
Alnylam Pharmaceuticals
@Alnylam
Innovative science is only part of the equation when it comes to developing new medicines. Clinical research relies on partnerships with health care professionals and patient advocates but most importantly, the people who choose to participate in #clinicaltrials.
-
Alnylam Pharmaceuticals
@Alnylam
We’re proud to celebrate our Director of Patient Recruitment, Tricia Bucheit, for being named one of @1nHealth’s Patient Engagement Leaders for 2025. This recognition reflects her contributions to advancing #patientengagement.
-
Alnylam Pharmaceuticals
@Alnylam
Our 2024 Corporate Responsibility Report shows how Alnylam is making an impact. We support patients and employees, advance science, uplift communities, and protect the planet. Our work reflects our values and ambition to give back to society.
#corporateresponsibility #csr #esg -
Alnylam Pharmaceuticals
@Alnylam
Ziggy’s parents knew something wasn’t right. Their persistence helped lead to his diagnosis of primary #hyperoxaluria type 1 (#ph1), a genetic #raredisease. For PH1 information and support, check out @OHFTweet. See how Jackie and Colin advocated for Ziggy: www.livingwithph1.eu/support-and-resources
-
Alnylam Pharmaceuticals
@Alnylam
From a bold idea to FDA-approved treatments—#rnaitherapeutics are changing the way we treat disease. Curious about how #genesilencing works? Read the story: news.alnylam.com/rnai/articles/rnai-therapeutics-possibil…
#sirna #rna -
Alnylam Pharmaceuticals
@Alnylam
U.S. HCPs: Navigating a #raredisease like PH1 requires a well-coordinated care team. In this article, pediatric nephrologist, Dr. Raymond Quigley, discusses how specialist collaboration can support timely diagnosis and highlights advances in disease management.
-
Alnylam Pharmaceuticals
@Alnylam
Neurological diseases have a devastating impact, and #rnaitherapeutics have the potential to offer a promising approach. At Alnylam, we’re exploring ways to silence brain diseases, such as Alzheimer’s and Huntington’s disease.
Read more: news.alnylam.com/rnai/articles/new-therapeutic-approach-s…
#rnai #neurology -
Alnylam Pharmaceuticals
@Alnylam
While Pride Month is ending, our commitment is not. We’re proud to support our LGBTQ+ colleagues every day of the year. Click through to see highlights from our month-long global celebration and the people who make our culture so strong.
#pride2025 #pridemonth #lgbtq -
Alnylam Pharmaceuticals
@Alnylam
The Alnylam Assist® program offers support services to patients who are prescribed one of our products. Our team of experts are here to help patients access and understand treatment.
-
Alnylam Pharmaceuticals
@Alnylam
We’re honored to be a Corporate Ally in the
@BosBizJournal 2025 Business of Pride awards. This recognition reflects our year-round commitment to supporting the LGBTQ+ community through visibility, inclusion & belonging in our workplace and beyond.
#pride2025 #pridemonth #lgbtq -
Alnylam Pharmaceuticals
@Alnylam
At #bio2025, Paul Nioi, SVP of Research, spoke on how genetic medicine is reshaping what’s possible in care.
Arun Skaria, Head of DEI & CR, joined a conversation on leadership, workforce & equity in a changing #biotech landscape.
#bioconvention #geneticmedicine #dei -
Alnylam Pharmaceuticals reposted
Nature Conferences
@NatureConf
New conference alert 🚨
Cracking The Code, our event on nucleic acid therapies and clinical translation is back and this time in Boston! Get your early bird registration >>go.nature.com/3T44wyv
@Alnylam @ionispharma @harvardstemcell @Nature @NatureBiotech @NatRevDrugDisc -
Alnylam Pharmaceuticals
@Alnylam
Last week, at #bio2025, our CCO Tolga Tanguler led a panel on expanding access through collaboration across biopharma, policy, and patient communities to accelerate access, remove barriers, and ensure innovation delivers real-world benefits.
#bioconvention #biotechleadership -
Alnylam Pharmaceuticals
@Alnylam
Supporting patients starts with listening to those living with – or caring for loved ones with – serious and chronic conditions
Proud to join @CaregiverAction’s Corporate Leadership Council to elevate and support the #caregiver community. 💙 -
Alnylam Pharmaceuticals
@Alnylam
We’re proud to be a recipient of a Part the Cloud grant for the Gene Targeting Challenge to advance our work silencing a gene associated with Alzheimer’s disease. This award will support our goal to bring new hope to patients and families facing AD and other neurological diseases
Alzheimer's Association
@alzassociation
The Association and Part the Cloud have just announced $5 million in new funding to support four cutting-edge studies focused on gene targeting therapies for Alzheimer’s.
This unique and unprecedented funding program is focused on therapeutics that explore the genes involved in Alzheimer's risk and resistance.The grants will allow research teams to significantly expand the investigation of how genetics can inform personalized treatments for Alzheimer's and other dementias. www.alz.org/news/2025/alzheimers-association-part-the-clo…
#endalz #partthecloud #alzresearch -
Alnylam Pharmaceuticals
@Alnylam
Our CEO, Dr. Yvonne Greenstreet, joined Kendalle Burlin O'Connell and other leaders to cut the ribbon on the Massachusetts Pavilion at @BIOConvention. Proud to sponsor @MassBio and spotlight the innovation in MA transforming human health.
#bioconvention #bostonbiotech -
Alnylam Pharmaceuticals
@Alnylam
With vibrant colors, cheers, and lots of love, Team Alnylam showed up strong at the 2025 #bostonpride parade! Led by our SAGA ERN and featuring an incredible float, it was a joyful day of celebration. Thanks to all who made it unforgettable!
#pride2025 #pridemonth #lgbtq -
Alnylam Pharmaceuticals
@Alnylam
We hosted a screening of Cracking the Code: Phil Sharp & The Biotech Revolution, followed by a Q&A with Dr. Sharp and filmmaker Bill Haney. The film hits theaters in Oct. and airs this fall on PBS @IndependentLens.
Learn more: www.uncommonproductions.com/cracking-the-code -
Alnylam Pharmaceuticals
@Alnylam
DYK that #rna interference (#rnai) is a naturally occurring cellular process that’s already at work inside your body? Alnylam scientists have harnessed this process to treat specific diseases. A new @NaturePortfolio article (sponsored content) explains how. #rnaitherapeutics
-
Alnylam Pharmaceuticals
@Alnylam
BIO Convention 2025 is next week. We're proud to have Tolga, Tim, Paul, Arun, and other Alnylam leaders speaking on panels about biomanufacturing and biotech innovation. Learn more about their sessions and join the conversation.
#bioboston #bioconvention #massbio #bostonbiotech -
Alnylam Pharmaceuticals
@Alnylam
Recently, more than 30 employees joined friends and family at Castle Island in Boston for the @HDSA's Team Hope Walk. Thank you everyone who donated to #hdsa to raise awareness and provide hope for those impacted by #huntingtonsdisease.
Learn more: www.hdsa.org/teamhope. -
Alnylam Pharmaceuticals
@Alnylam
Still feeling the energy from an incredible #bioball2025 last week! We were proud to hit the court at the Harvard Athletic Complex in support of @SpOlympicsMA and the amazing athletes who inspire us year after year.
#bioball2025 #specialolympmicsma #inclusion -
Alnylam Pharmaceuticals
@Alnylam
#bio2025 is almost here! Proud to help welcome 20k+ global peers to Boston. Alnylam will be on panels daily. Join us to connect, share, and drive biopharma forward. #bioboston
-
Alnylam Pharmaceuticals
@Alnylam
Proud to have supported the 10th annual Life Sciences Workforce Conference. People power innovation, and we're committed to building a strong and inclusive life sciences workforce in Massachusetts.
#lswc25 #biotech #biopharma #workforcedevelopment -
Alnylam Pharmaceuticals
@Alnylam
We’re excited to share that the results from the KARDIA-2 Phase 2 study evaluating our investigational RNAi therapeutic, zilebesiran, in patients with uncontrolled #hypertension when added #antihypertensives are now published in @JAMA. Find out more on our Capella page below 👇
-
Alnylam Pharmaceuticals
@Alnylam
A compelling look at what’s next for RNAi and Alnylam. Proud to see our CEO, Dr. Yvonne Greenstreet, share our bold ambition for the future of medicine in this Talks at GS conversation.
Goldman Sachs
@GoldmanSachs
CEO of Alnylam Pharmaceuticals Dr. Yvonne Greenstreet spoke with Jerry Lee, head of biopharmaceutical banking in the Global Healthcare Group in Global Banking & Markets, about the potential for RNA interference — what she believes will be a “generational technology.”
Watch on Talks at GS: click.gs.com/p163 -
Alnylam Pharmaceuticals
@Alnylam
At Alnylam, PRIDE is more than a month, it reflects who we are. This June, we’re updating our logo to honor the LGBTQ+ community and celebrate inclusion, visibility, and belonging.
#pride2025 #pridemonth #lgbtq -
Alnylam Pharmaceuticals
@Alnylam
Throughout May, Alnylam celebrated Asian American and Pacific Islander Heritage Month with workshops, a Holi Festival and a gala honoring AAPI culture and leadership. We also partnered with @AWforHealth for their CelebrAsians Gala highlighting local advocacy. #aanhpiheritagemonth
-
Alnylam Pharmaceuticals
@Alnylam
Living an amplified life with disease means your disease doesn’t dominate your day-to-day, allowing you to focus on doing what you love with the people who matter most. Helping people get to that place is why we’ve pioneered #rnaitherapeutics.
#silencedisease #amplifylife -
Alnylam Pharmaceuticals
@Alnylam
Our 2024 Corporate Responsibility Report shows how Alnylam is making an impact. We support patients and employees, advance science, uplift communities, and protect the planet. Our work reflects our values and ambition to give back to society.
#corporateresponsibility #csr #esg -
Alnylam Pharmaceuticals
@Alnylam
At Alnylam, we put patients at the center of all we do. Grateful to the #attr-CM patient who recently shared their powerful story with our manufacturing partner, @thermofisher Scientific – and thank you to the team for partnering with us to listen, collaborate, and drive impact.
-
Alnylam Pharmaceuticals
@Alnylam
Living with disease is noisy. The sounds of doctor visits, tests, managing medication, and declining things you want to do can mute the joy of life. But what happens when disease is silenced?
#silencedisease #amplifylife #rnai #rnaitherapeutics -
Alnylam Pharmaceuticals
@Alnylam
It was a busy #heartfailure2025. Missed the conference? Learn more about the design of the Phase 3 trial to evaluate our next-generation TTR silencer for patients with ATTR amyloidosis with cardiomyopathy (#attr-CM) and the new data from across our TTR franchise below. #hfa_esc
-
Alnylam Pharmaceuticals
@Alnylam
We’re proud to share our 2024 Corporate Responsibility Report, highlighting how we’re working to create a healthier, more equitable world through health equity, employee empowerment, and environmental sustainability.
#corporateresponsibility #csr #esg #sustainability -
Alnylam Pharmaceuticals
@Alnylam
We’re proud to be ranked in the top 20 on @BosBizJournal’s inaugural list of the Largest Massachusetts-Headquartered Manufacturers!
Early investment in local #manufacturing has helped strengthen our global supply chain and leadership delivering #rnai therapeutics to patients. -
Alnylam Pharmaceuticals
@Alnylam
Today is #globalporphyriaday (GPD)! Our teams around the world went #purpleforporphyria—standing with @GlobalPorphyria and the global porphyria community to raise awareness and continue driving progress for this #raredisease. Learn more about #gpd: www.gpac-porphyria.org
-
Alnylam Pharmaceuticals
@Alnylam
At #heartfailure2025 we shared new data from the HELIOS-B study showing reductions in risk of all-cause mortality and key indicators of disease progression in patients with ATTR #amyloidosis with cardiomyopathy (#attr-CM). Explore the details 👇
#hfa_esc -
Alnylam Pharmaceuticals
@Alnylam
Thank you to our manufacturing partner, Sharp Services, for honoring a visit from an ATTR amyloidosis with cardiomyopathy patient and everyone in the TTR community by planting a tree on their campus in Allentown PA. Together, we'll keep patients at the center of everything we do.
-
Alnylam Pharmaceuticals
@Alnylam
Ahead of #globalporphyriaday, sisters Sue and Liz of @BPA_Porphyria remind us why awareness, genetic testing and proactive care are essential for people living with #porphryia. @GlobalPorphyria
-
Alnylam Pharmaceuticals
@Alnylam
May is International #huntingtonsdisease Awareness Month, described as like having ALS, Parkinson's and Alzheimer's – at the same time. There are many ways to get involved in advocacy, including through the @HDSA Team Hope Walk: hdsa.org/team-hope-walk/
#letstalkabouthd -
Alnylam Pharmaceuticals
@Alnylam
We believe all patients, regardless of their diagnosis, have the potential to benefit from the promise that #rnaitherapeutics hold to #silencedisease and #amplifylife. That’s why we’ve pioneered this innovative approach and are working to bring it to as many patients as possible.
-
Alnylam Pharmaceuticals
@Alnylam
Our CEO, Dr. Yvonne Greenstreet has again been named one of Boston Magazine’s Most Influential Bostonians for 2025! From advancing RNAi science to her work with outside organizations, her influence extends beyond the lab.
#leadership #biotech #rnai #womeninstem #bostonleaders -
Alnylam Pharmaceuticals
@Alnylam
For U.S. Audiences: Helping your loved one navigate primary #hyperoxaluria type 1 (PH1) can be a difficult journey. Learn about PH1 from pediatric nephrologist Dr. Stone as she discusses this #raredisease and an FDA-approved treatment option.
-
Alnylam Pharmaceuticals
@Alnylam
Women’s pain is often dismissed, delaying diagnosis of serious conditions like Donna’s acute hepatic #porphyria (AHP), which took 10+ years. Recognizing seemingly unrelated symptoms can help AHP patients regain control.
-
Alnylam Pharmaceuticals
@Alnylam
As we reflect on a strong start to the year, our Chief Human Resources Officer, Melissa McLaughlin, explains how culture is more than a value statement — it’s a competitive advantage.
#challengeaccepted #rnai #leadership #companyculture -
Alnylam Pharmaceuticals
@Alnylam
This morning, we reported 1st Quarter 2025 financial results and key updates. Join our LIVE webcast TODAY at 8:30 am ET or catch the replay later: investors.alnylam.com/events
Read the full press release: investors.alnylam.com/press-releases
#rnai #rnaitherapeutics #sirna -
Alnylam Pharmaceuticals
@Alnylam
Receiving a diagnosis of acute hepatic #porphyria (#ahp) was a life-altering moment for Hannah, who felt separated by her "future" and "past" selves. But, a diagnosis also allowed her to begin to move forward. Learn more about Hannah’s AHP story expressed through dance.
-
Alnylam Pharmaceuticals
@Alnylam
Congratulations to our own Samip Dhakal, who joined the Timmerman Traverse for @DamonRunyon Cancer Research Foundation and reached #everest Base Camp! We're #alnylamproud to have sponsored Samip, part of a team that helped raise over $700K for #cancerresearch. #biotech
-
Alnylam Pharmaceuticals
@Alnylam
This Thursday, 5/1 at 8:30 am ET, we'll be sharing 1st Quarter 2025 financial results during a LIVE webcast. A replay will be available at the following link later in the day. investors.alnylam.com/events
#rnai #rnaitherapeutics #sirna -
Alnylam Pharmaceuticals
@Alnylam
U.S. HCPs: Attending the 2025 AUA Annual Meeting? Be sure to visit us at Booth 1272 to meet with our Alnylam team. We’ll also be presenting new data for our RNAi therapeutic for primary #hyperoxaluria type 1 (#ph1). @AmerUrological #aua25
-
Alnylam Pharmaceuticals
@Alnylam
U.S. HCPs: Attending #pas2025? Be sure to save the date for our symposium TOMORROW to learn more about the pediatric data available for our RNAi therapeutic for primary #hyperoxaluria type 1 (#ph1). @PASMeeting 2025.pas-meeting.org/index.asp?presTarget=3012957&li_fat_…
-
Alnylam Pharmaceuticals
@Alnylam
Hannah’s first acute hepatic #porphyria (#ahp) attack left her feeling as though her mind and body were out of sync, and she could no longer do what she loved most: dance. Today, she’s back on stage, sharing her journey with AHP through dance.
-
Alnylam Pharmaceuticals
@Alnylam
HCPs: We’re thrilled to be headed to the PAS Annual Meeting 2025! Be sure to stop by Booth 1022 to meet with our Alnylam team and learn more about our work in primary #hyperoxaluria type 1 (#ph1). We hope to see you there!
#pas2025 @PASMeeting -
Alnylam Pharmaceuticals
@Alnylam
We’re excited to sponsor this year’s Asembia Summit! Join us for “The Current State of Rare Disease Therapeutics in the Payer Landscape,” moderated by Stephen Meninger, PharmD, MS, MBA.
Explore insights from the 2025 Alnylam Rare Disease Trend Report: www.alnylam.com/sites/default/files/pdfs/payer-rare-disea… -
Alnylam Pharmaceuticals
@Alnylam
Excited to sponsor the 2025 MassBioEd Life Sciences Workforce Conference on June 3 at BU. As a Mass-based employer, we’re committed to growing the local life sciences talent pipeline.
#lifesciences #workforcedevelopment -
Alnylam Pharmaceuticals
@Alnylam
Doctor visits, tests, pharmacy trips, medication - the sounds of these things make living with disease noisy. But when you #silencedisease, these things become less prevalent and the joy of life can be amplified. We've pioneered #rnai therapeutics to do just that - #amplifylife.
-
Alnylam Pharmaceuticals
@Alnylam
We were honored to host the @MALifeSciences team, including CEO Dr. Kirk Taylor, at our Norton, MA #manufacturing facility. They learned how we make #rnaitherapeutics and we discussed #workforcedevelopment, public/private partnerships and growing the MA #lifesciences ecosystem.
-
Alnylam Pharmaceuticals
@Alnylam
From experiencing her first acute hepatic #porphyria (#ahp) attack in college, to being diagnosed with a #raredisease, Hannah’s journey with AHP is one of resilience and determination. Watch Hannah bring her AHP story to life through dance.
-
Alnylam Pharmaceuticals
@Alnylam
Later this month, Samip Dhakal, a Nepal native & dedicated employee, will trek to Everest Base Camp to raise $50K for @DamonRunyon. Stay tuned for his inspiring journey & updates! #cancerresearch
-
Alnylam Pharmaceuticals
@Alnylam
We’re proud to support the Massachusetts Science & Engineering Fair and celebrate future scientists. This year, the Alnylam Bioscience Excellence Award went to Adrita Samanta, recognizing innovation and curiosity in STEM. #stem #futurescientists
-
Alnylam Pharmaceuticals
@Alnylam
HCPs: We’re thrilled to share new pediatric data for our #rnaitherapeutic for primary #hyperoxaluria type 1 (PH1) at the 2025 NKF Spring Clinical Meetings (SCM25). We hope to see you there! cme.kidney.org/spa/app/resource/r649-2025-spring-clinical…
-
Alnylam Pharmaceuticals
@Alnylam
It's her big game. You want to be there AND be fully present. Living with disease makes that difficult. Over time, the sounds of disease - doctor visits, tests, managing medication - mute the joy of life. But what happens when you #silencedisease?
#amplifylife #rnaitherapeutics -
Alnylam Pharmaceuticals
@Alnylam
Women’s pain is often dismissed, delaying diagnosis of serious conditions like Donna’s acute hepatic #porphyria (AHP), which took 10+ years. Recognizing seemingly unrelated symptoms can help AHP patients regain control.
-
Alnylam Pharmaceuticals
@Alnylam
Big congratulations to our @HBAnet 2025 Rising Stars, Aimee Deaton and Paula Cavallieri! We’re thrilled to celebrate their achievements alongside this year’s honorees. Full list: hbanet.org/2025-hba-rising-stars
#alnylamproud #hbaimpact #hbawoty25 -
Alnylam Pharmaceuticals
@Alnylam
U.S. HCPs: Navigating a #raredisease like PH1 requires a well-coordinated care team. In this article, pediatric nephrologist, Dr. Raymond Quigley, discusses how specialist collaboration can support timely diagnosis and highlights advances in disease management.
-
Alnylam Pharmaceuticals
@Alnylam
Living with disease is noisy. The sounds of endless doctor visits, tests, managing medication and having to decline invitations to do things you really want to do...these sounds mute the joy of life. But what happens when disease is silenced?
#silencedisease #amplifylife #rnai -
Alnylam Pharmaceuticals
@Alnylam
That’s a wrap on #acc25 (@ACCinTouch)! We were thrilled to present new data from the HELIOS-B study about the impact of #rnai for #attr-CM and spend the weekend alongside the #cardiology community.
-
Alnylam Pharmaceuticals
@Alnylam
If you were unable to join us at #acc25 (@ACCinTouch) and want to learn about our latest data in #attr #amyloidosis, click here to see how Alnylam (and #rnai) are at the heart of cardiac innovation: capella.alnylam.com/2025/03/29/acc-2025
-
Alnylam Pharmaceuticals
@Alnylam
At #acc25 (@ACCinTouch), we presented new data for our #rnai therapeutic recently approved by the U.S. FDA for the treatment of the cardiomyopathy of #attr #amyloidosis (ATTR-CM).
-
Alnylam Pharmaceuticals
@Alnylam
Are you attending #acc25? If so, be sure to stop by Booth 1015 to say hello, meet our Alnylam team and learn about the use of #rnai (RNA interference) for the treatment of the cardiomyopathy of #attr #amyloidosis (ATTR-CM). @ACCinTouch
-
Alnylam Pharmaceuticals
@Alnylam
We’re honored to be named a @USATODAY #topworkplace for 2025 for the fourth year in a row. This recognition, based on employee feedback, highlights our commitment to a people-first culture.
#careers #culturematters #biotechnology #biopharma -
Alnylam Pharmaceuticals
@Alnylam
ICYMI: Last Thursday, the U.S. FDA expanded the indication of our #rnai therapeutic to include patients diagnosed with the cardiomyopathy of #attr #amyloidosis (ATTR-CM). Read the press release: investors.alnylam.com/press-release?id=04a38e19-c685-48d4…
#rnaitherapeutics #sirna -
Alnylam Pharmaceuticals
@Alnylam
We’re excited to welcome Melissa McLaughlin as our new Chief Human Resources Officer! With extensive expertise in HR leadership, talent development, and fostering inclusive workplaces, she will enhance our award-winning approach to people and culture. Welcome aboard, Melissa!
-
Alnylam Pharmaceuticals
@Alnylam
This month, we’re proud to support #amyloidosisawarenessmonth alongside the @Amyloidosisfdn in their “Light the Night for Amyloidosis” campaign. As they paint the town RED to raise awareness of #amyloidosis, we’re joining by illuminating our global headquarters in Cambridge!
-
Alnylam Pharmaceuticals
@Alnylam
After nearly 20 years of partnering with the #attr #amyloidosis community, we’re proud to offer the only FDA-approved therapeutic in the U.S. for the cardiomyopathy of ATTR and polyneuropathy of hATTR. We thank @AmyloidosisSupp for their shared dedication to this community.
-
Alnylam Pharmaceuticals
@Alnylam
Following yesterday’s U.S. FDA approval, patients prescribed our therapy for the #cardiomyopathy of #attr #amyloidosis (ATTR-CM) can receive help accessing treatment through Alnylam Assist®, our comprehensive, in-house patient support services program. www.alnylamassist.com/amvuttra
-
Alnylam Pharmaceuticals
@Alnylam
Yesterday’s U.S. FDA approval marks the arrival of the first #rnai therapeutic for the cardiomyopathy of #attr #amyloidosis (ATTR-CM), a rapidly progressive, debilitating disease that has historically had few treatment options. Read the press release: investors.alnylam.com/press-release?id=04a38e19-c685-48d4…
-
Alnylam Pharmaceuticals
@Alnylam
Tune in to our LIVE webcast today at 6:00 pm ET, where we will share additional information about the U.S. FDA approval of the expanded indication for AMVUTTRA® (vutrisiran): investors.alnylam.com/events. A replay will be available following the webcast.
#rnai #rnaitherapeutics -
Alnylam Pharmaceuticals
@Alnylam
We are thrilled to share that the U.S. FDA has approved our supplemental New Drug Application (sNDA) for AMVUTTRA® (vutrisiran), making it available as a treatment option for a new group of patients. Read the press release: investors.alnylam.com/press-release?id=04a38e19-c685-48d4…
#rnai #rnaitherapeutics -
Alnylam Pharmaceuticals
@Alnylam
HCPs: Hereditary #attr (#hattr) often progresses significantly before an accurate diagnosis is made. In an Alnylam-sponsored @GoHealio article, Johanna Contreras, MD, MSc and Said Beydoun, MD, FAAN share their unique expertise on this inherited #raredisease. #amyloidois
-
Alnylam Pharmaceuticals
@Alnylam
For U.S. Audiences: Helping your loved one navigate primary #hyperoxaluria type 1 (PH1) can be a difficult journey. Learn about PH1 from pediatric nephrologist Dr. Stone as she discusses this #raredisease and an FDA-approved treatment option.
-
Alnylam Pharmaceuticals
@Alnylam
HCPs: Meet Dr. Saurabh Malhotra, an expert on hereditary #attr (#hattr) #amyloidosis who knows that encouraging health history conversations can be the key to improving a patient's health. www.attrrevealed.com/living-with-hATTR-amyloidosis/family…
#hattroadtrip -
Alnylam Pharmaceuticals
@Alnylam
HCPs: As hereditary #attr (#hattr) progresses, the deposition of toxic misfolded TTR can cause irreversible damage. Learn more about the importance of early intervention in an Alnylam-sponsored article in @GoHealio. #amyloidosis
-
Alnylam Pharmaceuticals
@Alnylam
From rare diseases to neurodegenerative conditions, RNAi therapeutics are transforming medicine. Discover the science driving this innovation in
@sciam.
#rnaitherapeutics #sirna #genesilencing #rna
(sponsored content; for U.S. audiences only) -
Alnylam Pharmaceuticals
@Alnylam
With gratitude, we announce the retirement of Alnylam co-founder Dr. Phillip A. Sharp from our Board. His vision shaped #rnai therapeutics, impacting tens of thousands of patients. He’ll continue contributing to our Scientific Advisory Board. Read more: investors.alnylam.com/press-releases
-
Alnylam Pharmaceuticals
@Alnylam
HCPs: Did you know that patients you think may have conditions like diabetic neuropathy or Fabry disease could have hereditary #attr (#hattr)? Misdiagnoses like these can lead to delays in critical intervention. Read more in an Alnylam-sponsored @GoHealio article. #amyloidois
-
Alnylam Pharmaceuticals
@Alnylam
U.S. HCPs: Navigating a #raredisease like PH1 requires a well-coordinated care team. In this article, pediatric nephrologist, Dr. Raymond Quigley, discusses how specialist collaboration can support timely diagnosis and highlights advances in disease management.
-
Alnylam Pharmaceuticals
@Alnylam
On @rarediseaseday, we spotlight the 300M+ people living with a #raredisease.
Using gen AI, we brought to life the dreams of this community in a world that’s “More Than You Can Imagine.”
Thank you @Eurordis & @RareDiseases for working to make this imagined world a reality. -
Alnylam Pharmaceuticals
@Alnylam
Neurological diseases have a devastating impact, and #rnaitherapeutics have the potential to offer a promising approach. At Alnylam, we’re exploring ways to silence brain diseases, such as Alzheimer’s and Huntington’s disease.
Read more: news.alnylam.com/rnai/articles/new-therapeutic-approach-s…
#rnai #neurology -
Alnylam Pharmaceuticals
@Alnylam
For #rarediseaseday, we are using generative AI to bring to life the dreams of the #raredisease community.
See Laura’s dream illustrated for her daughter who is living with primary #hyperoxaluria type 1 (PH1), in a world that's “More Than You Can Imagine.” -
Alnylam Pharmaceuticals
@Alnylam
Today at our 2025 R&D Day, we shared significant pipeline progress, platform innovation, and more. Catch the replay of the webcast and presentation at investors.alnylam.com/events
#rnaitherapeutics #sirna -
Alnylam Pharmaceuticals
@Alnylam
Excited to kick off our 2025 R&D Day! Today, we’re sharing significant pipeline progress, platform innovation, and what’s ahead for #rnaitherapeutics.
Read the full press release here: investors.alnylam.com/press-releases
#sirna -
Alnylam Pharmaceuticals
@Alnylam
For #rarediseaseday, members of the acute hepatic #porphyria (AHP) community shared their dreams for the future. Katri, who lives with AHP, wishes for happiness & stability. See her dream brought to life through generative AI, depicting a world that’s “More Than You Can Imagine”
-
Alnylam Pharmaceuticals
@Alnylam
HCPs: Hereditary #attr (#hattr) often progresses significantly before an accurate diagnosis is made. In an Alnylam-sponsored @GoHealio article, Johanna Contreras, MD, MSc and Said Beydoun, MD, FAAN share their unique expertise on this inherited #raredisease. #amyloidois
-
Alnylam Pharmaceuticals
@Alnylam
RNAi therapeutics are changing how we manage disease! Learn how #rnaitherapeutics & #genesilencing are giving hope to patients with rare & common diseases. Alnylam’s inspiring journey proves innovation can transform medicine.
Read more: news.alnylam.com/rnai/articles/rnai-therapeutics-possibil…
#sirna #rna -
Alnylam Pharmaceuticals
@Alnylam
For @rarediseaseday, we asked the #raredisease community to share their dreams.
Rick, living with #hattr amyloidosis, dreams of celebrating his granddaughters' life milestones. See his dream transformed using generative AI, depicting a world that's “More Than You Can Imagine.” -
Alnylam Pharmaceuticals
@Alnylam
Join us for our 2025 R&D Day, streaming LIVE on Feb 25 at 9:00 am EST. Register now to tune in or watch the replay later at investors.alnylam.com/events.
#rnai #rnaitherapeutics #sirna -
Alnylam Pharmaceuticals
@Alnylam
For U.S. Audiences: Helping your loved one navigate primary #hyperoxaluria type 1 (PH1) can be a difficult journey. Learn about PH1 from pediatric nephrologist Dr. Stone as she discusses this #raredisease and an FDA-approved treatment option.
-
Alnylam Pharmaceuticals
@Alnylam
In honor of #blackhistorymonth, we’re recognizing the contributions of Black leaders in science and medicine while fostering conversations that inspire progress. Thanks to our Global Black Initiative ERN for leading meaningful dialogue and reflection this month.
-
Alnylam Pharmaceuticals
@Alnylam
This morning, we reported Q4 & full-year 2024 financial results & key updates. Join our LIVE webcast TODAY at 8:30 am ET or catch the replay later: investors.alnylam.com/events
Read the full press release: investors.alnylam.com/press-releases
#rnai #sirna -
Alnylam Pharmaceuticals
@Alnylam
This morning, we reported Q4 & full-year 2024 financial results & key updates. Join our LIVE webcast TODAY at 8:30 am ET or catch the replay later: investors.alnylam.com/events
Read the full press release: investors.alnylam.com/press-releases
#rnai #sirna -
Alnylam Pharmaceuticals
@Alnylam
HCPs: Meet Dr. Saurabh Malhotra, an expert on hereditary #attr (#hattr) #amyloidosis who knows that encouraging health history conversations can be the key to improving a patient's health. www.attrrevealed.com/living-with-hATTR-amyloidosis/family…
#hattroadtrip -
Alnylam Pharmaceuticals
@Alnylam
Science thrives when diverse voices are heard. This International Day of Women & Girls in Science, we celebrate the contributions of women in STEM and reaffirm our commitment to fostering the next generation of scientific leaders. #hervoiceinscience #womeninstem
-
Alnylam Pharmaceuticals
@Alnylam
This Thursday, 2/13 at 8:30 am ET, we'll be sharing 4th Quarter and full year 2024 financial results during a LIVE webcast. A replay will be available at the following link later in the day. investors.alnylam.com/events
#rnai #rnaitherapeutics #sirna -
Alnylam Pharmaceuticals
@Alnylam
From a bold idea to FDA-approved treatments—#rnaitherapeutics are changing the way we treat disease. Curious about how #genesilencing works? Read the story: news.alnylam.com/rnai/articles/rnai-therapeutics-possibil…
#sirna #rna -
Alnylam Pharmaceuticals
@Alnylam
We’re honored to be named one of Newsweek’s Most Responsible Companies 2025, jumping 223 spots to #153 overall & #14 in Health Care & Life Sciences!
Corporate responsibility is in our "RNA," and our team drives this impact every day. www.alnylam.com/page-not-found
#esg #newsweek -
Alnylam Pharmaceuticals
@Alnylam
HCPs: As hereditary #attr (#hattr) progresses, the deposition of toxic misfolded TTR can cause irreversible damage. Learn more about the importance of early intervention in an Alnylam-sponsored article in @GoHealio. #amyloidosis
-
Alnylam Pharmaceuticals
@Alnylam
How did Alnylam turn a scientific revolution into life-changing medicines? Hear from Kevin Fitzgerald, PhD, on The Long Run podcast as he talks RNAi breakthroughs, career lessons & the future of biotech. news.alnylam.com/rnai/podcasts/alnylams-kevin-fitzgerald-…
#sirna #rnaitherapeutics -
Alnylam Pharmaceuticals
@Alnylam
U.S. HCPs: Navigating a #raredisease like PH1 requires a well-coordinated care team. In this article, pediatric nephrologist, Dr. Raymond Quigley, discusses how specialist collaboration can support timely diagnosis and highlights advances in disease management.
-
Alnylam Pharmaceuticals
@Alnylam
HCPs: Did you know that patients you think may have conditions like diabetic neuropathy or Fabry disease could have hereditary #attr (#hattr)? Misdiagnoses like these can lead to delays in critical intervention. Read more in an Alnylam-sponsored @GoHealio article. #amyloidois
-
Alnylam Pharmaceuticals
@Alnylam
For U.S. Audiences: Helping your loved one navigate primary #hyperoxaluria type 1 (PH1) can be a difficult journey. Learn about PH1 from pediatric nephrologist Dr. Stone as she discusses this #raredisease and an FDA-approved treatment option.
-
Alnylam Pharmaceuticals
@Alnylam
We’re honored to receive the Swiss Tell Award, recognizing economic cooperation between 🇨🇭 and the 🇺🇸. Consul General Ambassador Niculin Jäeger presented the award to our CFO, Jeff Poulton, and members of our leadership team at a private dinner.
#tellawards #swissimpact -
Alnylam Pharmaceuticals
@Alnylam
HCPs: Meet Dr. Saurabh Malhotra, an expert on hereditary #attr (#hattr) #amyloidosis who knows that encouraging health history conversations can be the key to improving a patient's health. www.attrrevealed.com/living-with-hATTR-amyloidosis/family…
#hattroadtrip -
Alnylam Pharmaceuticals
@Alnylam
What’s the story behind RNAi therapeutics? Kevin Fitzgerald, PhD, joins The Long Run podcast to share his journey from uncertain beginnings to biotech leadership. A must-listen for anyone inspired by science & perseverance! news.alnylam.com/rnai/podcasts/alnylams-kevin-fitzgerald-…
#sirna #rnaitherapeutics -
Alnylam Pharmaceuticals
@Alnylam
HCPs: Hereditary #attr (#hattr) often progresses significantly before an accurate diagnosis is made. In an Alnylam-sponsored @GoHealio article, Johanna Contreras, MD, MSc and Said Beydoun, MD, FAAN share their unique expertise on this inherited #raredisease. #amyloidois
-
Alnylam Pharmaceuticals
@Alnylam
Doctors visits, tests, pharmacy trips, medication - the sounds of these things make living with disease noisy. But when you #silencedisease, these things become less prevalent and the joy of life can be amplified. We've pioneered #rnai therapeutics to do just that - #amplifylife.
-
Alnylam Pharmaceuticals
@Alnylam
Yesterday from #jpm2025, our CCO, Tolga Tanguler, joined @FierceBiotech for a fireside chat with Angus Liu. Tolga shared insights into our 2025 milestones, innovative pipeline programs, and the future of #rnaitherapeutics.
#sirna #biotech #drugdevelopment -
Alnylam Pharmaceuticals
@Alnylam
We’re empowering refugees in Europe with skills, jobs, & opportunities through Alnylam Challengers! From career coaching to business mentorship, we’re proud to support their journeys. Learn more: news.alnylam.com/responsibility/articles/supporting-refug…
#refugeesupport #healthequity #socialimpact -
Alnylam Pharmaceuticals
@Alnylam
It's her big game. You want to be there AND be fully present. Living with disease makes that difficult by holding you back. Over time, the sounds of disease - doctor visits, tests, managing medication - mute the joy of life. But what happens when you #silencedisease? #amplifylife
-
Alnylam Pharmaceuticals
@Alnylam
Yesterday from #jpm25, our CEO Yvonne Greenstreet joined @CNBC's @Angelica Peebles to talk about the continued advancement of our #rnaitherapeutics platform, deep pipeline and what's next for Alnylam in 2025. cnb.cx/3WevSnl
#rnai #sirna #biotechnology #biotech -
Alnylam Pharmaceuticals
@Alnylam
Living with disease is noisy. The sounds of endless doctor visits, tests, managing medication and having to decline invitations to the things you really want to do...these sounds mute the joy of life. But what happens when disease is silenced? #silencedisease #amplifylife #rnai
-
Alnylam Pharmaceuticals
@Alnylam
Earlier today, our CEO Dr. Yvonne Greenstreet presented at #jpm25, sharing updates on our pipeline, products, and upcoming 2025 milestones.
Missed our presentation? Watch the replay here: investors.alnylam.com/events
#rnai #rnaitherapeutics #sirna #biotech -
Alnylam Pharmaceuticals
@Alnylam
We’ve announced preliminary Q4 and FY2024 global net product revenues, 2025 net product revenue guidance and pipeline goals. Read the press release: investors.alnylam.com/press-releases
Listen to our live #jpm25 webcast tomorrow at 9:45 AM PT/12:45 PM ET. Watch here: jpmorgan.metameetings.net/events/healthcare25/sessions/58… -
Alnylam Pharmaceuticals
@Alnylam
HCPs: As hereditary #attr (#hattr) progresses, the deposition of toxic misfolded TTR can cause irreversible damage. Learn more about the importance of early intervention in an Alnylam-sponsored article in @GoHealio. #amyloidosis
-
Alnylam Pharmaceuticals
@Alnylam
Dr. Yvonne Greenstreet will join Noubar Afeyan for a FutureCast conversation at #jpm25, exploring innovation, leadership, and the future of therapeutic development. Learn more below.
Flagship Pioneering
@FlagshipPioneer
Check out the newly added programming being livestreamed from our studio at JPM the week of January 13. #flagshipjpm #jpm25
-
Alnylam Pharmaceuticals
@Alnylam
We’re honored to be named one of America’s Most Responsible Companies by @Newsweek for the 3rd year! This reflects our commitment to patients, communities, and sustainability. Learn more: www.alnylam.com/about-alnylam/corporate-responsibility
#corporateresponsibility #esg #sustainability -
Alnylam Pharmaceuticals reposted
Flagship Pioneering
@FlagshipPioneer
Tune in on Jan 14 at 11am PT/2pm ET for a conversation between Flagship Pioneering Founder and CEO @NoubarAfeyan and Yvonne Greenstreet, CEO of @Alnylam, on leading multi-product platform companies, pioneering innovation to bring about novel medicines for patients across multiple disease areas, and the future of therapeutic development. Learn more and register for the livestream: events.flagshippioneering.com/futurecastnoubarandyvonnevir
For more on our studio programming and livestreamed events at JPM: www.flagshippioneering.com/events/flagship-jpm-2025
#jpm25 #flagshipjpm -
Alnylam Pharmaceuticals
@Alnylam
U.S. HCPs: Navigating a #raredisease like PH1 requires a well-coordinated care team. In this article, pediatric nephrologist, Dr. Raymond Quigley, discusses how specialist collaboration can support timely diagnosis and highlights advances in disease management.
-
Alnylam Pharmaceuticals
@Alnylam
HCPs: Meet Dr. Saurabh Malhotra, an expert on hereditary #attr (#hattr) #amyloidosis who knows that encouraging health history conversations can be the key to improving a patient's health. www.attrrevealed.com/living-with-hATTR-amyloidosis/family…
#hattroadtrip -
Alnylam Pharmaceuticals
@Alnylam
For U.S. Audiences: Helping your loved one navigate primary #hyperoxaluria type 1 (PH1) can be a difficult journey. Learn about PH1 from pediatric nephrologist Dr. Stone as she discusses this #raredisease and an FDA-approved treatment option.
-
Alnylam Pharmaceuticals
@Alnylam
HCPs: Did you know that patients you think may have conditions like diabetic neuropathy or Fabry disease could have hereditary #attr (#hattr)? Misdiagnoses like these can lead to delays in critical intervention. Read more in an Alnylam-sponsored @GoHealio article. #amyloidois
-
Alnylam Pharmaceuticals
@Alnylam
Managing a #raredisease like primary #hyperoxaluria type 1 (PH1) can be difficult, so it’s helpful to work with patient advocacy groups to answer questions and get more information. Hear from Kim Hollander of @OHFTweet in an episode of Medical Stories. www.youtube.com/watch?v=kWTU1CPv7d8
-
Alnylam Pharmaceuticals
@Alnylam
HCPs: Hereditary #attr (#hattr) often progresses significantly before an accurate diagnosis is made. In an Alnylam-sponsored @GoHealio article, Johanna Contreras, MD, MSc and Said Beydoun, MD, FAAN share their unique expertise on this inherited #raredisease. #amyloidois
-
Alnylam Pharmaceuticals
@Alnylam
The Alnylam Assist® program offers support services
to patients who are prescribed one of our products.
Our team of experts are here to help patients access
and understand treatment. -
Alnylam Pharmaceuticals
@Alnylam
HCPs: With patients spending time with their families this holiday season, it’s a perfect time to encourage conversations about family health history to help them understand inherited diseases, like #hattr #amyloidosis. #hattroadtrip www.attrrevealed.com/living-with-hATTR-amyloidosis/family…
-
Alnylam Pharmaceuticals
@Alnylam
Last week, Alnylam’s 2024 #bioball team hit the court at #tdgarden for a friendly game between this year’s top fundraising teams with @SpOlympicsMA!
Proud to support #inclusion and make sport accessible for everyone. #specialolympics -
Alnylam Pharmaceuticals
@Alnylam
HCPs: As hereditary #attr (#hattr) progresses, the deposition of toxic misfolded TTR can cause irreversible damage. Learn more about the importance of early intervention in an Alnylam-sponsored article in @GoHealio. #amyloidosis
-
Alnylam Pharmaceuticals
@Alnylam
For U.S. Audiences: Helping your loved one navigate primary #hyperoxaluria type 1 (PH1) can be a difficult journey. Learn about PH1 from pediatric nephrologist Dr. Stone as she discusses this #raredisease and an FDA-approved treatment option.
-
Alnylam Pharmaceuticals
@Alnylam
U.S. HCPs: Navigating a #raredisease like PH1 requires a well-coordinated care team. In this article, pediatric nephrologist, Dr. Raymond Quigley, discusses how specialist collaboration can support timely diagnosis and highlights advances in disease management.
-
Alnylam Pharmaceuticals
@Alnylam
HCPs: Meet Dr. Saurabh Malhotra, an expert on hereditary #attr (#hattr) #amyloidosis who knows that encouraging health history conversations can be the key to improving a patient's health. www.attrrevealed.com/living-with-hATTR-amyloidosis/family…
#hattroadtrip -
Alnylam Pharmaceuticals
@Alnylam
Recently, Alnylam’s SAGA (Sexuality and Gender Alliance) employee resource network proudly hosted OUTbio’s December 2024 event with a Winter Wonderland celebration. It was a festive evening at our Corporate HQ, bringing together #biotech professionals from OUTbio and Alnylam employees. With great conversation, holiday-inspired food, and an atmosphere of inclusivity, we celebrated community and connection during this holiday season. Thank you to everyone who joined us! #lgbtq #diversityequityinclusion
-
Alnylam Pharmaceuticals
@Alnylam
Leaders from across Europe recently gathered in Zug, Switzerland, to celebrate our most recent class of Antares leadership program graduates and participate in an inspiring panel discussion on leadership and professional growth. Our Antares program is part of our commitment to leadership development at all levels of our organization and is conducted globally twice each year.
At Alnylam, we’re not just committed to advancing RNAi therapeutics — we’re also committed to helping our employees grow through building leadership skills.
To learn more about career development and working at Alnylam visit www.alnylam.com/careers/working-at-alnylam -
Alnylam Pharmaceuticals
@Alnylam
We’re thrilled to share that we reached our ambitious $20,000 goal for the #givewarmthgivehope fundraiser! Thanks to the generosity of our employees, these critical funds will provide over 2,000 essential winter items to support more than 600 individuals experiencing homelessness this winter through the incredible work of Cambridge and Somerville Programs for Addiction Recovery (CASPAR).
Learn more about #caspar and how you can help: baycovehumanservices.org/caspar
#communityimpact -
Alnylam Pharmaceuticals
@Alnylam
A decade as a Boston Globe #topplacetowork – and this year, the highest ranked #biotechnology company in the “Largest Companies” category – shows that Alnylam is built on a foundation that consistently prioritizes people, culture, innovation, and patients as critical for our success. Empowering employees while putting them first is a big part of what has made us the leaders in #rnai therapeutics and an employer of choice not just in Massachusetts but around the world. #alnyglobe10
Learn more: news.alnylam.com/careers-culture/articles/celebrating-dec…
#pharmacareers #companyculture -
Alnylam Pharmaceuticals
@Alnylam
On #givingtuesday we invite you to learn more about the charitable organizations we partner with throughout the year and around the globe to help improve the health and wellbeing of humanity. #csr
-
Alnylam Pharmaceuticals
@Alnylam
HCPs: With patients spending time with their families this holiday weekend, it’s a perfect time to encourage conversations about family health history to help them understand inherited diseases, like #hattr #amyloidosis. #hattroadtrip www.attrrevealed.com/living-with-hATTR-amyloidosis/family…
-
Alnylam Pharmaceuticals
@Alnylam
We’re #alnylamproud to be named a #gptw again in 🇫🇷 France, 🇩🇪 Germany, 🇮🇹 Italy, 🇳🇱 Netherlands, 🇨🇦Canada, 🇪🇸 Spain, 🇺🇸 USA - and congratulations to our🇨🇭 Switzerland and 🇬🇧 United Kingdom offices for being certified for seven consecutive years!
#gptwnl #gptwfrance #gptwswitzerland #gptwgermany #gptwdeutschland #gptwspain #gptwitalia #gptwcanada #gptwusa -
Alnylam Pharmaceuticals
@Alnylam
We are excited to share that the U.S. FDA has accepted our supplemental New Drug Application (sNDA) for vutrisiran, an investigational #rnai therapeutic in development for the treatment of #attr-CM.
#rnaitherapeutics #rnainterference #amyloidosis -
Alnylam Pharmaceuticals
@Alnylam
ICYMI: We presented new data at #aha24 for several investigational therapeutics across our #attr franchise and #hypertension program. Dive deeper into what we’re sharing. #rnaitherapeutics #rnai
-
Alnylam Pharmaceuticals
@Alnylam
We presented interim results at #aha24 from a Phase 1 study of nucresiran (ALN-TTRsc04), our next generation #rnai therapeutic in development for the treatment of transthyretin amyloidosis (#attr). See the results. #rnaitherapeutics
-
Alnylam Pharmaceuticals
@Alnylam
Will we see you at @american_heart Scientific Sessions 2024 (#aha24)? Visit us at Booth 2321 to learn more about our disease areas including #attr #amyloidosis and #hypertension.
-
Alnylam Pharmaceuticals
@Alnylam
We’re excited to join @AASLDtweets at The Liver Meeting 2024. Stop by Booth 1141 to meet the Alnylam team and learn more. We hope to see you there! #tlm24 #rnaitherapeutics #rnai #sirna
-
Alnylam Pharmaceuticals reposted
Nature Conferences
@NatureConf
Did you know that, with @ionispharma, @Alnylam, @UCSDMedSchool, and @NatureBiotech, we're bringing together academics in basic/ translational research and biotechnology peers for three days of talks on nucleic acid therapies?
Now you do. Join us🎟️👉 go.nature.com/4hzOAip -
Alnylam Pharmaceuticals
@Alnylam
Our CMO Pushkal Garg participated in a fascinating conversation on the past, present and future of biotech last week at #galienforum2024. Thank you to the organizers and panelists!
-
Alnylam Pharmaceuticals
@Alnylam
Last week during #hyperoxaluria Awareness Week, Alnylam colleagues around the world wore blue to show our support for Hyperoxaluria Warriors and the primary #hyperoxaluria type 1 (PH1) community.💙 @OHFTweet
-
Alnylam Pharmaceuticals
@Alnylam
On #veteransday, we express our deepest gratitude to all #veterans, especially those who are part of our Alnylam family. Your dedication, honor and service make us #alnylamproud.
-
Alnylam Pharmaceuticals
@Alnylam
During #hyperoxaluria Awareness Week, Dr. Shabbir Moochhala shares a message of hope for those living with primary hyperoxaluria type 1 (PH1) and discusses resources available to help. To learn more about PH1, visit: www.livingwithph1.eu
-
Alnylam Pharmaceuticals
@Alnylam
It’s #hyperoxaluria Awareness Week and we’re joining @OHFTweet in sending strength to Hyperoxaluria Warriors like Ziggy, who is living with primary hyperoxaluria type 1 (PH1). Hear Ziggy’s story and the importance of PH1 awareness. Learn more at: hyperoxaluriaweek.ohf.org
-
Alnylam Pharmaceuticals reposted
Rosie's Place
@RosiesPlace
Kicking off November with a big thank you to our October volunteer groups! We are so grateful for the time you spent with us and the enthusiasm and energy you brought to your work. Thank you! @Alnylam @Brightcove @KPMG_US @WeberShandwick
-
Alnylam Pharmaceuticals
@Alnylam
This #hyperoxaluria Awareness Week, hear from Hyperoxaluria Warrior Seth, who shares his journey navigating unexplained kidney failure and how genetic testing confirmed his diagnosis of primary hyperoxaluria type 1 (PH1).
Watch here: www.youtube.com/watch?v=wa8kUpQ32eo -
Alnylam Pharmaceuticals
@Alnylam
Taking strides together in the fight against #alzheimers disease! 💜 Alnylamites recently participated in the #walk2endalz. Along with colleagues around the world, they proudly raised funds in support of the @alzassociation and its mission to provide education and support to the millions of people impacted by dementia and support research to finally #endalz.
-
Alnylam Pharmaceuticals
@Alnylam
Primary #hyperoxaluria type 1 (PH1) is an inherited disease and can affect family members differently. For one family with three children with PH1, each has had a different experience. Hear from Aubrey, diagnosed with PH1, in an episode of Medical Stories. www.youtube.com/watch?v=kWTU1CPv7d8
-
Alnylam Pharmaceuticals
@Alnylam
We've reported Q3 2024 financial results and highlights of recent period activity. Join us LIVE TODAY at 8:30 AM ET to hear from our leadership and/or access the replay later today at: investors.alnylam.com/events
$ALNY #rnai #rnaitherapeutics #sirna -
Alnylam Pharmaceuticals
@Alnylam
HCPs: Do you have a patient presenting with severe, diffuse abdominal pain and seemingly unrelated symptoms? It could be acute hepatic #porphyria (AHP). Random (spot) urine tests are the primary method to help diagnose AHP and a genetic test can determine the type.
-
Alnylam Pharmaceuticals
@Alnylam
Today and every day, we stand with the #amyloidosis community!
In recognition of #worldamyloidosisday, Alnylam colleagues worldwide linked their messages of hope and support. We’re proud to help showcase the incredible power of connection in raising awareness around this disease.
A huge thank you to everyone who joined us! -
Alnylam Pharmaceuticals
@Alnylam
We are thrilled to share that Arun Skaria has been appointed to the expanded role of Head of Diversity, Equity & Inclusion and Corporate Responsibility. At Alnylam, we believe that our long-term success and ability to deliver medicines to patients requires a diverse, equitable and inclusive workforce. Congratulations, Arun!
-
Alnylam Pharmaceuticals
@Alnylam
We'll be sharing 3rd Quarter 2024 financial results this Thursday, 10/31 at 8:30 AM ET, during a LIVE webcast. Register here: investors.alnylam.com/events and access the replay at the same link later in the day. #rnai #rnaitherapeutics #sirna
-
Alnylam Pharmaceuticals
@Alnylam
On #worldamyloidosisday, we proudly stand with @AmyloidosisA in support of the amyloidosis community. Although no two journeys are the same, every patient’s journey is linked through shared experiences and connections that remind us that no one faces this disease alone.
-
Alnylam Pharmaceuticals
@Alnylam
As a company driven by #science, it's important to us to be regarded by our peers as a great place for scientists to work. That's why we're so deeply honored to be named a @ScienceMagazine Top Place to Work for 2024 - our 6th year in a row on this list! #sctopemployers
-
Alnylam Pharmaceuticals
@Alnylam
We’re excited to join @ASNKidney and thousands of kidney professionals at Kidney Week 2024. Stop by Booth 2034 to meet the Alnylam team and learn more. We hope to see you there!
#kidneywk #rnaitherapeutics #rnai #sirna -
Alnylam Pharmaceuticals reposted
Pine Street Inn
@PineStreetInn
Bingo! Volunteers from @Alnylam recently hosted an exciting bingo tournament and ice cream social for guests at the Men's Inn and Yawkey House. Thank you for providing an opportunity for Pine Street Inn guests to socialize, connect and have fun.
-
Alnylam Pharmaceuticals
@Alnylam
Our CEO Dr. Yvonne Greenstreet kicked off day 2 of #statsummit yesterday. She sat down with @statnews's @adamfeuerstein for a lively conversation about the future of our TTR franchise, our rapidly expanding pipeline and her vision for what's next in the #rnai revolution. #rnainterference #rnaitherapeutics #biotech
-
Alnylam Pharmaceuticals reposted
STAT
@statnews
.@ygreenst @Alnylam
#statsummit -
Alnylam Pharmaceuticals
@Alnylam
Having a #raredisease like primary #hyperoxaluria type 1 (PH1) requires lifelong monitoring. In an episode of Medical Stories, Dr. John Lieske, nephrologist, discusses the importance of early diagnosis and management in relation to one family’s experience. www.youtube.com/watch?v=kWTU1CPv7d8
-
Alnylam Pharmaceuticals
@Alnylam
U.S. HCPs: Learn more about helping your patients manage acute hepatic #porphyria (AHP) in a virtual program led by @AngelikaErwinMD. Dr. Erwin will discuss symptoms that suggest a diagnosis of AHP and disease management options for this #raredisease.
-
Alnylam Pharmaceuticals
@Alnylam
We are pleased to announce that we have submitted an sNDA to the U.S. FDA for vutrisiran, an investigational #rnai therapeutic in development for the treatment of #attr-CM. Read the press release: investors.alnylam.com/press-releases
#rnaitherapeutics #rnainterference -
Alnylam Pharmaceuticals
@Alnylam
Congratulations to our former, founding CEO @JMaraganore on being awarded the Lifetime Achievement Award by the @OTSociety for his incredible contributions to the advancement of #oligonucleotide therapeutics and pioneering leadership in the #rnairevolution! #ots24 #rnai #rnaitherapeutics
Oligonucleotide Therapeutics Society
@OTSociety
Congratulations to John Maraganore, Ph.D. for winning the OTS Lifetime Achievement Award!
#ots24 #ots #oligomeeting #oligotherapeutics #biotech #biotechnology #science #research -
Alnylam Pharmaceuticals
@Alnylam
Congrats to Victor Ambrose & Gary Ruvkun of @UMassChan & @harvardmed respectively on winning the #nobelprize in Physiology or Medicine for the discovery of microRNAs. This breakthrough research helped pave the way for the incredible era of #rna-based medicines we're living in and proud to be part of! www.nobelprize.org/prizes/medicine/2024/press-release/
-
Alnylam Pharmaceuticals
@Alnylam
Navigating life with a #raredisease, like primary #hyperoxaluria type 1 (PH1), can be filled with uncertainty, but it’s important to advocate for your or your loved one’s health. Hear from Becky, a PH1 caregiver, in an episode of Medical Stories. www.youtube.com/watch?v=kWTU1CPv7d8
-
Alnylam Pharmaceuticals
@Alnylam
Yesterday, we presented additional data from the HELIOS-B Phase 3 study of vutrisiran, an investigational #rnaitherapeutic in development for the treatment of #attr #amyloidosis with cardiomyopathy (ATTR-CM) at #hfsa2024. #cardiology
-
Alnylam Pharmaceuticals
@Alnylam
Sparking curiosity in #science, one "lava lamp" at a time! Our uLearn with Alnylam team was at the Alnylam booth at the @CambSciFest yesterday helping >400 local kids learn about #chemistry while creating their own lava lamps from household ingredients. Visit: cdn.flowcode.com/prodassets/CSF_Lava_Lamp_Instruction_vF.…, for the instructions on how to make your own!
#cambridgesciencefestival #cambridgesciencefest -
Alnylam Pharmaceuticals
@Alnylam
We are pleased to announce that additional data from the HELIOS-B Phase 3 clinical trial evaluating vutrisiran, an investigational #rnaitherapeutic in development for the treatment of #attr-CM, were presented virtually at #hfsa2024.
-
Alnylam Pharmaceuticals
@Alnylam
We are pleased to announce that additional data from the HELIOS-B Phase 3 clinical trial evaluating vutrisiran, an investigational #rnaitherapeutic in development for the treatment of #attr-CM, will be presented via @HFSA livestream on Sunday, 9/29, at 9:00 AM ET.
-
Alnylam Pharmaceuticals reposted
Nature Conferences
@NatureConf
Submit your abstract and present your research to global peers discussing the latest RNA/DNA biology breakthroughs, gene therapies, and cutting-edge biotech developments at #rnabench2bedside. go.nature.com/3XIAUIX
@ionispharma @Alnylam @UCSDMedSchool @NatureBiotech -
Alnylam Pharmaceuticals
@Alnylam
Developers use operating systems like iOS or Android to quickly and easily create new apps. We use our #rnaitherapeutics platform similarly to quickly develop investigational medicines. A new @NaturePortfolio article (sponsored content; for US audiences only) explains how. #rnai
-
Alnylam Pharmaceuticals
@Alnylam
HCPs: Every acute hepatic #porphyria (AHP) attack matters. Your patient’s next attack could have life-changing consequences, like irreversible neurologic damage. Learn how timely diagnosis and management can help avoid potentially devastating outcomes. www.porphyria.com/hcp/ahp-treatment-options
-
Alnylam Pharmaceuticals
@Alnylam
This World Alzheimer’s Month, learn about #alzheimersdisease (AD) and dementia. We're working with urgency to explore the potential for our RNAi therapeutics in helping to change the outlook for people living with AD. #worldalzmonth
-
Alnylam Pharmaceuticals
@Alnylam
We shared new results from a post hoc subgroup analysis of the ENVISION Phase 3 study evaluating long-term impact of our #rnai therapeutic for the treatment of acute hepatic #porphyria (AHP) in adults at ICPP 2024. Learn more: capella.alnylam.com/2024/09/24/givo-icpp-2024
-
Alnylam Pharmaceuticals
@Alnylam
We’re en route to the 56th Annual Meeting of the European Society for Pediatric Nephrology (ESPN). We hope to see you there!
#espn2024 #rnaitherapeutics #rnai #sirna -
Alnylam Pharmaceuticals
@Alnylam
We’re thrilled to be heading to The International Congress of Porphyrins and Porphyrias (ICPP 2024) together with members of the acute hepatic #porphyria (AHP) community.
#rnaitherapeutics #rnai #sirna -
Alnylam Pharmaceuticals
@Alnylam
As a pioneer in #rna-based therapeutics, we relish opportunities to engage with peers and discuss what's new and next in nucleic acid medicines. If you do too, join us in La Jolla, CA Dec 9-11 for the @Nature #rnabench2bedside conference.
#rnai #rnainterference #sirna -
Alnylam Pharmaceuticals
@Alnylam
Early diagnosis is critical in managing a #raredisease like primary #hyperoxaluria type 1 (PH1). Left undiagnosed, patients are at increased risk for complications. Learn from Dr. David J. Sas, pediatric nephrologist, in an episode of Medical Stories.
-
Alnylam Pharmaceuticals reposted
World Amyloidosis Day
@AmyloidosisDay
Let's make #amyloidosis visible to the world! 💪
Share to spread awareness and support patients. 🌏
______
#amyloidosisawareness #worldamyloidosisday #worldamyloidosisday2024 #raiseawareness #fightamyloidosis 🌟 #invisiblenomore #spreadawareness #amyloidosisalliance -
Alnylam Pharmaceuticals
@Alnylam
HCPs: Check out this interactive acute hepatic #porphyria (AHP) case study to review a hypothetical diagnostic journey with AHP — see how your knowledge of this #raredisease compares with other physicians.
-
Alnylam Pharmaceuticals
@Alnylam
HCPs: A combination of multisystem symptoms and family history are red flags of #hattr #amyloidosis and require urgent action. If your patient’s family has a history of the disease, or is experiencing a combination of these multisystem symptoms, consider hATTR amyloidosis.
-
Alnylam Pharmaceuticals
@Alnylam
Heard the news? We're a @FastCompany Best Workplace for Innovators for the 4th year in a row! The list recognizes companies whose cultures empower employees at all levels to innovate, improve, create and transform ways of doing business that result in true impact. #alnylamproud
-
Alnylam Pharmaceuticals
@Alnylam
HCPs: Characterized by severe, diffuse abdominal pain and a range of other seemingly unrelated symptoms, acute hepatic #porphyria (AHP) can be misleading and is often misdiagnosed.
-
Alnylam Pharmaceuticals
@Alnylam
Managing a #raredisease like primary #hyperoxaluria type 1 (PH1) can be difficult, so it’s helpful to work with patient advocacy groups to answer questions and get more information. Hear from Kim Hollander of @OHFTweet in an episode of Medical Stories. www.youtube.com/watch?v=kWTU1CPv7d8
-
Alnylam Pharmaceuticals
@Alnylam
HCPs: Do you have a patient presenting with severe, diffuse abdominal pain and seemingly unrelated symptoms? It could be acute hepatic #porphyria (AHP). Random (spot) urine tests are the primary method to help diagnose AHP and a genetic test can determine the type.
-
Alnylam Pharmaceuticals
@Alnylam
We're thrilled to be named to the #humankind100 Top 100 list for the 3rd consecutive year by @Humankindinvest! Our passion for improving the health of humanity with the innovative medicines we make and robust community engagement is more than just a commitment – it's personal.
-
Alnylam Pharmaceuticals
@Alnylam
As a pioneer in #rna-based therapeutics, we relish opportunities to engage with peers and discuss what's new and next in nucleic acid medicines. If you do too, join us in La Jolla, CA Dec 9-11 for the @Nature #rnabench2bedside conference.
#rnai #rnainterference #sirna -
Alnylam Pharmaceuticals
@Alnylam
We’re harnessing the potential of RNA interference (RNAi) and will be presenting new data at the European Society of Cardiology Congress 2024 8/30-9/2 in London. Learn more: investors.alnylam.com/press-releases
-
Alnylam Pharmaceuticals
@Alnylam
Happy #rnaday! RNA is A-mazing + critical to how your body functions. Did you know that a type of RNA called small interfering RNA (siRNA) can also be utilized to treat disease?
#rna #rnainterference #rnaitherapeutics #sirna -
Alnylam Pharmaceuticals
@Alnylam
We've reported Q2 2024 financial results and highlights of recent period activity. Join us LIVE TODAY at 8:30 AM ET to hear from our leadership and/or access the replay later today at: investors.alnylam.com/events.
$ALNY #rnai #rnaitherapeutics #sirna -
Alnylam Pharmaceuticals
@Alnylam
We'll be sharing 2nd Quarter 2024 financial results this Thursday, 8/1 at 8:30 AM ET, during a LIVE webcast. Register here: investors.alnylam.com/events and access the replay at the same link later in the day. #rnai #rnaitherapeutics #sirna
-
Alnylam Pharmaceuticals
@Alnylam
Our #corporateresponsibility (CR) efforts are driven by the passion of our employees to make a positive impact on the world beyond the medicines we make. Our 2023 report details our work, shares our progress and looks ahead to what we aim to accomplish in the years to come. #esg
-
Alnylam Pharmaceuticals
@Alnylam
We're celebrating being named a @Fortune Best Workplace for Millennials for the 2nd year in a row! Thank you to our millennial colleagues whose passion and contributions power our mission to develop and deliver innovative #rnaitherapeutics for patients in need.
-
Alnylam Pharmaceuticals
@Alnylam
Innovative science is only part of the equation when it comes to developing new medicines. Clinical research relies on partnerships with health care professionals and patient advocates but most importantly, the people who choose to participate in #clinicaltrials.
-
Alnylam Pharmaceuticals
@Alnylam
Well this looks like a fun group! A warm welcome to our 34 new co-ops from @Northeastern University who started their Alnylam experience yesterday. They'll learn the business of #biopharma and support our mission by working in a wide range of functions. #rnairevolutionary
-
Alnylam Pharmaceuticals
@Alnylam
US Healthcare Professionals: Have a medical inquiry? Connect with Alnylam Medical via our RNAiScience website to use our MSL Locator tool or submit a Medical Information Request.
-
Alnylam Pharmaceuticals
@Alnylam
Proteins are the "workers" in the biochemistry of life & are critical to almost everything your body does. They can also cause or contribute to disease. #rnaitherapeutics, pioneered by Alnylam, prevent the production of specific unwanted proteins. #rnai www.alnylam.com/our-science/the-science-of-rnai
-
Alnylam Pharmaceuticals
@Alnylam
HCPs: #hattr #amyloidosis is a progressive and often fatal disease that affects multiple organs and tissues, resulting in a highly varied symptom presentation. Learn more about some different patient types that could be in your practice. www.attr-amyloidosis.com/sites/default/files/resource-fil…
-
Alnylam Pharmaceuticals
@Alnylam
#rnainterference is a naturally occurring process of gene regulation that's already at work inside your body. #rnai therapeutics, pioneered by Alnylam, utilize this process to silence the genes that cause or contribute to disease.
#science #biology #chemistry #biotech -
Alnylam Pharmaceuticals
@Alnylam
Dr. Fontana, investigator on the HELIOS-B Phase 3 study of vutrisiran, an investigational #rnai therapeutic in development for the treatment of #attr #amyloidosis w/ cardiomyopathy, shares thoughts on the topline results. Full data to be presented at an upcoming medical meeting.
-
Alnylam Pharmaceuticals
@Alnylam
We’ve shared topline results from our HELIOS-B Phase 3 study of vutrisiran, an investigational #rnai therapeutic in development for the treatment of #attr #amyloidosis w/ cardiomyopathy. Full results will be presented at an upcoming medical meeting. #rnaitherapeutics #sirna
-
Alnylam Pharmaceuticals
@Alnylam
This morning, in a live webcast, we’ll discuss topline results from our HELIOS-B Phase 3 study of vutrisiran, an investigational #rnai therapeutic in development for the treatment of #attr #amyloidosis w/ cardiomyopathy. Access it here: investors.alnylam.com/events #rnaitherapeutics
-
Alnylam Pharmaceuticals
@Alnylam
We are pleased to share positive topline results from our HELIOS-B Phase 3 study of vutrisiran, an investigational #rnai therapeutic in development for the treatment of #attr #amyloidosis w/ cardiomyopathy. Read the press release: investors.alnylam.com/press-release?id=375a47d2-b563-48c9… #rnaitherapeutics #sirna
-
Alnylam Pharmaceuticals
@Alnylam
We recently presented updates from our Phase 2 KARDIA-2 and KARDIA- 3 studies for our investigational #rnai therapeutic for the treatment of #hypertension at #esh2024. Learn more: capella.alnylam.com/2024/06/06/zilebe-esh-2024
-
Alnylam Pharmaceuticals
@Alnylam
Of the many compelling potential applications of #rnai technology, #obesity stands out as one we believe could be particularly well suited for #rnaitherapeutics to deliver clinical benefit and differentiating characteristics in the fast-growing field of weight-loss medicines.
Alnylam Pharmaceuticals
@Alnylam
As the pioneer and leader in #rnaitherapeutics, we're driven to advance the science of #rnai so as many people as possible can benefit from this innovative approach to #genesilencing.
Alnylam Pharmaceuticals
@Alnylam
We're excited to see the effort and innovation #biopharma is bringing forward to address the global obesity crisis, and are proud to be leading the way in exploring the important role #rnai may be able to play.
-
Alnylam Pharmaceuticals
@Alnylam
On the Family Health History Road Trip, learn about the importance of sparking conversations with your family and doctor to understand your risk of developing an inherited disease like #hattr #amyloidosis.
Have you ever discussed health history with your relatives?
Alnylam Pharmaceuticals
@Alnylam
Follow along the journey and learn more about #hattr #amyloidosis at www.attrrevealed.com/living-with-hATTR-amyloidosis/family…. For medical advice, please consult a doctor. #hattroadtrip
-
Alnylam Pharmaceuticals
@Alnylam
We shared new results from a post hoc subgroup analysis of the ENVISION Phase 3 study evaluating long-term impact of our #rnai therapeutic for the treatment of acute hepatic #porphyria (AHP) at the @EASLnews Congress 2024. Learn more: capella.alnylam.com/2024/06/05/givo-easl-2024
#easlcongress -
Alnylam Pharmaceuticals reposted
MassBio
@MassBio
We're at #bio2024 in the Massachusetts Pavilion Booth 811 with @MALifeSciences.
Thank you to @MALifeSciences | @thermofisher | @VertexPharma | Organogenesis | @HalloranConsult | @KPMG_US | Life Sciences Corridor | @JoinSmartLabs | ABI-LAB | @Alnylam | @TakedaPharma -
Alnylam Pharmaceuticals
@Alnylam
US Healthcare Professionals: Explore RNAiScience, a website that provides educational, clinical, and scientific information about Alnylam’s therapeutic areas and the science of RNA interference.
-
Alnylam Pharmaceuticals
@Alnylam
Through the Alnylam Assist® program, patients have access to Alnylam Patient Education Liaisons (PELs), professionals who are experienced in providing disease and product education to patients and their family members.
-
Alnylam Pharmaceuticals
@Alnylam
Headed to Philadelphia for the @ATCMeeting? Stop by Booth 218 to learn about our work in primary #hyperoxaluria type 1 (PH1) and join us on Sunday, 6/2 for our PH1 symposium. Learn more: www.atcmeeting.org/Engage/Product-Theaters #atc2024philly #rnaitherapeutics
-
Alnylam Pharmaceuticals
@Alnylam
It was a waiting game for Aubrey, who had watched her brother experience #kidneyfailure due to primary #hyperoxaluria type 1 (PH1) and wondered if she would experience the same symptoms following her PH1 diagnosis. Read about her journey with this #raredisease on @TheMightySite.
-
Alnylam Pharmaceuticals
@Alnylam
Amalia’s acute intermittent #porphyria (AIP) symptoms grew increasingly severe during her sophomore year of college. Explore Amalia’s artwork and hear her explain how she tried to claw her way back to health while experiencing monthly AHP attacks and anxiety between attacks.
-
Alnylam Pharmaceuticals
@Alnylam
DYK that #rna interference (#rnai) is a naturally occurring cellular process that’s already at work inside your body? Alnylam scientists have harnessed this process to treat specific diseases. A new @NaturePortfolio article (sponsored content) explains how. #rnaitherapeutics
-
Alnylam Pharmaceuticals
@Alnylam
Amalia was diagnosed with acute intermittent #porphyria (AIP) after experiencing frequent, severe AHP attacks and other seemingly unrelated symptoms. Now, she’s using her artwork to share her experience navigating life with this #raredisease.
-
Alnylam Pharmaceuticals
@Alnylam
We recently shared subgroup results from the KARDIA-1 Phase 2 study of zilebesiran, an investigational #rnai therapeutic for the treatment of #hypertension.
-
Alnylam Pharmaceuticals
@Alnylam
In recognition of #gpd2024, we went #purpleforporphyria to show our support for the acute hepatic #porphyria (AHP) community. We also had the opportunity to hear from a patient living with AHP, advocacy leaders and a physician expert and feel #alnylamproud to stand by their side.
-
Alnylam Pharmaceuticals
@Alnylam
With warmer months and family gatherings ahead, summer is the perfect time to discuss health with your loved ones. Hear from Renee and her father, Julio, who discussed Julio’s #hattr #amyloidosis diagnosis and the importance of genetic testing at a family reunion. #hattroadtrip
-
Alnylam Pharmaceuticals
@Alnylam
We shared new 54-month results from the Phase 2 open-label extension study of our #rnai therapeutic for the treatment of primary #hyperoxaluria type 1 (PH1) at the 61st European Renal Association Congress (#era24).
-
Alnylam Pharmaceuticals
@Alnylam
Amy had taken her son, Owen, to countless providers until a doctor suspected primary #hyperoxaluria type 1 (PH1). However, Owen’s diagnosis was just the start of a long journey ahead. Learn about the caregiver’s role in advocating for a child’s health on @TheMightySite.
-
Alnylam Pharmaceuticals
@Alnylam
Living with a #raredisease like acute hepatic #porphyria (AHP) can be a challenging and isolating experience. Hear from Veronica to find out how she found strength in her loved ones while coping with her illness. #myporphyria #gpd2024
-
Alnylam Pharmaceuticals
@Alnylam
It took six years, countless tests and being told her symptoms were “just in her head” for Megan to be diagnosed with acute hepatic #porphyria (AHP). Find out more about Megan’s story and the many ways this #raredisease has impacted her life. #myporphyria #gpd2024
-
Alnylam Pharmaceuticals
@Alnylam
Alnylam Assist® is committed to providing support to patients throughout their treatment with an Alnylam product. Alnylam Case Managers can help verify insurance coverage benefits, discuss financial assistance options and provide educational resources.
-
Alnylam Pharmaceuticals
@Alnylam
Proud to be co-sponsoring this #rna-focused conference with @ionispharma and in partnership with @UCSanDiego, @yeo_lab and @NatureBiotech. We invite you to learn more and attend! #rnairevolution #rnai #rnaitherapeutics
Nature Conferences
@NatureConf
RNA at the Bench and Bedside IV is open!
Join us for the fourth event in this series covering RNA/ DNA biology, preclinical therapeutics and clinical translation of nucleic acid gene therapies.
@ionispharma @Alnylam @UCSanDiego @yeo_lab @NatureBiotech
🎟️conferences.nature.com/RNAbenchtobedside4 -
Alnylam Pharmaceuticals
@Alnylam
We've recently published our 2023 #corporateresponsibility Report which details our efforts to operate responsibly across our business and in an environmentally sustainable manner. We’re proud of what we accomplished in 2023 and are excited to continue our CR journey. #csr #esg
-
Alnylam Pharmaceuticals
@Alnylam
Our #corporateresponsibility (CR) efforts are driven by the passion of our employees to make a positive impact on the world beyond the medicines we make. Our 2023 report details our work, shares our progress and looks ahead to what we aim to accomplish in the years to come. #esg
-
Alnylam Pharmaceuticals
@Alnylam
HCPs: A combination of multisystem symptoms and family history are red flags of #hattr #amyloidosis and require urgent action. If your patient’s family has a history of the disease, or is experiencing a combination of these multisystem symptoms, consider hATTR amyloidosis.
-
Alnylam Pharmaceuticals
@Alnylam
Alnylam was honored to sponsor the Excellence in Bioscience Award at the @MassScienceFair! Congrats to Avery Leonard from St Mark’s School on her winning project “The Influence of Ginger Root Extract on Female Reproductivity in Caenorhabditis Elegans!" The future looks bright!
-
Alnylam Pharmaceuticals
@Alnylam
Although Amalia was relieved to finally know her diagnosis of acute intermittent #porphyria (AIP), she continued to struggle with painful, severe AHP attacks and frequent hospitalizations. Learn more about her journey with AHP at Alnylam’s online gallery, amaliasstory.com.
-
Alnylam Pharmaceuticals
@Alnylam
We’re on the road again! If you’re attending the @AmerUrological 2024 Annual Meeting, visit us at Booth 1168 to learn more about our work in primary #hyperoxaluria type 1 (PH1). #aua24 #urology #rnaitherapeutics
-
Alnylam Pharmaceuticals
@Alnylam
Attending the @PASMeeting? Be sure to stop by Booth 212 to meet our Alnylam team and learn more about our work in primary #hyperoxaluria type 1 (PH1). #pas2024 #rnaitherapeutics
-
Alnylam Pharmaceuticals
@Alnylam
We've reported Q1 2024 financial results and highlights of recent period activity. Join us LIVE TODAY at 8:30 AM ET to hear from our leadership and/or access the replay later at: investors.alnylam.com/events.
$ALNY #rnai #rnaitherapeutics #sirna -
Alnylam Pharmaceuticals
@Alnylam
We're thrilled to share that Evan Lippman, our Chief Corporate Development and Strategy Officer, has joined the @MassBio Board of Directors! Evan will help direct its mission to advance our home state's leadership in the #lifesciences and grow our already world-class #biopharma e
-
Alnylam Pharmaceuticals
@Alnylam
We’re excited to sponsor #axs24 & host an important discussion on “The Current State of Rare Disease Therapeutics in the Payer Landscape.” Join us to explore the emerging trends presented in this year's Alnylam Rare Disease Trend Report. Will we see you at #assembia24? @asembiarx
-
Alnylam Pharmaceuticals reposted
United Porphyrias Association
@UnitedPorphAssc
Until now, most research about acute hepatic #porphyria has focused on symptoms and care during an acute attack.
Take a closer look at the POWER study which explored the full burden of AHP on patients from around the world.
Read more: porphyria.org/experts-in-action-page/sumup9 -
Alnylam Pharmaceuticals
@Alnylam
Unlocking the full potential of #rnaitherapeutics, ensuring that patients at the center of all we do and delivering value to healthcare stakeholders are what drive us to innovate. Our CCO Tolga Tanguler discusses our approach to #patientaccess and shares our latest Patient Access
-
Alnylam Pharmaceuticals
@Alnylam
US Healthcare Professionals: Access educational, clinical, and scientific information intended to support scientific exchange about Alnylam’s therapeutic areas and the science of RNA interference.
-
Alnylam Pharmaceuticals
@Alnylam
It was a waiting game for Aubrey, who had watched her brother experience #kidneyfailure due to primary #hyperoxaluria type 1 (PH1) and wondered if she would experience the same symptoms following her PH1 diagnosis. Read about her journey with this #raredisease on @TheMightySite.
-
Alnylam Pharmaceuticals
@Alnylam
Many symptoms of #hattr #amyloidosis resemble those of other more common conditions. This means it often takes years before an accurate diagnosis is made. The Bridge provides educational resources to help recognize the signs and symptoms of this #raredisease.
-
Alnylam Pharmaceuticals
@Alnylam
Amy had taken her son, Owen, to countless providers until a doctor suspected primary #hyperoxaluria type 1 (PH1). However, Owen’s diagnosis was just the start of a long journey ahead. Learn about the caregiver’s role in advocating for a child’s health on @TheMightySite.
-
Alnylam Pharmaceuticals
@Alnylam
We're #alnylamproud to be ranked third on LinkedIn Top Companies list of midsize employers: www.linkedin.com/pulse/linkedin-top-midsize-companies-15-…
The list recognizes the top U.S. companies for their commitment to career growth and opportunities. Inclusion and rankings are based on LinkedIn’s aggregate data about a broad range of success factors such as low attrition rates, strong career paths, ability to recruit talent, gender diversity, educational opportunities, and promotion rates. Learn about our award-winning culture and careers at Alnylam! #linkedintopcompanies
www.linkedin.com/pulse/linkedin-top-midsize-companies-15-… -
Alnylam Pharmaceuticals
@Alnylam
Will you be at #amcp2024 this year? This Wednesday, April 17th at 10:45 CT Alnylam’s Sami Nasrawi, PharmD is leading a spotlight presentation: “ATTR Amyloidosis - Disease State Overview.” Join us in Theater 2 to learn more about ATTR #amyloidosis epidemiology, clinical presentation and diagnosis of both cardiomyopathy and polyneuropathy manifestations.
Learn more about @amcporg: amcpannual.org/agenda-program/spotlight-opportunities -
Alnylam Pharmaceuticals
@Alnylam
In 2023 we saw significant milestones with exciting advances in our #rnaitherapeutics pipeline and platform, and meaningful impact for patients with our approved medicines. Our CEO @ygreenst reflects on this year and what’s to come in 2024. #rnai
-
Alnylam Pharmaceuticals
@Alnylam
US HCPs: Going to #aanam this weekend?
Come find us at booth 725 to meet our team and learn more about exciting advancements in the use of #rnainterference (RNAi) for treating the polyneuropathy of #hattr #amyloidosis. Learn more: index.mirasmart.com/AAN2024/SearchResults.php?q=alnylam -
Alnylam Pharmaceuticals
@Alnylam
Learning that you or someone in your family has hereditary #attr #amyloidosis can come as a shock, and having to explain that the condition may run in your family can be intimidating. Nurse Tootie Bueser shares tips to help guide these important conversations. #hattr #raredisease
-
Alnylam Pharmaceuticals
@Alnylam
Following her first acute hepatic #porphyria (AHP) attack, Amalia spent months of her teenage years searching for a diagnosis to explain her debilitating, unbearable symptoms. Watch Amalia explain this difficult time in her life through her artwork at our online art gallery.
-
Alnylam Pharmaceuticals
@Alnylam
Another successful ACC in the books! We were thrilled to present important new data on #rnai therapeutics and interact with so many cardiologists interested in learning more about how we’re pushing the boundaries of science to improve patient outcomes. #rnaitherapeutics #sirna #cardiology #acc24
-
Alnylam Pharmaceuticals
@Alnylam
After a doctor prescribes one of our products to a patient, they are partnered with an Alnylam Case Manager who has expertise in helping patients get started on treatment and providing product support.
-
Alnylam Pharmaceuticals
@Alnylam
Today at #acc24, we shared full results from our KARDIA-2 Phase 2 study of investigational therapeutic zilebesiran. Join our webcast at 7:00 PM ET to learn more about our commitment to progressing #rnai research to help address the unmet needs of patients with #hypertension.
-
Alnylam Pharmaceuticals
@Alnylam
Today, we presented full results of our KARDIA-2 Phase 2 study as a late-breaking clinical trial at #acc24. The study evaluated zilebesiran, an investigational #rnai therapeutic for the treatment of #hypertension, when added to standard of care antihypertensives. #sirna
-
Alnylam Pharmaceuticals
@Alnylam
US Healthcare Professionals: Have a medical inquiry? Connect with Alnylam Medical via our RNAiScience website to use our MSL Locator tool or submit a Medical Information Request.
-
Alnylam Pharmaceuticals
@Alnylam
With one Alnylam-discovered CV medicine already approved and a robust pipeline of investigational #rnai therapeutics, we believe that Alnylam (and RNAi) are at the heart of cardiac innovation.
We’re excited to be at the American College of Cardiology Scientific Sessions this weekend sharing data in #hypertension and #attr #cardiomyopathy and invite #cardiologists to learn more about the science of #rnaitherapeutics: www.alnylam.com/our-science/the-science-of-rnai
#acc24 #rnainterference #sirna #cardiology #genesilencing -
Alnylam Pharmaceuticals
@Alnylam
Attending #acc24? We’re presenting new results from the Phase 2 study of zilebesiran, an investigational #rnai therapeutic for the treatment of #hypertension. Join us on April 7th at 8:00 AM ET. #rnaitherapeutics #sirna #cardiology
-
Alnylam Pharmaceuticals
@Alnylam
Have you or a family member recently been diagnosed with Acute Hepatic #porphyria (AHP)? On this Voices of AHP podcast episode, Alicia and Sue share their experiences of living with this #raredisease.
-
Alnylam Pharmaceuticals
@Alnylam
We're headed to #acc24 in Atlanta this week, presenting new results on the use of #rnai interference (RNAi) for the treatment of cardiovascular diseases. Visit Booth 1615 to meet the Alnylam team and learn more! #rnaitherapeutics #sirna #cardiology @ACCinTouch
-
Alnylam Pharmaceuticals
@Alnylam
Innovative science is only part of the equation when it comes to developing new medicines. Clinical research relies on partnerships with health care professionals and patient advocates but most importantly, the people who choose to participate in #clinicaltrials.
-
Alnylam Pharmaceuticals
@Alnylam
Since our founding, we've taken substantive actions to be a steward of our planet, including how we design and expand our drug manufacturing operations. Our Chief Technical Operations & Quality Officer, explains how we’re sourcing renewable energy for energy-intensive operations.
-
Alnylam Pharmaceuticals
@Alnylam
Despite three visits to the ER and undergoing countless tests, Amalia still had no answers to explain her recurring painful attacks. Learn how she found escape through her art as she navigated the challenging journey to receiving her diagnosis of acute hepatic #porphyria (AHP).
-
Alnylam Pharmaceuticals
@Alnylam
It was a waiting game for Aubrey, who had watched her brother experience #kidneyfailure due to primary #hyperoxaluria type 1 (PH1) and wondered if she would experience the same symptoms following her PH1 diagnosis. Read about her journey with this #raredisease on @TheMightySite.
-
Alnylam Pharmaceuticals
@Alnylam
We’re excited to sponsor #axs24 & host an important discussion on “The Current State of Rare Disease Therapeutics in the Payer Landscape.” Join us to explore the emerging trends presented in this year's Alnylam Rare Disease Trend Report. Will we see you at #assembia24? @asembiarx
-
Alnylam Pharmaceuticals
@Alnylam
#alnylamproud to be recognized as a 2024 @USATODAY #topworkplace, ranking 13 out of 100 in our category! This recognition highlights our continued commitment to fostering a positive and engaging work environment. Learn more about the @TopWorkplaces list: topworkplaces.com/company/alnylam-pharmaceuticals/
-
Alnylam Pharmaceuticals
@Alnylam
Join genealogist and health education specialist @BennettGenie4 on a cross-country Family Health History Road Trip to meet members of the #hattr #amyloidosis community & learn about the role health history can play in receiving a timely diagnosis. #hattroadtrip
-
Alnylam Pharmaceuticals
@Alnylam
Kidney stones in children are a common sign of primary #hyperoxaluria type 1 (PH1). However, not all children with PH1 experience kidney stones.
Learn more about this #raredisease and the signs to look for during #nationalkidneymonth. -
Alnylam Pharmaceuticals
@Alnylam
The hereditary nature of #hattr #amyloidosis means patients’ families are also at risk of developing this #raredisease. Hear from David about the impact on his family. #attr
-
Alnylam Pharmaceuticals
@Alnylam
On the last stop of the Family Health History Road Trip, we visit Julio and Renee to hear how Julio’s #hattr #amyloidosis diagnosis uncovered a long-standing health mystery in his family. #hattroadtrip
-
Alnylam Pharmaceuticals
@Alnylam
We're incredibly proud of our ongoing partnership with @RefugeeAction which is helping #refugees seeking asylum build safe, happy and productive lives in the UK. This partnership is a key component of our Alnylam Challengers program and reflects the passion our people have for having a positive impact in the world beyond the medicines we make.
Our corporate donation supports the ‘Pathways to Work’ program, which to date has provided nearly 400 people with vital support through mentorship by Alnylam employees and access to supplies to gain employment or start businesses. -
Alnylam Pharmaceuticals
@Alnylam
The symptoms of Acute Hepatic #porphyria can resemble those of many other diseases. If you think you may be experiencing signs of AHP, our doctor discussion guide can help start conversations about the management of this #raredisease.
-
Alnylam Pharmaceuticals
@Alnylam
The third stop of the Family Health History Road Trip brings us to Christine, who tells us about her journey with #hattr #amyloidosis and how discussing her uncle's health history with her doctor ultimately led to her own diagnosis. #hattroadtrip
-
Alnylam Pharmaceuticals
@Alnylam
During which life stage do symptoms of primary #hyperoxaluria type 1 (PH1) typically begin?
Alnylam Pharmaceuticals
@Alnylam
Answer: D. All of the above. PH1 can affect people during any stage of their life. Some experience symptoms in childhood, while others may not have symptoms until later in life. #nationalkidneymonth
-
Alnylam Pharmaceuticals
@Alnylam
Alnylam Patient Education Liaisons (PELs) help patients who are prescribed one of our products by providing disease and product education, connecting patients to additional resources, and answering questions about treatment with our products.
-
Alnylam Pharmaceuticals
@Alnylam
Congratulations to our @HBAnet 2024 Rising Stars Lauren Sheik and Agnes Qerimi and all of this year’s Rising Stars and Luminaries honorees! See the full list at hbanet.org #alnylamproud #hbaimpact #hbawoty24 #genderequality
-
Alnylam Pharmaceuticals
@Alnylam
On stop two of the Family Health History Road Trip, Giselle shares how her father's #hattr #amyloidosis diagnosis led to her own. Discover how discussing health history with a doctor can help families understand their risk for developing this inherited disease. #hattroadtrip
-
Alnylam Pharmaceuticals
@Alnylam
Innovative science is only part of the equation when it comes to developing new medicines. Clinical research relies on partnerships with health care professionals and patient advocates but most importantly, the people who choose to participate in #clinicaltrials.
-
Alnylam Pharmaceuticals
@Alnylam
On the first stop of the Family Health History Road Trip, Dr. Saurabh Malhotra shares information about #hattr #amlyoidosis. Learn more about this inherited disease, the role of genetic testing and importance of family health conversations. #hattroadtrip
-
Alnylam Pharmaceuticals
@Alnylam
#worldkidneyday is a reminder to consider children when thinking about kidney health. Primary #hyperoxaluria type 1 (PH1) is a #raredisease that can cause recurrent kidney stones in people of all ages. When stones occur, it’s important to consider PH1. #kidneyhealthforall
-
Alnylam Pharmaceuticals reposted
American Heart Association: Massachusetts
@AmericanHeartMA
We're celebrating a century of lifesaving impact at the Boston Heart and Stroke Ball on May 4th!
Join us and campaign chair Eric Green, of @Alnylam, as we pave the way for another 100 years of healthier hearts and longer lives. Learn more: heart.org/bostonhb -
Alnylam Pharmaceuticals
@Alnylam
Rapid advancement of the field of RNA Interference (#rnai) is changing the way that medicine treats rare and more common diseases. Having pioneered this innovative class of #genesilencing medicines, we are proud to be leading the charge. Sponsored content with
@NaturePortfolio -
Alnylam Pharmaceuticals
@Alnylam
Let’s hit the road! Join the Family Health History Road Trip to learn how health history conversations and genetic testing can help those who may be at risk for developing an inherited disease like #hattr #amyloidosis. #hattroadtrip
-
Alnylam Pharmaceuticals
@Alnylam
We’re excited to announce the launch of the Family Health History Road Trip program, which aims to inspire families to dig deeper when it comes to their health history to help drive earlier diagnosis of an inherited disease like #hattr #amyloidosis. #hattroadtrip
-
Alnylam Pharmaceuticals
@Alnylam
Excited to enter her freshman year of college, Amalia soon began experiencing unexplainable, excruciating symptoms. View Amalia’s artwork in Alnylam’s online gallery to learn more about her acute intermittent #porphyria (AIP) diagnosis and experience with this #raredisease.
-
Alnylam Pharmaceuticals
@Alnylam
Amy had taken her son, Owen, to countless providers until a doctor suspected primary #hyperoxaluria type 1 (PH1). However, Owen’s diagnosis was just the start of a long journey ahead. Learn about the caregiver’s role in advocating for a child’s health on @TheMightySite.
-
Alnylam Pharmaceuticals
@Alnylam
Happy #internationalwomensday! Our colleagues came together virtually and in-person to celebrate #iwd24 with a fireside chat hosted by our CEO and celebrations in our offices that included food and activities and at our HQ, featured a women-owned business marketplace.
-
Alnylam Pharmaceuticals
@Alnylam
#hattr #amyloidosis can impact multiple organs and symptoms can become more severe over time. So it’s important to be aware of the early signs and to talk to your doctor about them as soon as possible. #attr #raredisease
-
Alnylam Pharmaceuticals
@Alnylam
We shared topline results from our KARDIA-2 Phase 2 study of zilebesiran, an investigational #rnai therapeutic, as a combination therapy for the treatment of #hypertension. We’ll present full results at #acc24 in April. #rnaitherapeutics #sirna
-
Alnylam Pharmaceuticals
@Alnylam
The Alnylam Assist® program offers support services to patients who are prescribed one of our products. Our team of experts are here to help patients access and understand treatment.
-
Alnylam Pharmaceuticals
@Alnylam
We are pleased to share topline results from our KARDIA-2 Phase 2 study of zilebesiran, an investigational #rnai therapeutic for the treatment of #hypertension, when added to standard of care antihypertensives. #rnaitherapeutics #sirna
-
Alnylam Pharmaceuticals
@Alnylam
Acute Hepatic #porphyria (AHP) is an inherited #raredisease. If you have been diagnosed, your family members may want to consider genetic testing. Our Family Genetic Screening Brochure helps explain AHP and genetic testing to your family member.
-
Alnylam Pharmaceuticals
@Alnylam
Proud to be named to @HRC’s #cei2023. This accomplishment underscores our dedication to a diverse, inclusive workplace for #lgbtq+. Our policies, benefits, and culture strive for an environment where everyone thrives, regardless of sexual orientation or gender identity.
-
Alnylam Pharmaceuticals
@Alnylam
March is #amyloidosisawarenessmonth! We’re joining the @Amyloidosisfdn in their “Light the Night for Amyloidosis” campaign by illuminating our global headquarters red to help raise awareness of #amyloidosis.
-
Alnylam Pharmaceuticals reposted
Global Genes
@GlobalGenes
It is the rarest day of the year🦓!
Did you know that there are 10,000+ rare diseases worldwide? Share this post to spread awareness about World Rare Disease day & shed light on those affected. More on World Rare Disease Day: go.globalgenes.org/RDD-2024
#rarediseaseday #raredisease -
Alnylam Pharmaceuticals reposted
National Organization for Rare Disorders (NORD)
@RareDiseases
The rarest day of the year is finally here: it's #rarediseaseday! 🦓
Tag us in your posts today as you #showyourstripes and check out our website to add to our "Faces of Rare" dedication wall, download social media graphics, and more: rarediseases.org/rare-disease-day/🦓 -
Alnylam Pharmaceuticals
@Alnylam
#dyk? Today is the rarest day of the year, and also #rarediseaseday! Today, and every day, we come to work inspired to help the global #raredisease community live longer, healthier, and fuller lives.
-
Alnylam Pharmaceuticals
@Alnylam
#alnylamsciencespotlight: Our research leaders share how scientists harnessed #rnai to create a new class of medicines in a @NatureBiotech perspective piece. RNAi technology is now poised to help millions of patients.
-
Alnylam Pharmaceuticals
@Alnylam
#dyk? Songs with 100 beats per minute provide the right tempo to deliver CPR to someone in need. Learn more at @AmericanHeartMA's Hands-Only CPR Serve Day this week. We’re proud to sponsor (and we’re partial to ABBA’s “Dancing Queen.") #heartmonth
American Heart Association: Massachusetts
@AmericanHeartMA
Companies are joining together for a virtual presentation on Hands-Only CPR on Feb. 28 from 12-1 p.m. Register your company here: heart.zoom.us/webinar/register/WN_CCvYXKduSQa9_evdUZ_AaQ
Thanks to local sponsor @Alnylam for supporting this event! Together we are a relentless force for longer, healthier lives. -
Alnylam Pharmaceuticals
@Alnylam
In honor of #blackhistorymonth, our SHADES multi-cultural ERN and Global Black Initiative (GBI) group hosted a celebration of Black culture at our headquarters in Cambridge, MA. Attended by both Alnylam colleagues and the broader community, the evening included food, music, paintings from our featured guest artist, Jaleel Davis, poetry and networking.
Our CEO Yvonne Greenstreet, and others, spoke about the importance of #blackhistory and representation in #stem. The theme was reinforced by the presentation of checks for $5k each to @thepossiblezone and @SCFG – two long-time community partners who focus on providing educational and entrepreneurial opportunities for under-served youth. -
Alnylam Pharmaceuticals
@Alnylam
Out of the six children in Kim's family, Kim and her sister were affected by primary #hyperoxaluria type 1 (PH1), and their brother was also suspected to have this #raredisease.
As we approach #rarediseaseday, learn more about PH1. #shareyourcolors www.youtube.com/watch?v=I9w7UzHg31I&list=PLCHQLbyuZK3ndyC… -
Alnylam Pharmaceuticals
@Alnylam
Thrilled to sponsor @MassBioEd's #lifesceinces Workforce conference! At Alnylam we’re committed to helping build tomorrow’s high-tech workforce in our home state of #massachusetts, making our continued support of #massbioed's #workforcedevelopment efforts important and impactful.
-
Alnylam Pharmaceuticals
@Alnylam
Alnylam Patient Education Liaisons (PELs) help patients who are prescribed one of our products by providing disease and product education, connecting patients to additional resources, and answering questions about treatment with our products.
-
Alnylam Pharmaceuticals
@Alnylam
The challenges of #healthequity are daunting but social entrepreneurs from @AttaneHealth and @youaresamaritan, in partnership with @Acumen and Alnylam’s Challengers Program, are tackling them with innovative solutions. news.alnylam.com/responsibility/articles/health-equity-sy…
-
Alnylam Pharmaceuticals
@Alnylam
We’re celebrating Alnylam Italy on receiving SIX recognitions at the Life Science Excellence Awards (LSEA)! LSEA honors companies contributing to excellence and innovation in the #lifesciences industry.
We're extremely #alnylamproud of these awards, but more than that, these recognitions motivate and inspire us in the work we do every day to improve diagnosis and enable better access to treatment for patients in need.
Learn more about the awards:
www.lsea.it/vincitori-2023/ -
Alnylam Pharmaceuticals
@Alnylam
Catilena’s hATTR amyloidosis journey highlights challenges associated with diagnosis and showcases the resilience of the rare disease community. Learn more about hATTR amyloidosis, a rare disease: www.hattrbridge.eu
#rarediseaseday #shareyourcolors -
Alnylam Pharmaceuticals
@Alnylam
HCPs: Early diagnosis of #rarediseases like primary #hyperoxaluria type 1 (PH1) is crucial given the progressive nature of the disease. Read a publication in @jpurology to learn about the clinical features exhibited in children with PH1.
-
Alnylam Pharmaceuticals
@Alnylam
9️⃣ days until #rarediseaseday! We’re sharing our colors for the #raredisease community by lighting up our headquarters in Cambridge, MA all month long. How will you #lightupforrare this year?
-
Alnylam Pharmaceuticals
@Alnylam
The reality of living with a #raredisease goes beyond the physical impact. People with rare diseases like acute hepatic #porphyria (AHP) also face mental burdens. #rarediseaseday is an opportunity to shine a light on the need for increased support for the rare disease community.
-
Alnylam Pharmaceuticals
@Alnylam
A 2023 study published in @jpurology found that primary #hyperoxaluria type 1 (PH1) often has delayed diagnosis due to overlapping symptoms with non-PH1 related early-onset kidney stone disease. Learn more.
-
Alnylam Pharmaceuticals
@Alnylam
Today, results from the Phase 2 KARDIA-1 study of our investigational #rnai therapeutic in development for the treatment of #hypertension were published in @JAMANetwork. Learn more about our findings.
-
Alnylam Pharmaceuticals
@Alnylam
As “change the world” kind of people, we want employees to be proud of the mission we work towards every day. Feeling accomplished is a key pillar to our success and @GPTW_UK recognizes that. Learn about the 3️⃣ ways we foster a sense of pride at Alnylam. www.greatplacetowork.co.uk/resources/3-ways-alnylam-foste…
-
Alnylam Pharmaceuticals
@Alnylam
This morning, we reported Q4 2023 financial results and highlights of recent period activity. Join us for a LIVE webcast TODAY at 8:30 AM ET to hear from our leadership or access the replay later in the day at: investors.alnylam.com/events. $ALNY #rnai #sirna
-
Alnylam Pharmaceuticals
@Alnylam
Early, accurate diagnosis of Acute Hepatic #porphyria (AHP) may make a difference in a person's ability to maintain their quality of life. Listen to Sue who lives with the #raredisease and her sister Liz who both advocate for greater awareness of the condition.
-
Alnylam Pharmaceuticals
@Alnylam
This Thursday, 2/15 at 8:30 AM ET, we'll be sharing 4th Quarter 2023 financial results during a LIVE webcast. A replay will be available at the link below later in the day. #rnai #rnaitherapeutics #sirna
-
Alnylam Pharmaceuticals
@Alnylam
The countdown to #rarediseaseday is on, but for those living with a #raredisease, every day is Rare Disease Day. To learn more about how you can support the rare disease community, visit rarediseaseday.com.
-
Alnylam Pharmaceuticals
@Alnylam
Happy Lunar New Year! Our SHADES: InspirASIAN employee resource network helped us usher in the #yearofthedragon with a celebratory event filled with food, fun and traditional festivities.
From fortune picking to tapping into our creative sides with Chinese paper cutting, and getting tangled up (in a good way!) with Chinese knot tying, we embraced the traditions in full force! Wishing all a year of good health, prosperity and happiness! 🎉🐉✨
#lunarnewyear #chinesenewyear -
Alnylam Pharmaceuticals reposted
Healthcare Businesswomen’s Association (HBA)
@HBAnet
"It’s actually incredible to me that there are only 6 female CEOs of biotech companies that have market capitalizations of more than $5 billion. We have a lot of work to do." 2024 HBA Woman of the Year Yvonne Greenstreet, @Alnylam
#hbaimpact #hbawoty24 english.elpais.com/science-tech/2023-07-29/its-incredible… -
Alnylam Pharmaceuticals
@Alnylam
As he navigated his journey to diagnosis, John was his own superhero and pushed for answers to ensure his concerns weren’t overlooked. Hear about John’s experience with #hattr #amyloidosis in an Alnylam-sponsored episode of @AccessHealthTV airing on @Lifetimetv.
-
Alnylam Pharmaceuticals reposted
Great Place to Work® UK
@GPTW_UK
Discover how @Alnylam, a leading BioPharma company and a 2023 UK's Best Workplace™, fosters pride among employees across multiple countries in our latest case study: www.greatplacetowork.co.uk/resources/3-ways-alnylam-foste…
-
Alnylam Pharmaceuticals
@Alnylam
It can be overwhelming when you or someone you know has been diagnosed with primary #hyperoxaluria type 1 (PH1). If you have questions, know you are not alone. #raredisease
-
Alnylam Pharmaceuticals
@Alnylam
What does it take to challenge health inequality? It takes creativity, passion, resilience, and a drive to create a better world. Our 1st Health Equity Symposium showcased #socialentrepreneurs who embody these qualities. It also takes investment and support from organizations like @Acumen and programs like Alnylam Challengers to help social enterprises grow and scale. Thank you to Emily Brown from @AttaneHealth, Jonathan Kumar from @youaresamaritan, and Amon Anderson from Acumen America for sitting with Alnylam's Sara Nochur to share your inspiring stories and perspectives with our employees, community partners and other aspiring social entrepreneurs! #healthequity #alnylamchallengers
-
Alnylam Pharmaceuticals
@Alnylam
In celebration of #blackhistorymonth, we’re recognizing and honoring African Americans who have inspired us through their profound contributions to modern #science and #healthcare. Some are well-known, while others deserve to be. Their dedication, innovation, and resilience advanced their respective fields and healthcare in the U.S. and left an indelible mark on global health.
-
Alnylam Pharmaceuticals
@Alnylam
Our CEO @ygreenstreet is a trailblazer and global citizen with unique #biopharma perspective. She recently sat down with Sonathan Soroff for a fascinating and fun interview for the February issue of @BostonMagazine. #leadership #rnai #rnairevolutionary
-
Alnylam Pharmaceuticals
@Alnylam
Innovative science is only part of the equation when it comes to developing new medicines. Clinical research relies on partnerships with health care professionals and patient advocates but most importantly, the people who choose to participate in #clinicaltrials.
-
Alnylam Pharmaceuticals
@Alnylam
At Alnylam, being "a responsible company" is about more than pledging to make a difference or totaling up our volunteer hours. It's about the initiatives we undertake, the community organizations we work with and the decisions we make about how we grow. It's also about living by our values in the way that we do business and the example we aim to set within our industry. We're proud to be recognized by
@Newsweek for our efforts for the 2nd year in a row, being named one of America's Most Responsible Companies! Learn more: news.alnylam.com/responsibility/articles/alnylam-named-on…
#corporateresponsibility #esg #mostresponsiblecompanies -
Alnylam Pharmaceuticals
@Alnylam
Early detection and diagnosis of primary #hyperoxaluria type 1 (PH1) is critical in disease management, making it extra important to know how to spot red flag symptoms. #raredisease
-
Alnylam Pharmaceuticals
@Alnylam
Genetics and insights from the human genome are helping researchers identify new drug targets and improve the likelihood of successful outcomes in the clinical. Sponsored content with @NaturePortfolio.
go.nature.com/3vN8wuQ -
Alnylam Pharmaceuticals
@Alnylam
Getting an accurate #raredisease diagnosis can take a long time because symptoms often present as those of other conditions. We’re working to raise awareness of #hattr #amyloidosis to help shorten the time to diagnosis for people with this disease.
-
Alnylam Pharmaceuticals
@Alnylam
Pat and Laura, mothers and caregivers to children diagnosed with primary #hyperoxaluria type 1 (PH1) describe their families experiences with the journey to diagnosis with this #raredisease. See more perspectives, learn about PH1 & access resources at takeonph1.com.
-
Alnylam Pharmaceuticals
@Alnylam
Today at the @wef @Davos Forum, our CEO Yvonne Greenstreet joined a panel hosted by the @HBAnet to discuss how our industry can help shape the future of healthcare.
Yvonne shared her perspective on the need to focus on #healthequity in the development of innovative new therapies and the opportunity that exists for #biopharma to partner with the broad spectrum of healthcare stakeholders to ensure that the latest treatments and technology benefit all patients in need.
Mary Stutts moderated the panel, which included Chitkala Kalidas and Patrick Horber and was sponsored by @femalequotient.
#wef24 #equalitylounge #drugdevelopment -
Alnylam Pharmaceuticals reposted
Healthcare Businesswomen’s Association (HBA)
@HBAnet
Join HBA CEO Mary Stutts, #hbawoty24 Yvonne Greentstreet, @Alnylam, Patrick Horber, @Novartis, and Chitkala Kalidas, @Bayer for a discussion #healthcaretrends, technological advancements & policy shifts, & their impact.
Watch live: 1/17, 8:30am CET @FemaleQuotient
#hbaimpact -
Alnylam Pharmaceuticals
@Alnylam
Because the symptoms of acute hepatic #porphyria (AHP) vary widely, diagnosing this #raredisease can be difficult and take up to 15 years. pinpointahp.com can help you learn more about AHP and how it’s diagnosed.
-
Alnylam Pharmaceuticals reposted
BiotechTV
@BiotechTV
SF Healthcare Week: @Alnylam CEO Yvonne Greenstreet previews 2024, including HELIOS-B.
Full video: www.biotechtv.com/post/alnylam-january-09-2024This media couldn't be displayed. See it on the original post. -
Alnylam Pharmaceuticals
@Alnylam
People living with the #raredisease Acute Hepatic #porphyria (AHP) can often wait up to 15 years to receive an accurate diagnosis. Hear the stories of eight people living with the condition.
-
Alnylam Pharmaceuticals
@Alnylam
Since their inception, we’ve worked with @JoinGenUnity to support their #healthequity movement. Their 6 module program unlocks community-centered innovation and connects residents with experts in health-related institutions.
-
Alnylam Pharmaceuticals
@Alnylam
Many symptoms of #hattr #amyloidosis resemble those of other more common conditions. This means it often takes years before an accurate diagnosis is made. The Bridge provides educational resources to help recognize the signs and symptoms of this #raredisease.
-
Alnylam Pharmaceuticals
@Alnylam
HCPs: Although #kidneystones are the most common, and often the first symptom of primary #hyperoxaluria type 1 (PH1), not all people with PH1 will have stones. Learn to recognize the signs and symptoms of PH1 in children and adults and how you can test for this #raredisease.
-
Alnylam Pharmaceuticals reposted
Healthcare Businesswomen’s Association (HBA)
@HBAnet
Announcing our 2024 Honorees:
Woman of the Year: Yvonne Greenstreet, MBChB, @Alnylam
Honorable Mentor: Otis Johnson, Trial Equity
STAR: Kathrin Scheonborn, Kathrin Schoenborn Consulting
Join us 10 May at #hbawoty24!
hbanet.org/news/2024/01/4/healthcare-industry-equity-cham…
#hbaimpact #genderequality -
Alnylam Pharmaceuticals
@Alnylam
Deeply #alnylamproud to share that our CEO Yvonne Greenstreet has been named 2024 Woman of the Year by @HBAnet! This award honors a leader who has made extraordinary contributions to healthcare and the advancement of women in the workplace. #hbawoty24
-
Alnylam Pharmaceuticals
@Alnylam
We’ve announced preliminary Q4 and full-year 2023 global net product revenues and additional updates. Tune into our live #jpm24 webcast this morning at 9:45 AM PT/12:45 PM ET to learn more. Access the live webcast here: investors.alnylam.com/events. #rnai #rnaitherapeutics
-
Alnylam Pharmaceuticals
@Alnylam
While not every kid of Alnylam can pronounce our name (it’s AL-NY-LUM), or know exactly what their parents do here, they (and @GPTW_US) recognize it’s a great place for parents to work! Learn more: alnylam.com/Careers. #gptw #greatplacetowork #gptwcertified #workplaceculture #companyculture
-
Alnylam Pharmaceuticals
@Alnylam
What exactly is #healthequity and what are our community partners doing to help residents? Recognizing each community is different, @JoinGenUnity ensures that those who are proximal to the challenges are at the forefront of shaping the solutions. news.alnylam.com/responsibility/articles/community-spotli…
-
Alnylam Pharmaceuticals
@Alnylam
There are various symptoms associated with #hattr #amyloidosis which can be similar to those of other conditions. Talking to your doctor about your symptoms can help with an accurate diagnosis. Learn tips for starting this conversation with our Doctor Discussion Guide.
-
Alnylam Pharmaceuticals
@Alnylam
This year has been truly remarkable as we celebrated important advancements in the science of RNAi, worked to deliver innovative medicines and strengthened our award-winning culture. Wishing everyone a #happynewyear and sending our best wishes for a fantastic 2024! 🎉
 -
Alnylam Pharmaceuticals
@Alnylam
Amalia was diagnosed with acute intermittent porphyria (AIP) after experiencing frequent, severe AHP attacks and other seemingly unrelated symptoms. Now, she’s using her artwork to share her experience navigating life with this RareDisease.
-
Alnylam Pharmaceuticals
@Alnylam
Since our founding, we've taken substantive actions to be a steward of our planet, including how we design and expand our drug manufacturing operations. Our Chief Technical Operations & Quality Officer, explains how we’re sourcing renewable energy for energy-intensive operations.
-
Alnylam Pharmaceuticals
@Alnylam
During this year’s R&D Day, we shared updates demonstrating our continued innovation and leadership in #rnai. Our robust pipeline is primed to deliver 9 or more INDs by 2025. Read the full press release: investors.alnylam.com/press-release?id=a70f706e-7b54-4cd7…
#rnaitherapeutics #biotech -
Alnylam Pharmaceuticals reposted
CASPAR Shelters
@CASPARshelters
Proud to share the success of our Packing Day with @Alnylam Pharmaceuticals! 100 Wish List bags fulfilled, featuring gift bags of coats, boots, and pants! Shoutout to Alnylam Pharmaceuticals for sponsoring the highest number of folks in our #givehomelessnesstheboot campaign. 💙
-
Alnylam Pharmaceuticals
@Alnylam
This week employees at HQ got together for one of our favorite holiday traditions! They packed up donations in support of @CASPARshelters' #givehomelessnesstheboot campaign. Our team supported over 100 of our neighbors with bags of coats, boots and other essential winter gear.
-
Alnylam Pharmaceuticals
@Alnylam
We’re so #alnylamproud to have been named one of Fortune’s Best Workplaces for Women for 2023 by @FortuneMagazine and @GPTW_US! Thank you to all of our incredibly smart, talented, and passionate women employees for all they do every day to advance our mission.
At Alnylam, we believe that our long-term success and ability to deliver transformative medicines to patients requires a diverse, equitable and inclusive environment where all employees are enabled to achieve their full potential.
Learn more and see the full #bestworkplaces list: fortune.com/ranking/best-workplaces-for-women/ -
Alnylam Pharmaceuticals
@Alnylam
Amy had taken her son, Owen, to countless providers until a doctor suspected primary #hyperoxaluria type 1 (PH1). However, Owen’s diagnosis was just the start of a long journey ahead. Learn about the caregiver’s role in advocating for a child’s health on @TheMightySite.
-
Alnylam Pharmaceuticals
@Alnylam
Today during our 2023 R&D Day, we highlighted #rnai therapeutic platform advances, clinical pipeline updates and more. You can access the replay of the webcast and presentation at alnylam.com/events. #rnaitherapeutics #sirna #rnairevolution
-
Alnylam Pharmaceuticals
@Alnylam
Today during our 2023 R&D Day, we are highlighting #rnai therapeutic platform advances, clinical pipeline updates and more. #rnaitherapeutics #sirna #rnairevolution investors.alnylam.com/press-release?id=a70f706e-7b54-4cd7…
-
Alnylam Pharmaceuticals
@Alnylam
Excited to enter her freshman year of college, Amalia soon began experiencing unexplainable, excruciating symptoms. View Amalia’s artwork in Alnylam’s online gallery to learn more about her acute intermittent #porphyria (AIP) diagnosis and experience with this #raredisease.
-
Alnylam Pharmaceuticals
@Alnylam
After a doctor prescribes one of our products to a patient, they are partnered with an Alnylam Case Manager who has expertise in helping patients get started on treatment and providing product support.
-
Alnylam Pharmaceuticals
@Alnylam
Our SAGA (Sexuality and Gender Alliance) employee resource group hosted @OUTbioBoston's #winterwonderland celebration. #biotech professionals from OUTbio and @WESTorg (Women in the Enterprise of Science and Technology) joined Alnylam employees at our Corporate HQ for an evening of networking and holiday-themed food and fun. With over 250 attendees, this was the largest #outbio event yet! Thanks to all who joined to celebrate the holiday season. #lgbtq #womeninstem
-
Alnylam Pharmaceuticals
@Alnylam
As he navigated his journey to diagnosis, John was his own superhero and pushed for answers to ensure his concerns weren’t overlooked. Hear about John’s experience with #hattr #amyloidosis in an Alnylam-sponsored episode of @AccessHealthTV airing on @Lifetimetv.
-
Alnylam Pharmaceuticals
@Alnylam
#icymi: Alnylam was named @BostonGlobe’s #1 workplace in the largest employer category (for the 3rd year in a row)! We accepted the award at #bostonglobe’s celebration. We are incredibly proud of our employees — without you, we wouldn’t be a #topplacetowork!
-
Alnylam Pharmaceuticals
@Alnylam
Don’t miss our 2023 R&D Day, webcasting LIVE on Wednesday, December 13 at 8:30 am EST. If you do miss the live session, never fear – you’ll be able to watch the reply later in the day here: onlinexperiences.com/scripts/Server.nxp?LASCmd=AI:4;F:QS!…. #rnai #rnaitherapuetics #sirna
-
Alnylam Pharmaceuticals
@Alnylam
Learning that you or someone in your family has hereditary #attr #amyloidosis can come as a shock, and having to explain that the condition may run in your family can be intimidating. Nurse Tootie Bueser shares tips to help guide these important conversations. #hattr #raredisease
-
Alnylam Pharmaceuticals
@Alnylam
End-of-session poster presentations are a special opportunity for co-op classes to share what they learned and worked on during their Alnylam experience. Congratulations to the Fall 2023 Co-op class and thank you for all that you’ve contributed during your experience! We are #alnylamproud to have called you “colleagues” and wish you all the best in what’s next!
-
Alnylam Pharmaceuticals
@Alnylam
At Alnylam, being "a responsible company" is about more than pledging to make a difference or totaling up our volunteer hours. It's about the initiatives we undertake, the community organizations we work with and the decisions we make about how we grow. It's also about living by our values in the way that we do business and the example we aim to set within our industry. We're proud to be recognized by @Newsweek for our efforts for the 2nd year in a row, being named one of America's Most Responsible Companies!
Learn more: news.alnylam.com/responsibility/articles/alnylam-named-on…
#corporateresponsibility #esg #mostresponsiblecompanies -
Alnylam Pharmaceuticals reposted
The Boston Globe
@BostonGlobe
Employee engagement company Energage invited more than 7,800 organizations with employees in Mass. to participate.
In the largest company category, there's a repeat winner: @Alnylam.
View the other companies with 1,000 or more employees on the list: www.bostonglobe.com/2023/11/29/magazine/top-largest-compa… -
Alnylam Pharmaceuticals
@Alnylam
The #drugdevelopment process utilizes a significant amount of energy. We recognize our responsibility to minimize our impact on the environment and consider actions to take to improve the health of the planet while working to improve the health of humanity.
-
Alnylam Pharmaceuticals
@Alnylam
#alnyamproud to be ranked @BostonGlobe's #1 Largest Employer in Massachusetts for the THIRD year in a row! This makes us a Boston Globe top place to work nine years in a row. Thank you to our incredible employees. It’s YOU that makes Alnylam a great place to work!
-
Alnylam Pharmaceuticals
@Alnylam
To help prevent others from having a long road to diagnosis like Colin did with acute hepatic #porphyria (AHP), he helped pass state legislation requiring #raredisease screening in newborns. Read about the impact of Colin’s journey in an Alnylam-sponsored @porphyria_news article.
-
Alnylam Pharmaceuticals
@Alnylam
The hereditary nature of #hattr #amyloidosis means patients’ families are also at risk of developing this #raredisease. Hear from David about the impact on his family. #attr
-
Alnylam Pharmaceuticals
@Alnylam
On #givingtuesday we invite you to learn more about the organizations we partner with throughout the year and around the globe to help improve the health and wellbeing of humanity.
-
Alnylam Pharmaceuticals
@Alnylam
The Alnylam Assist® program offers support services to patients who are prescribed one of our products. Our team of experts are here to help patients access and understand treatment.
-
Alnylam Pharmaceuticals
@Alnylam
#hattr #amyloidosis can impact multiple organs and symptoms can become more severe over time. So it’s important to be aware of the early signs and to talk to your doctor about them as soon as possible. #attr #raredisease
-
Alnylam Pharmaceuticals
@Alnylam
As November comes to a close, we’d like to pause to recognize the family members, friends and others who are #caregivers to people living with #rarediseases and other conditions during #nationalcaregiversmonth and every day. #nfcm #caringaroundtheclock
-
Alnylam Pharmaceuticals
@Alnylam
Congratulations to the graduates of @MassBioEd’s #biomanufacturing Apprenticeship program! This graduating class included five new apprentices who are joining the Alnylam team.
We’re #alnylamproud to be an education partner for this important high-tech workforce development program in Massachusetts, and excited for all of the graduates!
#rnaitherapeutics #rnai #rnairevolution -
Alnylam Pharmaceuticals
@Alnylam
Colin began to have a myriad of health problems as an adult, including abdominal pain and episodes of paralysis in his arms and legs, which ultimately led to his acute hepatic #porphyria (AHP) diagnosis. Learn more about Colin in @porphyria_news, sponsored by Alnylam.
-
Alnylam Pharmaceuticals
@Alnylam
Congrats to Team Nephrogen - winners of the 2nd Alnylam Bioventure Challenge! Developed with @NucleateHQ, the Challenge seeks to support promising #biotech founders as they grow and scale their early-stage companies. Thank you to all of the impressive semi-finalists who pitched!
-
Alnylam Pharmaceuticals
@Alnylam
A big part of pioneering #rnaitherapeutics was developing the platform technology that makes this innovative new class of #genesilencing medicines possible. That’s why it’s so gratifying to be recognized by @Deloitte as part of their Technology #fast500 for the 4th in a row.
-
Alnylam Pharmaceuticals
@Alnylam
Our CEO @ygreenst joined industry leaders at #ftpharma, @ftlive's Global Pharma and Biotech Summit. Speaking on embracing disruption as a leader in #lifesciences, Yvonne was thrilled to talk about the impact and responsibility executive leaders have on company culture.
-
Alnylam Pharmaceuticals
@Alnylam
The symptoms of #hattr #amyloidosis can vary widely. Learn more about the signs to help identify this #raredisease more quickly and shorten the time to diagnosis. #attr
-
Alnylam Pharmaceuticals
@Alnylam
#icymi: We shared Phase 2 results evaluating zilebesiran, our investigational #rnai therapeutic being developed for the treatment of #hypertension in patients with high #cardiovascular risk, at #aha23. Learn more about the findings: investors.alnylam.com/press-releases
-
Alnylam Pharmaceuticals
@Alnylam
During Hyperoxaluria Awareness Week, we were #alnylamproud to wear blue in support of the #hyperoxalura community. Thank you to @OHFTweet and the entire hyperoxaluria community for coming together to help shed light on this #raredisease and enact positive change for people affected by the condition.
-
Alnylam Pharmaceuticals
@Alnylam
We love talking to students about #stem, sparking interest in careers in #biotech! At @Nature's recent #crackingthecode23 @NatureConf hosted at @WPI, colleagues including our Chief DE&I Officer and former head of Regulatory, Sara Nochur met and spoke with hundreds of students from local high schools. We were thrilled by their interest and excitement and expect to see many of them become the next generation of biotech leaders!
-
Alnylam Pharmaceuticals
@Alnylam
Happy (day after) Diwali! Our Shades InspirASIAN Employee Resource Network (ERN) hosted a celebration of #diwali at our Cambridge Campus for all employees to learn the importance of the Hindu #festivaloflights. It was an event filled with music, bright colors and a few friendly competitions! #alnylamproud to celebrate the cultures of our colleagues worldwide!
-
Alnylam Pharmaceuticals
@Alnylam
Our Alnylam team is thrilled to be at #aha23 this weekend engaging with cardiologists from across the U.S. Stop by Booth 715 to learn about the science of RNA interference (#rnai) and how we hope to contribute to the fight against #cardiovasculardisease. #rnaitherapeutics
-
Alnylam Pharmaceuticals
@Alnylam
Today at #aha23, we presented new results from the KARDIA-1 Phase 2 dose-ranging study of zilebesiran, our investigational #rnai therapeutic in development for the treatment of #hypertension in patients with high #cardiovascular risk #rnaitherapeutics
-
Alnylam Pharmaceuticals
@Alnylam
Eric Green, SVP and Head of Development Programs, has been named chair of the 2024 @AmericanHeartMA The Heart of Boston! #alnylamproud to continue celebrating and supporting the American Heart Association’s year-round effort to save lives from heart disease.
-
Alnylam Pharmaceuticals
@Alnylam
On #veteransday, we thank, honor and salute all #veterans for their service. Today at Alnylam, we’re proud to pay tribute to past and present service members among our colleagues who have served their countries. #alnylamproud
-
Alnylam Pharmaceuticals
@Alnylam
After enduring a lengthy journey to diagnosis with acute hepatic #porphyria (AHP), Colin developed a disease management plan that helped him feel like he could quit centering his life around AHP. Read about his experience in an Alnylam-sponsored article in @porphyria_news.
-
Alnylam Pharmaceuticals
@Alnylam
Kim battled kidney stones without explanation since childhood, but it wasn’t until after her sister passed away from primary #hyperoxaluria type 1 (PH1) that she, too, was diagnosed with PH1. This Hyperoxaluria Awareness Week, learn more about Kim’s story. youtu.be/I9w7UzHg31I
-
Alnylam Pharmaceuticals reposted
Oxalosis & Hyperoxaluria Foundation
@OHFTweet
It's officially HYPEROXALURIA AWARENESS WEEK!!!
🎉🎊
We're raising awareness and generating change for people worldwide living with hyperoxaluria, their families and caregivers!
1/2 -
Alnylam Pharmaceuticals reposted
American Kidney Fund
@KidneyFund
Primary hyperoxaluria is a liver disease characterized by the accumulation of a substance known as oxalate in the kidneys and causes kidney stones & kidney damage. This #hyperoxluria Awareness Week, learn more & help raise awareness of this rare condition: hyperoxaluriaweek.ohf.org
-
Alnylam Pharmaceuticals reposted
American Kidney Fund
@KidneyFund
This #hyperoxaluria Awareness Week, tune into a special episode of Medical Stories 📺 Follow one family’s journey with #ph1, including the diagnosis of 3 of their children. Watch on your local @PBS or learn more on @Alnylam’s YouTube channel: www.youtube.com/watch?v=kWTU1CPv7d8&list=PLCHQLbyuZK3ndyC…
-
Alnylam Pharmaceuticals
@Alnylam
During #hyperoxaluria Awareness Week, join us in raising awareness of the inherited #raredisease primary hyperoxaluria type 1 (PH1), alongside @OHFTweet and the broader hyperoxaluria community. Learn more about PH1 and its impact on patients.
-
Alnylam Pharmaceuticals
@Alnylam
HCPs: We’re committed to advancing care for those with primary #hyperoxaluria type 1 (PH1), including patients like Seth. Our research at #kidneywk shows our continued focus on this #raredisease www.youtube.com/watch?v=wa8kUpQ32eo
-
Alnylam Pharmaceuticals
@Alnylam
HCPs: Patients with severe renal impairment due to advanced primary #hyperoxaluria type 1 (PH1) can face many challenges, including oxalate build-up throughout the body causing organ damage. Learn more about PH1, such as the importance of early diagnosis. #kidneywk
-
Alnylam Pharmaceuticals
@Alnylam
At the @ASNKidney meeting, we presented 24-month results from the ILLUMINATE-C Phase 3 study of our #rnai therapeutic for the treatment of advanced primary #hyperoxaluria type 1 (PH1), as well as a retrospective analysis of advanced PH1. Learn more about the findings. #kidneywk
-
Alnylam Pharmaceuticals
@Alnylam
Calling all #pharmd's interested in exploring a career in #biopharma. The application period for the Alnylam/@Northeastern University PharmD Fellowship Program is still open! This 2-year paid program provides fellows with hands-on experience as they take on meaningful projects & roles and explore interests in multiple expertise areas across the company. Learn more: www.alnylam.com/sites/default/files/pdfs/PharmD-Fellowshi…
-
Alnylam Pharmaceuticals
@Alnylam
This morning, we reported Q3 2023 financial results and highlights of recent period activity. Join us for a LIVE webcast TODAY at 8:30 AM ET to hear from our leadership or access the replay later in the day at: investors.alnylam.com/events. $ALNY #rnai #sirna
-
Alnylam Pharmaceuticals
@Alnylam
We’re thrilled to be at the International ATTR Amyloidosis Meeting for Patients and Doctors where we’ll be presenting recommendations calling for a more holistic approach to #hattr #amyloidosis. Learn more about how we can make these a reality. #raredisease #attramyloidosis2023
-
Alnylam Pharmaceuticals reposted
NATA - Nucleic Acid Therapy Accelerator
@NATA_MRC_UK
🌟Today at TIDES Europe 2023, we heard from Muthiah Manoharan, SVP of Drug Innovation Chemistry at @Alnylam. Mano shared insights on AOCC click chemistry for oligonucleotide therapeutics and discussed novel modifications to improve siRNA therapeutics.
📢 Follow for more updates! -
Alnylam Pharmaceuticals
@Alnylam
This Thursday, 11/2 at 8:30 AM ET, we'll be sharing 3rd Quarter 2023 financial results during a LIVE webcast. A replay will be available at the link below later in the day. #rnai #rnaitherapeutics #sirna
-
Alnylam Pharmaceuticals
@Alnylam
We’re #alnylamproud to have joined @AmyloidosisA and the #amyloidosis community across the globe to raise awareness of this #raredisease for #worldamyloidosisday.
-
Alnylam Pharmaceuticals
@Alnylam
Led by our SHADES: InspirASIAN Employee Resource Network, we’re proud to Celebrate #filipinoamericanhistorymonth. 🇵🇭 All year, InspirASIAN helps us acknowledge and honor #aapiheritage, through education and celebrations. #fahm
-
Alnylam Pharmaceuticals
@Alnylam
Another Global Community Service Week done and dusted! We had an incredible week with 1,000+ Alnylam colleagues donating 3,000+ total hours during 48 total volunteer projects throughout 11 countries!
This year’s projects ranged from environmental conservation, supporting #stem education, aiding homelessness, and refugee populations, and so much more, each contributing to a collective effort to achieve #healthequity for all.
Thank you to our community partners and our Alnylam colleagues for the incredible effort to come together across the globe to serve our local communities! 💙 -
Alnylam Pharmaceuticals
@Alnylam
We’re #alnylamproud to be a @ScienceMagazine #sctopemployer, this being the 5th consecutive year in the top 5! Rooted in our core values, Alnylam’s culture of innovation and inclusion, scientific excellence, and commitment to our people is reflected in everything we do. Read the full story: news.alnylam.com/careers-culture/articles/alnylam-named-t…
-
Alnylam Pharmaceuticals
@Alnylam
#icymi: Our 12th @NEJM manuscript was published, “Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis,” detailing results from the APOLLO-B Phase 3 study of investigational patisiran in patients with the cardiomyopathy of #attr #amyloidosis. #rnaitherapeutics
-
Alnylam Pharmaceuticals
@Alnylam
On #worldamyloidosisday we shine a light on people like Sophia and learn from their stories about living with #hattr #amyloidosis. Hear from Sophia about her experience and what keeps her looking towards the future. @AmyloidosisDay #raredisease
-
Alnylam Pharmaceuticals
@Alnylam
We are proud to share that @NEJM has published results from the APOLLO-B Phase 3 study of investigational patisiran in patients with the cardiomyopathy of #attr #amyloidosis. #rnaitherapeutics #sirna
-
Alnylam Pharmaceuticals
@Alnylam
Today at the @CTADconference, we presented additional interim Phase 1 clinical data on ALN-APP, an investigational #rnai therapeutic in development for the treatment of #alzheimersdisease and cerebral amyloid angiopathy. #rnaitherapeutics #sirna #ctad23
-
Alnylam Pharmaceuticals
@Alnylam
We are excited to join the acute hepatic #porphyria community at the 2023 International Porphyrias Symposium (IPS). Check out the exciting agenda and join us to learn more about our presentations, including findings from the POWER survey on Patient Day. @UnitedPorphAssc
-
Alnylam Pharmaceuticals
@Alnylam
#worldamyloidosisday is on the horizon! We will be joining @AmyloidosisA and the #amyloidosis community to raise awareness about this #raredisease. Learn more about the condition and what you can do to support. @AmyloidosisDay
-
Alnylam Pharmaceuticals
@Alnylam
HCPs: Join us on Thursday, 10/26 for an educational program on a treatment option for acute hepatic #porphyria (AHP), featuring insights from hematologist Dr. Elizabeth Bowhay-Carnes. Tune in to learn more.
-
Alnylam Pharmaceuticals
@Alnylam
We’re excited to share recent recognition – @usnews has named us as one of the Best Companies to Work for in #healthcare AND @FortuneMagazine ranked us #5 on their #bestworkplaces in #biopharma list. #bctwf #greatplacetowork @GPTW_US
Learn what makes our culture so special! ⬇️ -
Alnylam Pharmaceuticals
@Alnylam
Amy had taken her son, Owen, to countless providers until a doctor suspected primary #hyperoxaluria type 1 (PH1). However, Owen’s diagnosis was just the start of a long journey ahead. Learn about the caregiver’s role in advocating for a child’s health on @TheMightySite.
-
Alnylam Pharmaceuticals
@Alnylam
We’re delighted to be recognized for our innovation in developing #rnai therapeutics. This week, we proudly celebrated a WIN at the @Citeline Pharma Intelligence Awards #japan! Congratulations to the Alnylam Japan team, we are #alnylamproud and grateful for all you do every day to support people living with #raredisease.
-
Alnylam Pharmaceuticals reposted
WPI
@WPI
WPI is proud to host and co-organize the @NatureConf. It begins with a career day for @worcesterpublic schools. Students are learning about biotech and were welcomed with comments from arts & sciences Dean Jean King and @Alnylam CEO Yvonne Greenstreet. #crackingthecode23
-
Alnylam Pharmaceuticals
@Alnylam
It was a waiting game for Aubrey, who had watched her brother experience #kidneyfailure due to primary #hyperoxaluria type 1 (PH1) and wondered if she would experience the same symptoms following her PH1 diagnosis. Read about her journey with this #raredisease on @TheMightySite.
-
Alnylam Pharmaceuticals
@Alnylam
Alnylam Patient Education Liaisons (PELs) help patients who are prescribed one of our products by providing disease and product education, connecting patients to additional resources, and answering questions about treatment with our products.
-
Alnylam Pharmaceuticals
@Alnylam
Today we are celebrating National #comingoutday, highlighting the significance of #lgbtq+ visibility, the need to support those coming out and the importance of inclusivity and in and outside the workplace.at Alnylam, we cultivate a diverse, equitable and inclusive environment where employees feel that they belong and can bring their authentic selves to work. We’re proud of the progress we’ve made and proud to highlight leaders and members of SAGA, our LGBTQIA+ employee resource network. #nationalcomingoutday
-
Alnylam Pharmaceuticals
@Alnylam
This morning, we shared an update on our supplemental New Drug Application (sNDA) for patisiran for the treatment of the cardiomyopathy of ATTR amyloidosis. Read the press release: www.businesswire.com/news/home/20231009982660/en/Alnylam-…
-
Alnylam Pharmaceuticals
@Alnylam
People living with hATTR amyloidosis can experience symptoms that affect many different parts of the body which resemble those of other conditions. Cece reached her tipping point and talked to her doctor to seek the right diagnosis.
-
Alnylam Pharmaceuticals
@Alnylam
Our dedicated uLearn with Alnylam team had another successful weekend at @cambscifest, championing #stem education! 🚀 Our team had a blast educating young minds about #rna complementarity by building #dna with pipe cleaners. Thank you to all the volunteers who made this event a success! 🙌
-
Alnylam Pharmaceuticals
@Alnylam
Alnylam Assist® is committed to providing support to patients throughout their treatment with an Alnylam product. Alnylam Case Managers can help verify insurance coverage benefits, discuss financial assistance options and provide educational resources.
-
Alnylam Pharmaceuticals
@Alnylam
Once a decorated gymnast, Glauciene’s dream was interrupted when she began experiencing painful attacks from acute hepatic #porphyria (AHP) that worsened over time – often resulting in hospitalization. Hear Glauciene describe her life since being diagnosed with this #raredisease
-
Alnylam Pharmaceuticals
@Alnylam
#dyk?: As the most common form of #dementia, #alzheimersdisease (AD) affects over 30 million people worldwide. During #worldalzheimersmonth, take time to learn more about the signs, symptoms and risk factors for Alzheimer's Disease and dementia. #worldalzmonth
-
Alnylam Pharmaceuticals
@Alnylam
¡Feliz mes de la herencia hispana y latina! Happy #hispanicheritage Month!
All year long at Alnylam, we celebrate Hispanic and Latin American culture with Armonía, our Latine-based employee resource network.
To celebrate #hispanicheritagemonth2023, we’re partnering with our #biopharma neighbors Takeda alongside Latinos in Bio, a non-profit dedicated to creating opportunities for Latine professionals in the #lifesciences industry. We’re bringing together Hispanic and Latine professionals and allies for an immersive celebration of culture through music, food, and lots of salsa dancing!
Learn more about Alnylam culture: www.alnylam.com/careers/working-at-alnylamThis media couldn't be displayed. See it on the original post. -
Alnylam Pharmaceuticals
@Alnylam
Symptoms of #hattr #amyloidosis can vary widely and resemble other conditions. If you’ve reached your tipping point where symptoms can no longer be overlooked, take the next steps - learn more about this #raredisease and talk to your healthcare provider.
-
Alnylam Pharmaceuticals
@Alnylam
Proud to partner with @nature on their upcoming @natureconf focusing on the development of nucleic acid medicines. Excited for three days of discussing recent clinical successes, and current and upcoming challenges in the development of nucleic acid #medicines. #crackingthecode23
-
Alnylam Pharmaceuticals
@Alnylam
Herzlichen glückwunsch, congratulations, to our German team who is celebrating the opening of our new office in #munich! We’re #alnylamproud and thrilled for them as they begin a new chapter together in a city of science and innovation.
-
Alnylam Pharmaceuticals
@Alnylam
Because the symptoms of acute hepatic #porphyria (AHP) vary widely, diagnosing this #raredisease can be difficult and take up to 15 years. pinpointahp.com can help you learn more about AHP and how it’s diagnosed.
-
Alnylam Pharmaceuticals reposted
Nature Conferences
@NatureConf
Our event exploring recent clinical and research developments of #nucleicacid medicines is now open! Get your tix and submit abstracts at conferences.nature.com/CrackingCode
In partnership with @moderna_tx @Alnylam @WPI @UMassChan @Nature @natBME @NatureBiotech @NatImmunol @NatRevDrugDisc -
Alnylam Pharmaceuticals
@Alnylam
If you think you or a family member may have primary hyperoxaluria type 1 (PH1), or have recently been diagnosed, life can be confusing and stressful. The “My PH1 Handbook” can help with straightforward information about the rare disease PH1, management, monitoring and more.
-
Alnylam Pharmaceuticals
@Alnylam
We’ve announced the outcome of today’s U.S. FDA Advisory Committee Meeting on patisiran, an investigational #rnai therapeutic in development for the treatment of the cardiomyopathy of ATTR #amyloidosis.
-
Alnylam Pharmaceuticals
@Alnylam
Alnylam’s Thirusha Lane discusses her involvement in the development of the first recommendations for patient- and family-centered holistic care for people living with #hattr #amyloidosis, and what these mean for the community living with this #raredisease. #attrv
-
Alnylam Pharmaceuticals
@Alnylam
Today we shared topline results from our KARDIA-1 Phase 2 study of zilebesiran, an investigational #rnai therapeutic in development for the treatment of #hypertension in patients at high cardiovascular risk. #rnaitherapeutics #sirna
-
Alnylam Pharmaceuticals
@Alnylam
We are pleased to share topline results from our KARDIA-1 Phase 2 study of zilebesiran, an investigational #rnai therapeutic in development for the treatment of #hypertension in patients with high cardiovascular risk. #rnaitherapeutics #sirna
-
Alnylam Pharmaceuticals
@Alnylam
An expert panel of patient advocates and HCPs has called for a more holistic approach to #hattr #amyloidosis care to better support patients and their families living with this #raredisease. First-of-their-kind recommendations have been published in @BMJ_Open. #attrv
-
Alnylam Pharmaceuticals
@Alnylam
Pain and reduced strength may appear to be signs of aging, but they could also be symptoms of hATTR amyloidosis. Rick reached his tipping point when his symptoms worsened, and learned more, including about the hereditary nature of this rare disease.
-
Alnylam Pharmaceuticals
@Alnylam
If you’re overwhelmed and frustrated by unexplained symptoms, you’ve reached your tipping point. The right diagnosis of #hattr #amyloidosis is the first step in addressing this #raredisease and its impact on your body.
-
Alnylam Pharmaceuticals
@Alnylam
Following her first acute hepatic #porphyria (AHP) attack, Amalia spent months of her teenage years searching for a diagnosis to explain her debilitating, unbearable symptoms. Watch Amalia explain this difficult time in her life through her artwork at our online art gallery.
-
Alnylam Pharmaceuticals
@Alnylam
We presented new results from a post hoc analysis of the APOLLO-B Phase 3 study of patisiran, an investigational #rnai therapeutic in development for the treatment of the cardiomyopathy of ATTR #amyloidosis, during the @escardio Congress 2023. #rnaitherapeutics #esccongress
-
Alnylam Pharmaceuticals
@Alnylam
Not all people respond to a medicine in the same way. Diversity in clinical trials is critical in evaluating new treatments. Chief DE&I Officer Sara Nochur, Ph.D. joins "Dr. P On The Pod" to talk about the importance of diversity in #clinicaltrials.
-
Alnylam Pharmaceuticals
@Alnylam
After a doctor prescribes one of our products to a patient, they are partnered with an Alnylam Case Manager who has expertise in helping patients get started on treatment and providing product support.
-
Alnylam Pharmaceuticals
@Alnylam
#alnylamproud to be named a Humankind 100 Company for the 2nd year in a row! Learn more about @humankindinvest's list. ⬇️ news.alnylam.com/responsibility/articles/alnylam-named-hu…
-
Alnylam Pharmaceuticals
@Alnylam
Rick, who has hATTR amyloidosis, reached his tipping point when unexplained symptoms could no longer be ignored and decided to have a conversation with his doctor about this hereditary rare disease.
-
Alnylam Pharmaceuticals
@Alnylam
At Alnylam, we understand the importance of supporting our employees with robust childcare benefits. It’s not just about attracting and retaining the best talent – it’s about fostering an environment where they can thrive both personally and professionally. When our employees feel supported in their everyday lives, they can bring their very best to our mission of bringing innovative, transformational medicines to the patients. We’ve joined @theskimm and @MomsFirstUS in their #showusyourchildcare movement, promoting open conversation and transparency around employer childcare benefits in the US.
Learn more about life at Alnylam: www.alnylam.com/careers/working-at-alnylam -
Alnylam Pharmaceuticals
@Alnylam
If you are frustrated by the unexplained symptoms of hATTR amyloidosis, you may have reached your tipping point. The right diagnosis is the first step in addressing this rare disease and its impact on your body. Learn more about Cece’s experience.
-
Alnylam Pharmaceuticals
@Alnylam
Primary hyperoxaluria (PH) is an inherited #raredisease that causes overproduction of oxalate in the body. Primary hyperoxaluria type 1 (PH1) is the most common form of PH. Learn about the signs and symptoms of PH1, including recurrent #kidneystones, at takeonph1.com.
-
Alnylam Pharmaceuticals
@Alnylam
The Alnylam Assist® program offers support services to patients who are prescribed one of our products. Our team of experts are here to help patients access and understand treatment.
-
Alnylam Pharmaceuticals
@Alnylam
In Cambridge, our summer internship program wrapped up with poster presentations! At the end of our internship and co-op sessions, students share their Alnylam experience with employees, giving an inside look at projects they’ve worked on and discoveries they’ve made. Our programs are designed to create a meaningful learning experience for students, and to learn from them too is a bonus. #alnylamproud
Special thanks to our partners at @LS_Cares &
@ProjectOnramp who helped connect us to many of our summer interns. -
Alnylam Pharmaceuticals
@Alnylam
Increasingly, fast-growing companies with engaged employees are realizing that living up to employee and #esg stakeholders' expectations means having a formal #corporateresponsibility program. But where to begin? Arun Skaria, Head of CSR, offers practical advice from our journey.
-
Alnylam Pharmaceuticals reposted
Life Science Cares
@LS_Cares
Thanks to an incredible list of sponsors and donors, the 2023 #timmermantraverse team has cracked their goal of raising $1M to support Life Science Cares' work in the community. And now they're aiming to see just how high they can go! Read more at lifesciencecares.org/news/3rd-annual-timmerman-traverse-c….
-
Alnylam Pharmaceuticals reposted
Dataminr
@Dataminr
Global pharmaceutical company @Alnylam has seen significant success in using Dataminr Pulse to safeguard its workforce and critical facilities that manufacture life-saving medicines.
Check out the case study: sta.mx/c4e
#dataminrpulse -
Alnylam Pharmaceuticals
@Alnylam
What’s the latest on the clinical development and manufacturing of #rnaitherapeutics? Alnylam’s Paul Nioi, VP of Discovery and Translational Research joined @PharmaReview to discuss the benefits and challenges of developing #rnai medicines.
-
Alnylam Pharmaceuticals
@Alnylam
Years after watching his father battle debilitating symptoms of #hattr #amyloidosis, John began to experience similar symptoms. In a new Alnylam-sponsored @AccessHealthTV episode airing on @Lifetimetv, learn more about John’s story and his path to diagnosis.
-
Alnylam Pharmaceuticals
@Alnylam
Recently, results from the Phase 3 study of our #rnai therapeutic for the treatment of acute hepatic #porphyria (AHP) in adults were published in @JHepatology. Learn more about our findings.
-
Alnylam Pharmaceuticals reposted
Agios
@AgiosPharma
We're thrilled to announce an exclusive worldwide agreement w/ #rnai pioneers @Alnylam and add to our pipeline a novel preclinical siRNA targeting TMPRSS6 as a potential disease-modifying treatment for patients w/ #polycythemiavera. Read the press release: investor.agios.com/news-releases/news-release-details/agi…
-
Alnylam Pharmaceuticals
@Alnylam
This morning, we reported Q2 2023 financial results and highlights of recent period activity. Join us for a LIVE webcast TODAY at 8:30 AM ET to hear from our leadership or access the replay later in the day at: investors.alnylam.com/events. $ALNY #rnai #sirna
-
Alnylam Pharmaceuticals
@Alnylam
.@NEJM published results from the Phase 1 study of our investigational #rnai therapeutic in development for treatment of #hypertention. Learn more about the study and its findings in the NEJM Quick Take video.
-
Alnylam Pharmaceuticals
@Alnylam
This year we celebrate #rnaday and the 5th anniversary of the world’s 1st approved #rnai therapeutic (and our 1st commercial medicine), approved by the FDA on Aug. 10, 2018, ushering in the #rnairevolution.
Expand your RNA knowledge by learning more about #rnaitherapeutics and our pipeline: www.alnylam.com/our-science/the-science-of-rnai
#genesilencing #sirna #dna #mrna th
Alnylam Pharmaceuticals
@Alnylam
Video description: Graphics featuring text and different types of DNA move in a slide show formation.
Text on graphics: "DYK? RNA DAY EDITION. Messenger RNA (mRNA is a type of RNA which transports DNA's instructions for making new proteins. Blue graphics of protein molecules. Proteins are essential to all life and how your body functions, but they can also cause or contribute to disease. RNAi therapeutics disrupt the protein making process utilizing a type of RNA called small interfering RNA (siRNA). siRNA targets and degrades specific mRNA before they can make new disease-causing proteins. Alnylam pioneered RNAi therapeutics & 5 years ago this month, the world's 1st RNAi therapeutic was approved. (We've had 4 more approved since!)" -
Alnylam Pharmaceuticals
@Alnylam
This Thursday, 8/3 at 8:30 AM ET, we'll be sharing 2nd Quarter 2023 financial results during a LIVE webcast. A replay will be available at the link below later in the day. #rnai #rnaitherapeutics #sirna investors.alnylam.com/events
-
Alnylam Pharmaceuticals
@Alnylam
HCPs: Timely diagnosis of #hattr #amyloidosis is critical, as the disease can progress rapidly. In this sponsored article, Dr. Polydefkis discusses the polyneuropathy manifestations of this #raredisease, when to suspect it & an available treatment option.
-
Alnylam Pharmaceuticals
@Alnylam
#nowhiring: Commercial Business Account Executives, TTR and Rare focused. More about these BAE opportunities. ⬇
Within their territories, these roles will:
🔹 Build relationships with healthcare professionals
🔹 Identify market development opportunities
🔹 Work closely with stakeholders across commercial, market access, and patient care centers
Learn more about Alnylam’s award-winning culture and how you can be part of the #rnairevolution that’s transforming the lives of patients worldwide: alnylam.com/Careers.
#sarasota #grandrapids #nashville #sandiego -
Alnylam Pharmaceuticals
@Alnylam
This summer, Alnylam employees joined Courageous Sailing's Corporate Challenge in support of the #courageoussailing Summer Youth Program! Our sailors competed in 4 races in the #bostonharbor with 15 other corporate teams. Through this Charity Regatta, we're #alnylamproud to help #boston kids dive into hands-on science, develop leadership skills, gain confidence and explore the Boston Harbor! #csr
-
Alnylam Pharmaceuticals
@Alnylam
#dyk? July is #disabilitypride Month! Led by our recently launched ACCESS disability ERN (employee resource network), Alnylam employees work year-round to promote #accessibility and equity by fostering a culture where disabled individuals feel safe, inspired and empowered to be themselves while advancing their career and our mission. #disabilitypridemonth #a11y #disabilityinclusion
-
Alnylam Pharmaceuticals
@Alnylam
.@FortuneMagazine and @GPTW_US named Alnylam a Best Workplace for Millennials for 2023! #alnylamproud to be #19 out of the top 100 “Large” companies, making us the highest ranked #biotechnology & Pharmaceuticals company listed.
-
Alnylam Pharmaceuticals reposted
CAS_LMU
@cas_lmu
Living in the World of RNA Therapeutics! We thank Muthiah Manoharan @Alnylam for the fantastic overview over the current state of the art in the development of novel RNA therapeutics. Thanks also to Olivia Merkel for initiating and moderating the event. @LabMerkel @CarellGroupLMU
-
Alnylam Pharmaceuticals
@Alnylam
#alnylamproud our CEO @ygreenst has been named by @endpts as one of the top 20 women leading #biopharma R&D. She shares Alnylam's outlook on the #rnairevolution and her plans for the next 20 years.
endpts.com/meet-20-women-leaders-reshaping-biopharma-in-2… -
Alnylam Pharmaceuticals
@Alnylam
As he navigated his journey to diagnosis, John was his own superhero and pushed for answers to ensure his concerns weren’t overlooked. Hear about John’s experience with #hattr #amyloidosis in an Alnylam-sponsored episode of @AccessHealthTV airing on @Lifetimetv.
-
Alnylam Pharmaceuticals
@Alnylam
Evan Lippman, our Chief Corp. Development & Strategy Officer discusses our new partnership w/ @Roche to co-develop/commercialize our investigational #rnaitherapeutic for the treatment of #hypertension in patients w/ high #cardiovascular risk, currently in Phase 2. #rnai
-
Alnylam Pharmaceuticals
@Alnylam
Tune in this morning at 8 AM ET to learn more about our new partnership with @Roche to co-develop & co-commercialize zilebesiran, our investigational #rnai therapeutic in development for the treatment of #hypertension in patients w/ high #cardiovascular risk. #rnaitherapeutics
-
Alnylam Pharmaceuticals
@Alnylam
This morning, Alnylam and @Roche are pleased to announce a partnership to co-develop & co-commercialize zilebesiran, our investigational #rnai therapeutic in development for the treatment of #hypertension in patients w/ high #cardiovascular risk. #rnaitherapeutics #genesilencing
-
Alnylam Pharmaceuticals
@Alnylam
HCPs: The symptoms of #hattr #amyloidosis can mirror those of more common conditions, often leading to misdiagnosis. In a new sponsored article, Dr. Polydefkis discusses diagnosis and management of this #raredisease, and an available treatment option.
-
Alnylam Pharmaceuticals
@Alnylam
Recently, our 11th @NEJM manuscript was published. “Zilebesiran, an RNA Interference Therapeutic for Hypertension” discusses the Phase 1 results of our investigational #rnai therapeutic in development for the treatment of #hypertension. #rnaitherapeutics #cardiology
-
Alnylam Pharmaceuticals
@Alnylam
We are proud to share that @NEJM has published the Phase 1 study results for zilebesiran - an investigational #rnai therapeutic in development for the treatment of #hypertension targeting liver-expressed angiotensinogen (AGT). #rnaitherapeutics #sirna #cardiology #bloodpressure
-
Alnylam Pharmaceuticals
@Alnylam
Today at #aaic23, we presented updated interim results for the ongoing single ascending dose portion of the Phase 1 study of ALN-APP, an investigational RNAi therapeutic in development w/ @Regeneron for the treatment of #alzheimersdisease and cerebral #amyloid angiopathy. #rnai
-
Alnylam Pharmaceuticals
@Alnylam
Years after watching his father battle debilitating symptoms of #hattr #amyloidosis, John began to experience similar symptoms. In a new Alnylam-sponsored @AccessHealthTV episode airing on @Lifetimetv, learn more about John’s story and his path to diagnosis.
-
Alnylam Pharmaceuticals reposted
Novartis US
@NovartisUS
Novartis continues to work to address long-standing healthcare & education inequities & is proud to announce the expansion of our US Beacon of Hope initiative. We’re excited to welcome @Alnylam @Amgen @VirbInc @Advarra @BeeKeeperAI & @GBEF_. #dei Learn more:
-
Alnylam Pharmaceuticals
@Alnylam
At Alnylam, we’re committed to doing our part to increase diversity in #clinicaltrials, which is why we’re proud to be part of the Beacon of Hope Initiative. Led by @Novartis and the Novartis US Foundation, Beacon of Hope seeks to address root causes of disparities in health and education and help create greater diversity, equity, inclusion and trust across the research and development ecosystem. With this collaboration, Alnylam will work with Historically Black Medical School Centers of Excellence and offer fellowship opportunities to students. Learn more about the Initiative: www.prnewswire.com/news-releases/novartis-strengthens-com… #hbcubeaconofhope
-
Alnylam Pharmaceuticals
@Alnylam
Thank you @FastCompany for recognizing Alnylam as a Best Workplace for Innovators 3x in a row! Without innovative people (and a workplace culture that nurtures innovation), a company can't innovate. Our team's focus on sustained innovation is necessary to continue advancing the #rnairevolution so that as many patients as possible can benefit from this revolutionary new class of medicines.
Read more about this recognition ➡️ www.businesswire.com/news/home/20231009982660/en/Alnylam-…
#fcbestworkplaces #rnai #rnaitherapeutics #sirna #innovation -
Alnylam Pharmaceuticals
@Alnylam
Last week we attended @CxHealth’s Communiqué Awards and won! #alnylamproud to take home the “Leadership Award for Action on Workforce Diversity and Inclusion.” From the inside out, we’re building a strong #dei platform to ensure employees feel they belong and can bring their authentic selves to work. Congrats team! #communiquéAwards2023
-
Alnylam Pharmaceuticals
@Alnylam
Pat and Laura, mothers and caregivers to children diagnosed with primary #hyperoxaluria type 1 (PH1) describe their families experiences with the journey to diagnosis with this #raredisease. See more perspectives, learn about PH1 & access resources at takeonph1.com.
-
Alnylam Pharmaceuticals
@Alnylam
Many symptoms of #hattr #amyloidosis resemble those of other more common conditions. This means it often takes years before an accurate diagnosis is made. The Bridge provides educational resources to help recognize the signs and symptoms of this #raredisease.
-
Alnylam Pharmaceuticals
@Alnylam
Around the globe, Alnylam colleagues celebrated #pride2023 all month long. Our Sexuality and Gender Alliance (SAGA) employee resource network led the way with various events, including tie-dye parties, discussion panels, and of course, attending #bostonpride for the People in our home state!
We’re #alnylamproud of our employees who show their pride and continue to advance, advocate for and support diversity, equity and inclusion at Alnylam and in our communities. #pridemonth #pride -
Alnylam Pharmaceuticals
@Alnylam
HCPs: Although #kidneystones are the most common, and often the first symptom of primary #hyperoxaluria type 1 (PH1), not all people with PH1 will have stones. Learn to recognize the signs and symptoms of PH1 in children and adults and how you can test for this #raredisease.
-
Alnylam Pharmaceuticals
@Alnylam
HCPs: Although #kidneystones are the most common, and often the first symptom of primary #hyperoxaluria type 1 (PH1), not all people with PH1 will have stones. Learn to recognize the signs and symptoms of PH1 in children and adults and how you can test for this #raredisease.
-
Alnylam Pharmaceuticals
@Alnylam
#icymi: Earlier today, a new episode of @AccessHealthTV aired on @Lifetimetv featuring John’s journey to being diagnosed with #hattr #amyloidosis, an inherited #raredisease, and perspectives from Dr. Robert Gottlieb, an expert in the condition.
-
Alnylam Pharmaceuticals
@Alnylam
Last week 42 Alnylam team members competed in the 38th @jpmorgan Corporate Challenge in #boston to benefit the @UnitedWayMABay’s Fifty Years Fund! #alnylamproud #jpmcc
-
Alnylam Pharmaceuticals
@Alnylam
A popular #netflix series is prompting discussions on the emotional impact of #porphyria. Data from the POWER survey shows that patients with #ahp are more likely to suffer from depression and anxiety compared to the general public. Learn more about porphyria and its symptoms.
-
Alnylam Pharmaceuticals
@Alnylam
Mark your calendars! On Wed, 6/28 at 7:30am ET/PT, a new episode of @AccessHealthTV airing on @Lifetimetv premieres featuring perspectives from John, who is diagnosed with #hattr #amyloidosis, and Dr. Robert Gottlieb, an expert in this inherited #raredisease.
-
Alnylam Pharmaceuticals
@Alnylam
Diversity matters everywhere, including in the genetic data that informs the drug development process. That’s why we’re proud to be a partner in the Discover Me South Africa study, which will enroll up to 100,000 individuals from South Africa to better understand how genetic differences impact health and can be used to improve patient care. Learn more about the study here: www.discovermestudy.com/dmsa
Discover Me South Africa is a collaboration between Omnigen Biodata, the University of KwaZulu-Natal, Inkosi Albert Luthuli Central Hospital, the KwaZulu-Natal Department of Health, Alnylam’s Human Genetics group, @RegeneronDNA, @AstraZeneca, @Roche, including @Genentech, a member of the Roche Group, @GSK, and @Pfizer. -
Alnylam Pharmaceuticals
@Alnylam
Our 2023 #cambridge summer interns are here! This group of 16 students are with us for the next three months, working across many expertise areas, including Analytical Sciences, Talent Acquisition, Supply Chain, Bioinformatics, and more.
In addition to supporting their expertise areas, Alnylam interns will attend events to help them develop industry knowledge and further develop their professional skill sets. Events include lab and manufacturing tours, career pathways in biotech, drug development 101, patient advocacy programming, and more.
Special thanks to our partners at @LS_Cares & #projectonramp who help underserved students start their careers in #lifesciences by connecting them with companies like Alnylam. We’re grateful for this local source of diverse talent and look forward to a summer with them! -
Alnylam Pharmaceuticals
@Alnylam
#alnylamproud of Board of Directors member @CarolynBertozzi who has been named the recipient of the 2024 Priestley Medal,
@AmerChemSociety
's highest honor! -
Alnylam Pharmaceuticals
@Alnylam
We had a blast playing in our 17th @BioBall_MA basketball tournament for @SpOlympicsMA! We partnered with Heller’s Angels team again, who helped us make it to finals at @TDGarden last season.
We love joining Greater #boston’s #biotech community to support #specialolympics year after year. And we were thrilled to watch our teammate Hannah take the court with her new Alnylam-provided sports wheelchair!
#bioball has shared a commitment to inclusion, sport, and fun while supporting over 14,000 Special Olympics athletes with intellectual disabilities. #choosetoinclude -
Alnylam Pharmaceuticals
@Alnylam
Alluded to in a popular #netflix series, #porphyria is making headlines. However, Hollywood’s depiction does not always reflect the real-world experience of patients today. Watch Two of Me: Living with Porphyria to hear firsthand from people living with #ahp.
-
Alnylam Pharmaceuticals
@Alnylam
At Alnylam we’re committed to helping build tomorrow's high-tech workforce in our home state of #massachusetts. Our participation and sponsorship of the @MassBioEd #lifesciences Workforce conference is one way we do this.
This year, Alnylam’s Cory Siddons, VP, Internal Manufacturing, spoke on the “Industry Best Practices to Attract and Develop Talent" panel. He shared experiences from his 21+ years in the industry, including his 8-year tenure at Alnylam.
#lswc23 #biomanufacturing #biotech -
Alnylam Pharmaceuticals
@Alnylam
HCPs: A combination of multisystem symptoms and family history are red flags of #hattr #amyloidosis and require urgent action. If your patient’s family has a history of the disease, or is experiencing a combination of these multisystem symptoms, consider hATTR amyloidosis.
-
Alnylam Pharmaceuticals
@Alnylam
Today, we recognize and honor #juneteenth, “Freedom Day,” commemorating the emancipation of enslaved African Americans. On this day in 1865, enslaved African Americans in Texas finally learned that they were free – approximately 2 months after the end of the American Civil War. Juneteenth became a US federal holiday in 2021.
To celebrate Juneteenth this year, Alnylam, our Global Black Initiative ERN (employee resource network) and The Color of Biotech are proud to host a Juneteenth Celebration of the Arts at our Global HQ in Cambridge. This event, which will take place on June 22 is open to all but registration is required. -
Alnylam Pharmaceuticals
@Alnylam
Our Cambridge team hosted a visiting delegation of German graduate students from @JungChemiker and @GDCh_aktuell as part of @NESACS’ exchange program, fostering chemistry collaborations between Germany and the greater #boston area. Hearing from some of our scientists, students had the opportunity to learn all about our award-winning science #rnaitherapeutics and how siRNA oligonucleotides are synthesized.
-
Alnylam Pharmaceuticals
@Alnylam
Communicating with and explaining the needs of your child diagnosed with primary #hyperoxaluria type 1 (PH1) to those who care for your child on a day-to-day basis can be challenging. This printable handout can help you or your patients communicate more easily and effectively.
-
Alnylam Pharmaceuticals
@Alnylam
#nucleate's activator program has been making waves across 18 U.S. and European cities, and we are proud to be a sponsor! 🎉
Through @NucleateHQ's activator program, 177 bio innovation teams had the opportunity to showcase their scientific ventures before world-renowned judges and an esteemed audience of program mentors, academics, industry veterans, and the broader #biotech community.
As part of our commitment to scientific excellence, we proudly supported the Alnylam Scientific Excellence Award in the participating 18 cities across the U.S. and Europe. We were blown away by the talent and creativity displayed by these teams. 👏
But the excitement doesn't end there! We can't wait for the second-ever Alnylam BioVenture Challenge coming this fall. Mark your calendars for November 9th when top teams from the program will compete for the prestigious John Maraganore Science Entrepreneurship Award.
Stay tuned for more updates as we continue to support and empower the scientific community in their pursuit of transformative innovation. Together, we're shaping the future of @! -
Alnylam Pharmaceuticals
@Alnylam
#hattr #amyloidosis is a #raredisease that can resemble other conditions, making it difficult to diagnose. After many visits to the hospital, Roland reached his tipping point and sought an accurate diagnosis of his symptoms.
-
Alnylam Pharmaceuticals
@Alnylam
#bostonpride this weekend was incredible! Led by our Sexuality and Gender Alliance (SAGA) employee resource network, members of our #lgbtqia+ community and allies marched in the #prideparade for the People. 🏳️🌈🏳️⚧️
We’re #alnylamproud of our employees who show their pride and continue to advance, advocate for and support diversity, equity and inclusion at Alnylam and in our communities.
#pridemonth #pride #showyourpride #pride2023 -
Alnylam Pharmaceuticals
@Alnylam
HCPs: PH1 is a genetic disease caused by mutations in the AGXT gene that renders the liver enzyme AGT dysfunctional. This causes the overproduction of oxalate which combines with calcium to create crystals, which can cause progressive, irreversible damage throughout the body.
-
Alnylam Pharmaceuticals
@Alnylam
Alnylam Canada has been recognized as one of the Best Workplaces in Health Care by @GPTW_Canada! We’re #alnylamproud of this team who continues to be a critical part of our global mission. Congratulations and felicitations team! #gptwcertified #gptw #biotech #companyculture
-
Alnylam Pharmaceuticals
@Alnylam
Acute hepatic #porphyria (AHP) is unpredictable, and symptoms can interfere with daily life, disrupting everything from sleep to the ability to work and socialize. Some symptoms of this #raredisease can be acute, while others may be chronic.
-
Alnylam Pharmaceuticals
@Alnylam
Happy #pridemonth! We’re #alnylamproud to have SAGA, Alnylam’s #lgbtq+ employee resource network, lead our global celebrations to bring our colleagues together all month long. 🏳️🌈🏳️⚧️🌈
This year’s theme, Diverse Equal Proud, is about recognizing the diversity of people within the LGBTQ+ community and the fact that everyone deserves to be proud of who they are and to be treated with equal respect and dignity, regardless of gender, sexuality, ethnicity, or background. #pride #pride2023 -
Alnylam Pharmaceuticals
@Alnylam
Being a #caregiver for a child living with primary #hyperoxaluria type 1 (PH1) can feel daunting, from understanding PH1 progression and management, to communicating with your care team and even explaining PH1 in child-friendly terms. This guide can help. #raredisease
-
Alnylam Pharmaceuticals
@Alnylam
Led by our SHADES: InspirASIAN Employee Resource Network, we’re proud to Celebrate #aapiheritagemonth. All year long, InspirASIAN helps us acknowledge and honor Asian and Asian American Pacific Islander heritage, through education and celebrations. #aapimonth #aapi
-
Alnylam Pharmaceuticals
@Alnylam
David and three of his family members have a #raredisease called #hattr #amyloidosis. The highly hereditary nature of the disease means that other members of his family might be at risk for the disease also. Learn more about David’s story.
-
Alnylam Pharmaceuticals
@Alnylam
At Alnylam, we're recognizing #mentalhealth Awareness Month while also recognizing that employee health and well-being must be a focus year-round. We're proud of the range of resources available to our employees, including colleagues who exemplify our 'commitment to people' core value.
Learn more about our approach to health and well-being and why it’s part of what makes us a globally recognized #bestplacetowork: www.alnylam.com/careers/working-at-alnylam. -
Alnylam Pharmaceuticals
@Alnylam
.@GPTWItalia has ranked Alnylam as the #1 #bestworkplace in Pharma & Biotechnology! We’re so #alnylamproud of our colleagues in Italy who have created a special culture that always puts people first and enables us to do the best we can on behalf of the patients who depend on us. Congratulazioni team!
#gptw #greatplacetowork #companyculture -
Alnylam Pharmaceuticals
@Alnylam
Engaged employees are not only productive employees but collectively, an incredible force for social change and doing good in our communities. We're so proud of how our employees have been the driving force behind our #corporateresponsibility efforts and invite you to learn more.
-
Alnylam Pharmaceuticals
@Alnylam
Alnylam Patient Education Liaisons (PELs) help patients who are prescribed one of our products by providing disease and product education, connecting patients to additional resources, and answering questions about treatment with our products.
-
Alnylam Pharmaceuticals
@Alnylam
Members of our Latinx-focused Employee Resource Network, Armonia, attended #hfgala23 last month. As a sponsor, Alnylam supports @HispanicFed's mission of championing various economic development and educational opportunities for the Hispanic community. We’re inspired by #hispanicfederation’s work and thrilled our team had the opportunity to be surrounded by many #latinx leaders.
-
Alnylam Pharmaceuticals
@Alnylam
We recently presented new data from the APOLLO-B Phase 3 study of patisiran, an investigational #rnai therapeutic in development for the treatment ATTR #amyloidosis with cardiomyopathy, during #heartfailure2023. #rnaitherapeutics
-
Alnylam Pharmaceuticals
@Alnylam
Today at #heartfailure2023, we presented 18-month results from the APOLLO-B Phase 3 study of patisiran, an investigational #rnai therapeutic in development for the treatment ATTR #amyloidosis with cardiomyopathy. #rnaitherapeutics
-
Alnylam Pharmaceuticals
@Alnylam
In this video, Dan (a caregiver) and John (a patient), describe the challenges of explaining what primary #hyperoxaluria type 1 (PH1) is like to others because the effects of this #raredisease are largely internal. To see more perspectives & learn about PH1, click the link below.
-
Alnylam Pharmaceuticals
@Alnylam
HCPs: Primary #hyperoxaluria type 1 (PH1) is a progressive genetic #raredisease which is potentially life-threatening, and often presents w/ kidney stones. Watch this video to learn more about the PH1 mechanism of disease & disease characteristics. #urology #nephrology
-
Alnylam Pharmaceuticals
@Alnylam
Our CEO @ygreenst shares her thoughts about innovating against injustice in health care and how #biotech companies can take steps to address #healthinequity in a @ProSyn opinion piece. #healthequity www.project-syndicate.org/commentary/biotech-industry-mus…
-
Alnylam Pharmaceuticals
@Alnylam
#hypertension, or high blood pressure, is the leading preventable risk factor for cardiovascular disease and premature death worldwide. This World Hypertension Day learn more about the challenges people face while trying to manage their blood pressure. #worldhypertensionday
-
Alnylam Pharmaceuticals
@Alnylam
We want to help people with #hattr #amyloidosis ‘Bridge the Gap’ in awareness of the condition by providing resources and guidance for having important and difficult conversations with friends and family about the disease.
-
Alnylam Pharmaceuticals
@Alnylam
Alnylam Assist® is committed to providing support to patients throughout their treatment with an Alnylam product. Alnylam Case Managers can help verify insurance coverage benefits, discuss financial assistance options and provide educational resources.
-
Alnylam Pharmaceuticals
@Alnylam
If you think you or a family member may have primary #hyperoxaluria type 1 (PH1), or have recently been diagnosed, life can be confusing and stressful. The “My PH1 Handbook” can help with straightforward information about PH1, management, monitoring and more. #raredisease
-
Alnylam Pharmaceuticals
@Alnylam
We’ve learned a lot on our #corporateresponsibility journey, and continue to do so every day. Arun Skaria, our Director of Corporate Responsibility shares 5️⃣ key learnings from our efforts that may be helpful to your organization.
-
Alnylam Pharmaceuticals
@Alnylam
Excited to enter her freshman year of college, Amalia soon began experiencing unexplainable, excruciating symptoms. View Amalia’s artwork in Alnylam’s online gallery to learn more about her acute intermittent #porphyria (AIP) diagnosis and experience with this #raredisease.
-
Alnylam Pharmaceuticals
@Alnylam
As part of our commitment to #corporateresponsibility and protecting our planet, last month our Green Team helped colleagues celebrate #earthday around the world.
In Massachusetts, volunteers cleaned up with @EsplanadeBoston and helped Norton Land Preservation Society and @attleboroymca with kid-friendly environmental activities.
Plus, our facilities team collected over 1,600LB of E-waste across the International region. Thank you to all who participated! -
Alnylam Pharmaceuticals
@Alnylam
Getting an accurate #raredisease diagnosis can take a long time because symptoms often present as those of other conditions. We’re working to raise awareness of #hattr #amyloidosis to help shorten the time to diagnosis for people with this disease.
-
Alnylam Pharmaceuticals
@Alnylam
After a doctor prescribes one of our products to a patient, they are partnered with an Alnylam Case Manager who has expertise in helping patients get started on treatment and providing product support.
-
Alnylam Pharmaceuticals
@Alnylam
We've made #healthequity a key component of our corporate responsibility efforts. You can read about our programs and partnerships in our just-released 2022 report, which details our progress in #esg and patient-focused innovation. #corporateresponsibility
-
Alnylam Pharmaceuticals
@Alnylam
Alnylam’s 2022 Corporate Responsibility Report is now available for download. Read more about our efforts and progress in #esg, patient-focused innovation and #healthequity. #csr
-
Alnylam Pharmaceuticals
@Alnylam
This morning, we reported Q1 2023 financial results and highlights of recent period activity. We will host a LIVE webcast TODAY at 8:30 AM ET to discuss them and a replay will be available following. Access the webcast and replay here: investors.alnylam.com/events $ALNY #rnai #sirna
-
Alnylam Pharmaceuticals
@Alnylam
We endeavor to make a positive impact on our communities and the planet beyond the innovative medicines we make. Each year, we report on our #corporateresponsibility mission and progress in our 6 key areas of focus: patients, sciences, employees, communities, planet & governance.
-
Alnylam Pharmaceuticals
@Alnylam
This Thursday, 5/4 at 8:30 AM ET, we'll be sharing 1st Quarter 2023 financial results during a LIVE webcast. A replay will be available at the link below later in the day. #rnai #rnaitherapeutics #sirna
-
Alnylam Pharmaceuticals
@Alnylam
As a long-time supporter of @CASPARCamSom’s mission to support our homeless neighbors in Massachusetts, we look forward to attending their upcoming “Strengthening Our Community” event at @MITMusuem on May 4. We encourage our neighbors and #biotech peers to learn more about CASPAR’s incredible impact in the communities where we live and work. baycovehumanservices.org/casparevent
-
Alnylam Pharmaceuticals
@Alnylam
During the @PASMeeting, we will present new 30-month results from the ILLUMINATE-B Phase 3 study of our #rnai therapeutic for the treatment of primary #hyperoxaluria type 1 (PH1). Learn more about our findings. #pas2023 #rnaitherapeutics #sirna
-
Alnylam Pharmaceuticals
@Alnylam
ICYMI: Yesterday, w/ @Regeneron, we shared interim Phase 1 clinical data on ALN-APP, an investigational #rnai therapeutic in development for the treatment of #alzheimersdisease and cerebral amyloid angiopathy. We’ll present full results at an upcoming medical meeting. #neurology
-
Alnylam Pharmaceuticals
@Alnylam
We’ve shared interim Phase 1 clinical data on ALN-APP, an investigational #rnai therapeutic in development w/ our partner @Regeneron for the treatment of #alzheimersdisease & cerebral amyloid angiopathy. We’ll present full results at an upcoming med. meeting. #rnaitherapeutics
-
Alnylam Pharmaceuticals
@Alnylam
This afternoon at 4:30 pm ET, we’ll be providing information about the interim Phase 1 clinical data on ALN-APP, an investigational #rnai therapeutic in development for the treatment of #alzheimersdisease and cerebral amyloid angiopathy. @Regeneron #rnaitherapeutics #sirna
-
Alnylam Pharmaceuticals
@Alnylam
With our partner @Regeneron, we are pleased to share interim Phase 1 clinical data on ALN-APP, an investigational #rnai therapeutic in development for the treatment of #alzheimersdisease and cerebral amyloid angiopathy. #rnaitherapeutics #sirna
-
Alnylam Pharmaceuticals
@Alnylam
2022 was an exciting year for Alnylam with significant milestones as we continue leading the #rnairevolution. Our CEO @ygreenst reflects on last year’s highlights and the next chapter for #rnaitherapeutics. Download our 2022 annual report to learn more. #rnai #sirna
-
Alnylam Pharmaceuticals
@Alnylam
We recently presented new data for vutrisiran and patisiran during the 2023 AAN Annual Meeting. @AANmember #aanam #rnaitherapeutics
-
Alnylam Pharmaceuticals
@Alnylam
The Alnylam Assist® program offers support services to patients who are prescribed one of our products. Our team of experts are here to help patients access and understand treatment.
-
Alnylam Pharmaceuticals
@Alnylam
In support of Global Porphyria Day and #porphyriaawarenessweek, our employees are wearing #purpleforporphyria. We’re #alnylamproud to join @GlobalPorphyria and @Porphyria_Help in raising awareness of #porphyria and giving a voice to this global community.
-
Alnylam Pharmaceuticals
@Alnylam
Patients are at the center of everything we do. The opportunity to hear about their journeys (and those who advocate for them) first-hand is always a powerful experience. That’s what made our U.S. Patient Impact Day last week so special. Guests shared their perspectives and (1/2)
Alnylam Pharmaceuticals
@Alnylam
insights with leadership, participated in an all-company panel discussion and Q&A, and toured our Norton facility to learn how #rnai therapeutics are made. Thank you to the patients & advocates for generously giving your time to be with us and for your ongoing partnership. (2/2)
-
Alnylam Pharmaceuticals
@Alnylam
We’re excited to announce that our US TTR Marketing team was named a Gold winner yesterday evening at the 2023 DTC Advertising Awards in the category of Best Patient Engagement, Support, or CRM Program. #alnylamproud @XpectivesHealth
-
Alnylam Pharmaceuticals
@Alnylam
We’re so very #alnylamproud of Christina Zhao, Senior Director, US TTR Marketing, for being recognized by @XpectivesHealth as a 2023 Top DTC Marketer for her innovative thinking and contributions to patient communications.
-
Alnylam Pharmaceuticals
@Alnylam
Today, on the first ever Global Porphyria Day, and every day, we applaud the strength of those affected by #porphyria and pledge our ongoing commitment to support them. Hear from one family affected by this #raredisease and their message for those searching for answers. #gpd2023
-
Alnylam Pharmaceuticals
@Alnylam
Excited to share the renewal of our partnership with @NucleateHQ, a student-led, non-profit org removing barriers faced by the next-gen of #biotech leaders. With our own entrepreneurial past, we’re proud of the progress made so far and look forward to what’s next for Nucleate.
-
Alnylam Pharmaceuticals
@Alnylam
We’re #alnylamproud to be ranked by @GPTWItalia for the first time at number 10 on their #bestworkplaces list! Congratulations to our amazing colleagues in #italy who continually embody our “Challenge Accepted” ethos and make Alnylam a Great Place to Work. #gptw #greatplacetowork #companyculture
-
Alnylam Pharmaceuticals
@Alnylam
Kasha Witkos, International Region Head at Alnylam, was recently interviewed by @Medicine_Maker. She describes career experiences she’s learned from, emerging innovations and how service and partnership are key for pharma to better support patients in the future.
The Medicine Maker
@medicine_maker
We spoke to Kasha Witkos, head of @Alnylam’s international division, to discuss her work, career, and how each has intersected with questions around rural poverty, prison healthcare, visions for the future, and the values that constitute a civilization.
themedicinemaker.com/business-regulation/alnylams-kasha-w… -
Alnylam Pharmaceuticals reposted
womenspowergap
@womenspowergap
Biotechnology companies like @Alnylam are leading the way in advancing women’s representation and #dei. According to @ygreenst, that progress is a result of greater transparency and a strong foundation of corporate responsibility. #genderparitynow #womenspowergap #massachusetts
-
Alnylam Pharmaceuticals
@Alnylam
During the National Kidney Foundation (@nkf) Spring Clinical Meetings, we presented positive 36-month results from the ILLUMINATE-A Phase 3 study of our #rnai therapeutic for the treatment of primary #hyperoxaluria type 1 (PH1). #scm23
-
Alnylam Pharmaceuticals
@Alnylam
Symptoms of #hattr #amyloidosis vary widely and can affect multiple parts of the body. Roland experienced tingling in his hands and pins and needles in his legs. His tipping point? When he collapsed and stopped breathing. Learn more about the symptoms of this #raredisease.
-
Alnylam Pharmaceuticals
@Alnylam
#alnylamsciencespotlight: New research published in @NatureComms details non-clinical results exploring the utility of #rnai-mediated knockdown with our REVERSIR technology in modulating adeno-associated virus (AAV) transgene expression in the setting of #genetherapy. #genetics
-
Alnylam Pharmaceuticals
@Alnylam
Today is #worldhealthday and this year’s theme is #healthforall. At Alnylam, we believe that all patients deserve the opportunity to live longer, healthier and fuller lives, regardless of diagnosis. That’s why we pioneered #rnai therapeutics and are working tirelessly to develop new medicines to treat diseases for which there are limited or inadequate treatment options and to bring our medicines to those who may benefit from them. @WHO #who75
-
Alnylam Pharmaceuticals
@Alnylam
Our Global Commercial team recently gathered to assemble backpacks filled with educational #stem items for Cambridge’s @SCFG. At Alnylam, we believe we can only thrive when the communities surrounding us are resilient and sustainable.
Throughout the year, our teams worldwide dedicate time to support local non-profit organizations. Learn more about our community-driven mission: www.alnylam.com/about-alnylam/corporate-responsibility.
#girlsinstem #womeninstem #communityengagement -
Alnylam Pharmaceuticals
@Alnylam
Although kidney stones are the most common symptom of primary #hyperoxaluria type 1 (PH1), not all people with PH1 experience stones. When you have PH1, your kidneys are at risk for damage even if you’re not getting stones. Learn more about this #raredisease.
-
Alnylam Pharmaceuticals reposted
RARE Revolution Magazine®
@RareRevolutionM
A huge thank you to all our contributors in this digital spotlight on #hereditaryamyloidosis (#attrv). Curation has been independently conducted by RARE Revolution Magazine, although made possible with financial support from @Alnylam Pharmaceuticals.
rarerevolutionmagazine.com/digital_spotlights/hereditary-… -
Alnylam Pharmaceuticals
@Alnylam
HCPs: The symptoms of #hattr #amyloidosis can mirror those of more common conditions, often leading to misdiagnosis. In a new sponsored article, Dr. Polydefkis discusses diagnosis and management of this #raredisease, and an available treatment option.
-
Alnylam Pharmaceuticals reposted
RARE Revolution Magazine®
@RareRevolutionM
Thirusha Lane from @Alnylam reflects on her 15 years of work in the #attr #amyloidosis space. She celebrates the advances she has seen in therapy options, disease state knowledge, and awareness and advocacy.
rarerevolutionmagazine.com/digitalspotlight/a-reflection-…
#attrv #hereditaryamyloidosis -
Alnylam Pharmaceuticals
@Alnylam
So, you know what #genetics are, but do you know how they’re used in drug development? This new article explains. Since our founding, we’ve focused on harnessing #humangenetics to identify targets and improve the probability of success. Now, this focus is powering the next wave of #rnaitherapeutics. #rnai #rnairevolution #biotech news.alnylam.com/rnai/articles/harnessing-human-genetics-…
-
Alnylam Pharmaceuticals
@Alnylam
We believe representation matters. We're proud to be ranked #1 among MA companies in board of directors #genderdiversity & #3 in #executiveleadership gender diversity. Thank you @EosFoundation for providing important data via the @womenspowergap Initiative. #genderparitynow
-
Alnylam Pharmaceuticals
@Alnylam
In the latest issue of @RareRevolutionM, Alnylam’s Thirusha Lane reflects on 15 years as a nurse and patient advocacy professional in the field of #attr #amyloidosis. Hear her perspectives on the remaining and emerging needs for those impacted by this #raredisease.
-
Alnylam Pharmaceuticals
@Alnylam
Because the symptoms of acute hepatic #porphyria (AHP) vary widely, diagnosing this #raredisease can be difficult and take up to 15 years. pinpointahp.com can help you learn more about AHP and how it’s diagnosed.
-
Alnylam Pharmaceuticals
@Alnylam
If you think you or a family member may have primary hyperoxaluria type 1 (PH1), or have recently been diagnosed, life can be confusing and stressful. The “My PH1 Handbook” can help with straightforward information about the rare disease PH1, management, monitoring and more.
-
Alnylam Pharmaceuticals
@Alnylam
HCPs: Timely diagnosis of #hattr #amyloidosis is critical, as the disease can progress rapidly. In this sponsored article, Dr. Polydefkis discusses the polyneuropathy manifestations of this #raredisease, when to suspect it & an available treatment option.
-
Alnylam Pharmaceuticals
@Alnylam
We were honored to host last evening’s SIM Boston CIO Roundtable event at our headquarters in Cambridge, MA. The group, chaired by Alnylam CIO James Bilotta, discussed topics around digitization and information security strategy with presentations from Alnylam IT and Security leaders Murtaza Cherawala and Sanju Misra. #informationsecurity #simboston
-
Alnylam Pharmaceuticals
@Alnylam
Our #medicalpublications team is hiring for a variety of roles based in our #cambridge, MA office. Learn about our award-winning culture, pioneering science and how you can be part of the #rnairevolution that’s transforming the lives of patients worldwide. #nowhiring #biotech
-
Alnylam Pharmaceuticals
@Alnylam
There are various symptoms associated with #hattr #amyloidosis which can be similar to those of other conditions. Talking to your doctor about your symptoms can help with an accurate diagnosis. Learn tips for starting this conversation with our Doctor Discussion Guide.
-
Alnylam Pharmaceuticals
@Alnylam
Congratulations to our Healthcare Businesswomen’s Association 2023 Rising Stars Izanne Garofalo and Maja Janas De Angelis and all of this year's Rising Stars and Luminaries honorees! #alnylamproud @HBAnet #hbaimpact #hbawoty23
-
Alnylam Pharmaceuticals
@Alnylam
We’re thrilled to share that amaliasstory.com – which features the story of Alnylam Patient Ambassador Amalia and how she has chronicled her journey with acute hepatic #porphyria (AHP) through art – was named a 2023 Pharma Choice Award Silver Winner by @PM360online.
-
Alnylam Pharmaceuticals
@Alnylam
For many #kidneydiseases, like primary #hyperoxaluria type 1 (PH1), early detection and diagnosis is critical in disease management. This #nationalkidneymonth, read about red flag symptoms of and when to suspect PH1.
-
Alnylam Pharmaceuticals
@Alnylam
Paul Nioi, our VP of Discovery & Translational Research, delivered a keynote on the topic of using #genetics to advance #rnaitherapeutics for cardiometabolic diseases at #rnaleaders Europe Congress in Basel yesterday. This meeting brought together more >450 leaders in the #rna therapeutics and vaccines field. #sirna #rnai #biotech #healthtech
-
Alnylam Pharmaceuticals
@Alnylam
This week, our SHADES InspirAsian ERN (employee resource network) invited Cambridge colleagues to celebrate Holi, the #festivalofcolours, Love and Spring. #holi is traditionally celebrated with friends and family with food, dancing, and playing with colorful powder (gulal).
-
Alnylam Pharmaceuticals reposted
Sano Genetics
@sanogenetics
In episode 94 of The Genetics Podcast, we’re joined by VP of Discovery & Translational Research at @Alnylam, @PNioi, to discuss:
🧬genetics & drug target discovery
🧬population genomics' value
🧬RNAi, the Nobel-Prize-winner underpinning Alnylam's approach
podfollow.com/dna -
Alnylam Pharmaceuticals
@Alnylam
Congratulations to our CEO @ygreenst on being named to the #statuslist list for the 2nd year in a row. This list, selected by the editors of @statnews, recognizes standout individuals in the #lifesciences. #biotech #leadership #rnai
-
Alnylam Pharmaceuticals
@Alnylam
Once a decorated gymnast, Glauciene’s dream was interrupted when she began experiencing painful attacks from acute hepatic #porphyria (AHP) that worsened over time – often resulting in hospitalization. Hear Glauciene describe her life since being diagnosed with this #raredisease
-
Alnylam Pharmaceuticals
@Alnylam
In celebration of #iwd2023, our iTHRIVE: Women @ Alnylam employee resource network hosted screenings of the #emmy-nominated documentary “Picture a Scientist” in our offices around the world. This compelling documentary discusses the challenges, biases and struggles for acceptance, equity and resources faced by #womeninscience. Following the screening, we held an open discussion about ongoing diversification, equity and inclusion efforts, both within Alnylam and the larger #lifesciences industry.
#genderequality #embraceequity #womenshistorymonth
#internationalwomensday #iwd #dei -
Alnylam Pharmaceuticals
@Alnylam
Today on #worldkidneyday, join us in pledging your ongoing commitment to support the millions of Americans affected by #kidneydisease and to advance kidney care. Learn about the signs and symptoms of primary #hyperoxaluria type 1 (PH1), a #raredisease that affects the kidneys.
-
Alnylam Pharmaceuticals
@Alnylam
Our CEO @ygreenst and other female #biopharma leaders sat down w/ @TDCowen to discuss the state of #genderinclusivity in the industry. They talked about allyship, the need for inclusive and diverse representation and shared advice for the next gen of talent. #iwd #embraceequity
-
Alnylam Pharmaceuticals
@Alnylam
HCPs: Recurrent kidney stones in an adult, any kidney stone in a child, nephrocalcinosis, and renal failure may all be signs of a metabolic stone disease, such as primary #hyperoxaluria type 1 (PH1). Learn more at aboutph1.com - a resource for healthcare professionals
-
Alnylam Pharmaceuticals
@Alnylam
Today’s approval of GIVLAARI (givosiran) by the @US_FDA marks the arrival of a much needed new treatment option for adults in the U.S. living with a devastating #raredisease.
-
Alnylam Pharmaceuticals
@Alnylam
#alny & @Sanofi rpt Phase 3 results for RNAi tx: patisiran meets primary & all secondary endpts #hattr #amyloidosis cards.twitter.com/cards/18ce53zdfri/4tbnf


































































































































































































































































































































































































































